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Abstract 
Proliferation of cerebellar granule neuronal progenitors (GNPs) is known 
to be mediated by Sonic Hedgehog (SHH) signalling and dysfunction of this 
signalling is known to underlie the formation of a major subset of 
medulloblastomas (MBs), the most common brain tumours of children; however, 
the mechanism by which this proliferation is regulated is not well understood. 
Recent data from our lab have demonstrated that neural adhesion molecules 
belonging to the L1CAM-contactin (L1-CNTN) family are involved in modulating 
GNP proliferation and differentiation. F3/contactin, a GPI-linked member of the 
L1-CNTN family, is able to induce the mitotic exit and neuronal differentiation of 
GNPs, counteracting the normal effect of SHH in vitro, whereas TAG-1, another 
member of CNTN family, acts antagonistically to F3 activity. F3 appears to act 
on GNPs through binding to NRCAM, an L1 family member, and can no longer 
suppress SHH-induced proliferation of GNPs from Nrcam-/- mice. Therefore F3 
and NRCAM appear to be important for suppressing SHH-induced proliferation 
in GNPs. 
It is known that in vertebrates Hedgehog signalling requires a primary 
cilium. Signalling occurs when SHH binds to its receptor Patched (PTCH) and 
causes it to translocate out of the cilium, which in some way allows the seven-
transmembrane protein, Smoothened (SMO) to translocate into the cilium to 
activate SHH signalling. Exactly how these translocations occur is not fully 
understood, but evidence suggests that this requires endocytosis and 
intracellular trafficking. Since in other contexts L1-CNTNs are known to be 
involved in such processes, the hypothesis of this study is that L1-CNTNs might 
be involved in modulating SHH signalling by trafficking of SHH pathway 
component proteins into or out of primary cilia of SHH-induced GNP 
proliferation.  
Here I demonstrate the presence of NRCAM and TAG-1 in primary cilia 
and show that loss of NRCAM affects both PTCH and SMO ciliary localisation, 
most likely, therefore, implicating NRCAM in PTCH trafficking. Consistent with 
this, my co-immunoprecipitation studies suggest that NRCAM physically 
interacts with PTCH1, but not SMO. I show also that the kinetics of SHH 
signalling in GNPs is affected by loss of NRCAM. Taken together, my data seem 
to suggest that NRCAM plays a role in modulating SHH signalling by regulating 
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the trafficking of PTCH1 in the primary cilia of GNPs. The discovery of a role for 
L1-CNTNs in modulating SHH signaling in principle could lead to novel 
treatments for MB in the future. 
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1.1 Introduction 
Abnormal regulation of cell proliferation resulting in many kinds of cancer raises 
the question of how normally the cell proliferation is controlled. It is not sufficient 
to simply programme a cell to undergo a certain number of divisions when an 
organised tissue is formed. The proliferation of cells must be coordinated 
between cells and environment. Cellular communication is therefore very 
important, particularly when a tissue or structure is being formed in the 
developing embryo, as it needs to expand the number of cells and organise 
specific cell types into particular places. Not surprisingly, therefore, it has been 
found that molecules mediating cell-cell interactions play a vital role in 
controlling cell proliferation and differentiation. Among such molecules are 
secreted proteins such as Fibroblast Growth Factors (FGFs) (Gallagher, 2007) 
and Sonic Hedgehog (SHH), which can diffuse between cells to pattern growth 
and differentiation over long distances (Briscoe and Therond, 2013). However, it 
is clear that short range, cell contact interactions are also important in 
coordinating morphogenesis in the nervous system (Bizzoca et al., 2003, Louvi 
and Artavanis-Tsakonas, 2006, Kamiguchi, 2007, Decker et al., 2004, Hirano 
and Takeichi, 2012, Xenaki et al., 2011). Moreover, there are clear examples 
that these interact with signals from diffusible patterning molecules to modulate 
their effect (Pons et al., 2001, Blaess et al., 2004, Zhang et al., 2013). Precisely 
how these two different kinds of signal interact, however, is not well understood.  
In the cerebellum, SHH secreted from Purkinje cells stimulates an increase in 
the number of dividing cerebellar granule neuron progenitors (GNPs) (Dahmane 
and Ruiz i Altaba, 1999, Wallace, 1999, Wechsler-Reya and Scott, 1999) and 
loss of SHH leads to a failure of the granule cell layer to expand normally and a 
severe reduction in cerebellar size (Lewis et al., 2004). SHH is therefore an 
essential mitogen in the growth of the cerebellar cortex and SHH signalling is a 
key pathway driving proliferation of GNPs. Moreover, it is clear that modulation 
of SHH signalling levels can affect the size and morphogenesis of the 
cerebellum (Corrales et al., 2004, Corrales et al., 2006). However, how SHH 
levels are modulated locally in the developing cerebellum is not clear. While 
there is some evidence that this may be done at the transcriptional level to vary 
signalling between lobules (Corrales et al., 2004), how local modulation is 
achieved is not understood. A particular puzzle, for example, is why GNP 
proliferation is strongest in those cells most distant from the source of SHH, the 
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Purkinje cells. One suggestion is that the morphogen is shaping the tissue by 
integrating its signal with those arising from cell contacts and in fact there is 
evidence for contacts affecting SHH signals (Bizzoca et al., 2003, Pons et al., 
2001, Blaess et al., 2004, Xenaki et al., 2011). Therefore the main aim of this 
study is to understand the mechanism by which cell contacts affect SHH 
signalling in the context of cerebellar development looking specifically at the 
interaction between adhesion molecules of L1-CNTN family and SHH signalling. 
L1-CNTNs are a family of neural adhesion molecules named for their founder 
members L1CAM (L1; (Maness and Schachner, 2007)) and F3/contactin 
(CNTN; (Shimoda and Watanabe, 2009)), immunoglobulin-like glycoproteins 
linked to the plasma membrane by transmembrane or glycosyl 
phosphatidylinositol (GPI) anchors, respectively. Their expression is extensive in 
the nervous system, albeit not exclusively, as they also expressed in endothelial 
tissues (Glienke et al., 2000). In the nervous system they have been implicated 
in a broad range of post-mitotic processes, including cell migration, axon 
guidance, synaptogenesis, myelination and the generation of axon potentials 
(Maness and Schachner, 2007, Shimoda and Watanabe, 2009). However, 
recent evidence suggested that they might also be involved in controlling earlier, 
mitotic events (Bizzoca et al., 2003, Hu et al., 2003, Ma et al., 2008, Xenaki et 
al., 2011) and indeed L1-CNTNs have been implicated in a number of cancers 
(Katidou et al., 2008). 
The work of Xenaki et al (2011) showed that F3/contactin (hereafter referred to 
as F3) antagonises TAG-1, also a CNTN-like molecule, to suppress SHH-
induced proliferation of GNPs. F3 binds to NRCAM, an L1-like member of the 
family, on the GNP cell surface and SHH-induced proliferation of NRCAM 
knockout GNPs fails to be inhibited by F3, suggesting that NRCAM is the 
receptor mediating F3 inhibition. However, the mechanism underlying this 
inhibition is not understood.  
In this thesis, I have investigated how NRCAM controls SHH-induced 
proliferation of GNPs. Since mis-regulation of GNP proliferation resulting from 
aberrant SHH signalling can result in medulloblastoma (MB), the most common 
malignant brain tumor in children and young adults (Behesti and Marino, 2009), 
this study not only sheds light on the control of GNP proliferation in normal 
cerebellar development, but may also be relevant to the process of MB 
tumorigenesis and perhaps offer a method of modulating SHH signalling by 
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identifying novel therapeutic targets for the treatment of MB. 
 
1.2 Cerebellum 
The cerebellum has served as an excellent model system for studying cell 
proliferation and differentiation in the brain, as it largely develops post-natally, it 
has a relatively small number of cell types and a simple basic structure (Altman 
and Bayer, 1997). Moreover, the anatomical organisation of cerebellar cortex is 
well characterised and all cell types and the neuronal circuits have been studied 
extensively (Hatten and Heintz, 1995, Goldowitz and Hamre, 1998). For these 
reasons, the cerebellum is used as a model for this study.  
1.2.1 Cerebellar structure, functions and circuits 
The cerebellum is located on the dorsal part of the brainstem. Its structure is 
composed of the deep cerebellar nuclei in a central core of white matter and a 
large cortical region, which contains several cell types such as Purkinje neurons, 
Bergmann glial cells (BG), granule neurons (GN). After the cerebellum is fully 
developed, there are three layers in the surface gray matter of the adult 
cerebellum. As shown in figure 1.1, the most superficial layer is the molecular 
layer (ML), which consists of the axons of granule cells, known as parallel fibers, 
and dendrites of Purkinje cells. The middle layer, the Purkinje cell layer (PCL), is 
made up of the large cell bodies of Purkinje cells and Bergmann glia. The 
deepest layer, the granular layer, consists primarily of the cell bodies of granule 
neurons, very small neurons, which are also the most numerous in the brain 
(Altman and Bayer, 1997). 
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Figure 1.1. Three layers in the surface gray matter of the cerebellum. 
Molecular layer, Purkinje cell layer and Granule cell layer (modified from (Dale 
Purves, 2001). 
 
Previously, it was thought that the major functional roles of the cerebellum are 
only coordination, maintenance of equilibrium and regulation of muscle tone. 
More recently it is evident that the cerebellum functions in motor learning 
processes, through which it can adapt and finely adjust motor programs in order 
to perform correct and precise movements via an error-driven induction of long-
term depression (LTD) (Ito, 1998, Yeo and Hesslow, 1998, Ito, 2000). 
The cerebellar circuitry integrates data among neurons inside and outside the 
cerebellum such as inferior olive, pontine nuclei (from cerebral cortex), spinal 
cord, vestibular system and thalamus. The functional integration of signals is 
mainly mediated by two types of neurons, Purkinje cells and granule neurons 
(Altman and Bayer, 1997). Purkinje cell axons constitute the main output 
projections from the cerebellum and cerebellar granule neurons control this 
cerebellar output by regulating Purkinje cell activity. Mice that lack cerebellar 
granule cells exhibit severe ataxia indicating the crucial function of these cells 
(Kofuji et al., 1996, Hamre and Goldowitz, 1997, Mullen et al., 1997).  
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As shown in Fig 1.2, axons from granule neurons ascend towards the cortical 
surface and then bifurcate to form T-shaped branches in the ML, forming parallel 
fibres. The parallel fibres relay information via synapses on the dendrites of the 
Purkinje neurons, as well as exciting the Golgi, stellate, and basket neurons, 
which here are grouped and called inhibitory interneurons. These latter also 
synapse on Purkinje neurons, which thus receive excitatory input from the 
parallel fibres and from climbing fibres from the inferior olive, and inhibitory input 
from the inhibitory interneurons. The granule neurons themselves receive an 
excitatory input from the axons extending from pontine nuclei, called mossy 
fibres. The deep cerebellar nuclei also receive excitatory synapse from the 
mossy fibres as well as the excitatory input from climbing fibres. However, they 
also receive inhibitory input from axons extended from Purkinje neurons. In the 
same time, the deep cerebellar nuclei provide an inhibitory feedback to the 
inferior olive. This complex interaction of inhibitory and excitatory inputs allows 
the cerebellum to perform its core function of LTD-mediated error correction to 
refine motor performance 
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Figure 1.2. The cerebellar circuitry. Purkinje neurons, GABAergic neurons 
located in the Purkinje cell layer, exert an inhibitory input on the deep cerebellar 
nuclei, whereas the Purkinje neurons themselves receive inhibitory input from 
the inhibitory interneurons. However, they are stimulated by excitatory input from 
both climbing fibres from inferior olive and parallel fibres, bifurcated axons from 
the granule neurons. Although the granule neurons receive excitatory input from 
mossy fibres, axons from the pontine nuclei, they are also inhibited by inhibitory 
interneurons. The mossy fibres as well as climbing fibres send signal stimulating 
the deep cerebellar nuclei; at the same time, the deep cerebellar nuclei give rise 
axons to send the inhibitory input to the inferior olive (modified from (Ito, 2002)).  
 
1.2.2 Cerebellar development 
During cerebellar development cells arise from two different regions. The first 
area is the ventricular zone, from which the cells of the deep cerebellar nuclei, 
the Purkinje neurons, and stellate, basket and Golgi interneurons all arise. The 
second region is a diamond-like structure between the 4th ventricle and the 
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neural tube called rhombic lip, where the progenitors of cerebellar granule 
neurons are born. As this study focuses on the proliferation of GNPs, this 
introduction highlights mainly the development of GNPs in the cerebellum, 
which, along with the progenitors of the neurons of the lateral pontine nuclei, 
arise from the rostral (or cerebellar) rhombic lip (fig 1.3); cells of the medial 
pontine, the reticulotegmental, lateral reticular, external cuneat and inferior olive 
nuclei all derive from the caudal rhombic lip (Wingate, 2001). 
In early development of cerebellum (from mid-gestation in the mouse), GNPs 
arise from the rostral rhombic lip and migrate tangentially over the dorsal surface 
of the rostral hindbrain (Hatten and Heintz, 1995) to form the external germinal 
layer (EGL). Because GNPs continue to proliferate into the early postnatal 
period, the thickness of EGL increases considerably. After the final mitotic 
division, there is also lateral tangential migration of post-mitotic granule neurons 
within 20-48 hours while they remain in EGL (Komuro et al., 2001, Yacubova 
and Komuro, 2003, Kumada et al., 2009). Then, the migratory direction of 
granule neurons turns to radial migration to form the internal granule layer (IGL) 
(figure 1.3). In this process, BG provides radial glial fibers through the ML, which 
direct the majority of the migrating neurons to the IGL. Meanwhile, the granule 
cells give rise to axons that bifurcate in the molecular layer and these T-shaped 
axons extend long distance to synapse on the dendrites of Purkinje cells. 
However, the cell bodies of granule cells continue to migrate past the PCL until 
they reach into the IGL. 
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Figure 1.3. The development of granule neurons until early period in mice. 
(A) The formation of EGL from the rhombic lip. Schematic sagittal section of 
developing embryonic cerebellum shows the migration paths of GNPs from the 
rhombic lip over the surface of anlage to form the external granular layer (EGL). 
The GNPs then massively expand until early postnatal period. (B) The postnatal 
radial migration of post-mitotic granule neurons. After birth, the GNPs still 
extensively proliferate within EGL. Whenever they exit cell cycle, the 
appearance of their cell bodies changes from horizontal to vertical in order to 
migrate again along the radial fibers of Bergmann glia (BG) though molecular 
layer (ML) to form the internal granular layer (IGL) (modified from (Wang and 
Zoghbi, 2001, Marques and Fan, 2002).  
 
A substantial amount is now known about how the proliferation and 
differentiation of GNPs is controlled (Behesti and Marino, 2009).  Although, there 
are many signalling pathways known to regulate GNP production and 
proliferation, including FGF (Gao et al., 1991, Tao et al., 1996, Wechsler-Reya 
and Scott, 1999), BMPs (Alder et al., 1999, Rios et al., 2004, Machold et al., 
2007), Notch (Solecki et al., 2001), IGF (Ye et al., 1996, Lin and Bulleit, 1997), 
WNT, (Anne et al., 2013), a key player in this process is the secreted factor 
Sonic hedgehog (SHH), which is made by Purkinje cells and drives the 
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proliferation of GNPs in the EGL (Dahmane and Ruiz i Altaba, 1999, Wallace, 
1999, Wechsler-Reya and Scott, 1999, Lewis et al., 2004, Corrales et al., 2004, 
Corrales et al., 2006). Dysregulation of this pathway can cause the cerebellar 
tumor, medulloblastoma (MB), for example through mutation of the SHH 
receptors Patched (Ptch1) and Smoothened (Smo) (Goodrich et al., 1997, Oro 
et al., 1997, Xie et al., 1998). MB is the most common malignant brain tumor in 
children and young adults (Fan and Eberhart, 2008). Below I first briefly review 
the clinical classification of MB and introduce how a substantial proportion of MB 
involves dysfunction of the SHH pathway. Then I go on to consider in more 
detail the involvement of the Hedgehog (HH) signalling pathway in normal 
cerebellar morphogenesis and how this may relate to MB. 
 
1.3 Medulloblastoma 
Medulloblastoma (MB) is the most common pediatric malignant brain tumor 
(Chintagumpala et al., 2001), with origins in the cerebellum. According to the 
Surveillance, Epidemiology and End Results (SEER) database, MB affects 
1:150,000 children (Smoll and Drummond, 2012) and this accounts for 
approximately 20% of all pediatric central nervous system tumors (Dhall, 2009). 
MB is thought to be caused by deregulation of neural cerebellar precursor cell 
proliferation. Since the main focus of this thesis is to investigate the mechanism 
of how L1-CNTNs modulate the SHH signalling, which is the key pathway of 
driving GNP proliferation, findings from this study may be applied to new 
treatments of MB to specifically regulate the SHH signalling in the future. 
Therefore, here I briefly introduce a clinical perspective of MB, which includes 
the current treatment of MB and the signaling pathways thought to contribute to 
MB tumorigenesis.  
1.3.1 Clinical aspect 
According to the 2007 WHO classification of the tumors of the central nervous 
system, MB are sub-classified onto 5 histologic types (Giangaspero et al., 2007): 
(1) classic MB which is characterised by the presence of small cells with small 
round nuclei, which are are arranged in layers or sheets, (2) 
desmoplastic/nodular MB which is defined by small mitotic cells and in which the 
nodules of tumour cells are surrounded by collagen rich tissue (Gilbertson, 
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2004). It has been shown that the desmoplastic MB is linked to the SHH 
signalling aberration (Pietsch et al., 1997, Wolter et al., 1997), (3) MB with 
extensive nodularity (MBEN), (4) anaplastic MB which the tumor cells are large 
and they are not differentiated and (5) large cell MB which the tumor cells are 
relatively high ratio of cytoplasm to nuclei. 
MB is also molecularly sub-classified into four subtypes (Taylor et al., 2012, Kool 
et al., 2012) as follow: 
(1) Subtype 1: MB with aberration of the WNT signalling pathway which 
accounts for 10-15% of MB (Li et al., 2013): this subtype is characterized by the 
gene expression signature of WNT signalling and beta-catenin nuclear staining. 
It is usually classified as the classic MB on the basis of histological examination. 
(2) Subtype 2: MB with the aberration of SHH signalling pathway, which 
accounts for 25-30% of MB (Li et al., 2013): this subtype is characterised by 
frequent deletion of chromosome 9q, desmoplastic/nodular histology and SHH 
pathway gene mutations, such as Ptch1, Smo and SuFu. The tumor is thought 
to arise from the EGL of the cerebellum. The SHH subset normally occurs in 
children younger than 3 years and also in adolescents and adults.  
(3) Subset 3 (Group 3): This subtype appears histologically as classic MB or 
large cell MB or anaplastic MB. A variety of mutations are present in this 
subtype, including the presence of 17q isochromosome (i17q, in which the short 
arm of chr 17 is lost and the long arm duplicated), which is a negative prognostic 
factor in the disease. Subset 3 occurs throughout childhood and also in infants. 
(4) Subset 4 (Group 4): This subset shows molecularly a CDK6 amplification 
and MYCN amplification, and it may also present with i17q. The histology of the 
subset 4 is classic MB, large cell MB or anaplastic MB. The subset 4 tumour is 
observed from infancy into childhood and adulthood. 
As this study is focused on SHH signalling, which is important for the GNP 
proliferation during the cerebellar development, the findings from this study may 
be useful and implicated in the desmoplastic MB/Subtype 2. Below, I review how 
the SHH pathway is implicated in medulloblastic transformation and 
pathogenesis 
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It has been shown that mutation of the genes encoding the key proteins of SHH 
pathway (PTCH, SUFU and SMO; see below for a detailed description of the 
pathway) results in 25% of sporadic human MB (Zurawel et al., 2000). 
Moreover, a number of studies in mouse have shown that activation of the SHH 
pathway causes MB: the classic example is the development of MB in Patched 
heterozygotes (Ptch+/-). PTCH is a negative regulator of the pathway (see 
below); although Ptch null (Ptch-/-) mice die during embryonic stages, Ptch+/- 
mice are viable but develop MB from around 5 weeks after birth and 
approximately 30% of Ptch+/- mice developed MB within the 12-25 weeks of age 
(Goodrich et al., 1997). This mimics the human condition known as Gorlin (or 
nevoid basal cell carcinoma) syndrome, suffers of which also develop a variety 
of generalised overgrowth problems, MB and rhabdomyosarcoma, many of 
which have also been found in Ptch+/- mice and can be related to increased SHH 
signalling (Hahn et al 1998).  
Similar to the Ptch-/- mouse, Sufu-/- mice are also early embryonic lethal around 
E10 due to failures of neural tube closure and heart defects. Although the MB 
formation is not frequent in Sufu+/- mice, it is present in 58% of Sufu+/- p53-/- mice, 
whereas this is not observed in p53-/- mice alone (Lee et al., 2007). Moreover, 
94% of homozygous transgenic mice, which express the constitutive active form 
of Smo (SmoA1), shows MB formation within 2 months after birth (Hatton et al., 
2008). Taken together, the studies clearly demonstrate that aberration of SHH 
pathway regulation contribute to MB tumorigenesis. 
Similar to the other brain cancers, MB treatment commonly involves surgery, 
chemotherapy and radiotherapy. Although advances in the current treatment of 
MB can cure patients, leading to a five year overall survival about 70%-90% with 
standard to high risk patients (Carlotti et al., 2008), the majority of the surviving 
children still suffer from the long-term neurocognitive and neuroendocrine 
complications due to the side-effects of the therapy (Mulhern et al., 2005, Ribi et 
al., 2005), as well as other long term consequences, resulting from the 
cytotoxicity and lack of specificity of the treatment (Marino, 2005). Therefore, 
better understanding of aberrant signalling pathway involving in MB 
pathogenesis and how to regulate the signalling would provide potential 
pharmaceutical target treatment or new perspectives of therapeutic development 
of the MB in the future.  
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1.4 Hedgehog signalling 
The hedgehog (hh) gene was originally discovered as a regulator of body 
segment polarity in Drosophila melanogaster (Nusslein-Volhard and Wieschaus, 
1980). This gene was found later to encode a lipid-modified secreted signalling 
molecule, Hedgehog (HH), which plays a crucial role by acting as a local 
mediator in many developmental processes in vertebrates. The HH signalling 
pathway has been studied extensively particularly in embryogenesis (Ingham 
and Placzek, 2006). Abnormal regulation in the HH pathway can lead to organ 
malformation or even lethality and cancer such as basal cell carcinoma, MB 
(McMahon et al., 2003, Nieuwenhuis and Hui, 2005).  
Although there is only 1 hh gene in Drosophila, there are 3 mammalian Hh 
genes encoding similar secreted proteins: Sonic Hedgehog (SHH), Indian 
Hedgehog (IHH) and Desert Hedgehog (DHH). DHH plays an important role in 
spermatogenesis (Bitgood et al., 1996), whereas IHH controls endochondral 
ossification (Vortkamp et al., 1996) and also regulates blood island angiogenesis 
(Byrd et al., 2002). Among these ligands, SHH is the most extensively studied 
(Gilbert, 2000) and it is involved in development of left-right axis as well as 
regulation of the ventral cell fate in the central nervous system. Moreover, it 
plays a vital role in specification of anteroposterior axis of the limb development 
and morphogenesis of various organs, including eye development (McMahon et 
al., 2003). Abnormal regulation of the level of HH signalling, including complete 
loss of SHH (Chiang et al., 1996) is associated with variety of defects during the 
development including cyclopia, defective axial patterning and limb 
abnormalities. Complete loss of SHH is embryonic lethal (Chiang et al., 1996). 
1.4.1 Lipid modifications and release of HH from producing cells to target 
cells 
The HH protein undergoes various processing steps before it can function. As 
shown in fig 1.4 (a HH secreting cell is on the left), HH is produced as a 45kDa 
precursor protein, followed by the post-translational modification. First, the HH 
precursor protein is autocatalytically cleaved, resulting in a 20kDa N-terminal 
domain (HH-N) and 25kDa C-terminal domain. After autocatalytic cleavage, 
cholesterol is added to the carboxyl end of HH-N, followed by addition of 
palmitate to the N-terminal. This mature HH is then released to the secretory 
pathway via Dispatched (Disp), a 12-transmembrane protein that works as a HH 
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transporter. 
 
Figure 1.4. Hedgehog protein production and signal transduction. In HH-
secreting cell (left), full-length HH is autocatalytically cleaved to yield an N-
terminal fragment (HH-N), which is modified by cholesterylation. After 
palmitoylation, Dispatched (Disp) mediates the secretion of a mature HH-N. In 
Drosophila, when HH is released to the cell receiving HH (middle), it binds to its 
receptor, Patched (PTCH). This binding relieves PTCH inhibition of Smoothened 
(SMO), leading to the accumulation of SMO on the cell surface and the 
downstream pathway can be activated via CIA, resulting in the transcription of 
HH target genes. In the absence of HH (right), SMO activation is blocked by 
PTCH, resulting in the phosphorylation of full-length CI (CI) to repressor form 
(CIR), which prevents the transcription of HH target genes in the nucleus. The 
diagram is adapted from (Nieuwenhuis and Hui, 2005, Goetz and Anderson, 
2010)  
 
1.4.2 Principles of HH signal transduction 
The HH pathway in Drosophila is much simpler than that in the mammals. In 
Drosophila, there is only one Patched (PTCH) protein, which is a 12-
transmembrane HH receptor. In the absence of HH, PTCH represses the 
activation of Smoothened (SMO), a 7-transmembrane receptor (Figure 1.4, 
right). Although it has been shown that the subcellular localisation of SMO is 
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affected in HH-stimulated cells in Drosophila salivary gland (Zhu et al., 2003), 
how exactly SMO is repressed by PTCH in unstimulated cells remains unclear. 
A full-length zinc-finger transcription factor Cubitus interruptus (Ci), which 
normally forms a microtubule-associated complex with kinesin-like protein 
Costal-2 (Cos2), Fused (Fu) and Suppressor of fused (SuFu), is phosphorylated 
by multiple protein kinases, including Protein kinase A (PKA), Casein kinase I 
(CKI) and Glycogen synthase kinase 3β (GSK3β), resulting in a subsequent 
cleavage to truncated repressor form (CiR), which inhibits HH target genes. Cos-
2 acts as a scaffold to bind Ci and the protein kinases, whereas, SuFu inhibits 
the nuclear translocation of the full-length Ci. The HH signalling occurs when the 
HH protein binds PTCH, which relieves the SMO repression (Figure 1.4, 
middle), allowing SMO to accumulate on the cell surface and disrupt the 
phosphorylation of the full-length Ci and subsequent cleavage to the repressor 
form, CiR by dissociating Cos-2/Ci/kinase complexes. Fu antagonises the 
inhibition of SuFu, when a high level of HH is present to convert the full-length Ci 
to become a transcriptional activator (CiA), which can activate HH target genes.  
The binding of HH to PTCH results in the removal of PTCH from the cell surface 
by dynamin-dependent endocytosis and its accumulation in intracellular vesicles 
with subsequent degradation in lysosomes (Incardona et al., 2000, Martin et al., 
2001). However, it has been suggested that the HH signal transduction does not 
require the internalisation of HH-PTCH complex (Torroja et al., 2004). Instead, 
the internalisation and degradation of HH-PTCH complex may be required to 
limit HH availability which may play a role in the formation of HH gradients 
(Chen and Struhl, 1996, Torroja et al., 2004), 
In mammals, there are 2 HH receptors, PTCH1 and PTCH2. Although, there are 
three HH proteins in mammals, they bind both receptors with similar affinity 
(Carpenter et al., 1998). However, PTCH2 is expressed at high level in the testis 
and the signal is mediated by DHH (Carpenter et al., 1998). As in Drosophila, 
however, there is only one vertebrate SMO which is implicated in all HH 
signalling (Zhang et al., 2001, Chen et al., 2001). The Kinesin proteins, KIF7 and 
KIF27 are vertebrate homologue proteins of Cos-2 protein in fly (Tay et al., 
2005, Katoh and Katoh, 2004), and they act as positive and negative regulators 
of HH signalling pathway (Endoh-Yamagami et al., 2009, Liem et al., 2009, 
Cheung et al., 2009, Tay et al., 2005). The Ci homologs in mammals are the GLI 
family transcription factors GLI1, GLI2 and GLI3. GLI1 acts as a transcriptional 
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activator, while GLI3 plays a repressor role. Critically, however, GLI2 can act as 
either transcriptional activator or repressor, which is an essential part of the 
signalling pathway (see below). 
1.4.3 Mammalian SHH signalling and primary cilia 
In the last ten years or so, it has been shown that the activity of the mammalian 
SHH signalling pathway requires tiny subcellular structures known as primary 
cilia for its function (Huangfu et al., 2003, Corbit et al., 2005, Huangfu and 
Anderson, 2005, Rohatgi et al., 2007, Han et al., 2008, Spassky et al., 2008) 
(Figure 1.5). Several essential components in the transduction of SHH signalling 
have been detected in the primary cilia including PTCH1, SMO and the GLIs 
(Corbit et al., 2005, Haycraft et al., 2005, Huangfu and Anderson, 2006). 
 
 
Figure 1.5. SHH signalling in primary cilia. In vertebrates, the primary cilium 
is required for SHH signalling. In the absence of SHH, PTCH1 localises in the 
primary cilium and this inhibits SMO ciliary localisation. The GLI accumulation in 
the cilium is blocked by the localisation of KIF7 at the base of the primary cilium, 
resulting in the production of the repressor form of GLI (GLIR). In the presence of 
SHH, SHH binds to PTCH1 and the complex translocates out of the cilium. This 
allows SMO entry to the cilium. KIF7 localises at the tip of the cilium, leading to 
the accumulation of GLI at the cilia tip. The function of SUFU is inhibited by 
KIF7, which now localises at the tip of cilia. The activator form of GLIs is 
promoted resulting in the transcription of SHH target genes. 
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However, the localization of SMO to cilia normally is dependent on the presence 
of SHH. In its absence, PTCH1 in some way normally prevents SMO 
translocation, although SMO ciliary translocation can occur without PTCH 
removal when using SMO-agonists, such as SAG (Rohatgi et al., 2007). As SHH 
binds to PTCH1, translocation of PTCH1 out of primary cilia occurs (Rohatgi et 
al., 2007). This allows SMO localisation to primary cilia and causes the 
activation of the GLI family of transcription factors (Ingham, 1998). SMO 
stimulates the activation of GLI2 and prevents GLI3 repressor formation, 
resulting in SHH target gene expression (Corbit et al., 2005). Exactly how the 
translocation of PTCH1 and SMO is controlled, however, is not well understood. 
The signalling of HH through the primary cilium appears to be important in most 
circumstances when HH signals in vertebrates (Goetz and Anderson, 2010), 
however, the way in which HH signals differs considerably according to the 
cellular context. Below, I will highlight the different functions of HH that relate to 
this study.  
1.4.4 Multiple roles of HH signalling  
Classically, The HH proteins functions as morphogens in regulating various 
developmental processes of both invertebrate and vertebrate. However, in other 
circumstances, it appears to act as a mitogen, driving proliferation (Ho and 
Scott, 2002). Moreover, it also may be involved in directing axon growth or 
directing cell migration (Marti and Bovolenta, 2002, Fu et al., 2004). Differences 
in the way it acts in some of these latter circumstances may be attributed to 
signalling outside of the cilium (Bijlsma et al., 2012). However, the core 
mechanism, involving PTCH and SMO translocations in primary cilia, seems to 
be acting both when SHH works as a morphogen and as a mitogen. Therefore, 
in this section I will focus on only the morphogenic and mitogenic functions of 
HH.  
1.4.4.1 Morphogenic and mitogenic functions of HH 
1.4.4.1.1 HH functions as a morphohen 
The idea of how a signal gradient can give rise to order cell fates in a 
tissue was introduced in 1969 and explained in the form of the ‘French flag 
model’ (Wolpert, 1969, Wolpert, 1996). As shown in Fig. 1.6, the French flag 
colors: blue, white, red represent different cell states affected by the different 
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signal gradient concentrations. The secreted signal is released from the source 
towards the target tissue, and so generates a signalling gradient. The different 
concentrations of signal affect the cells locating at the different positions of the 
tissue by turning on the different sets of target genes. A signal that functions in 
this way is called a morphogen. The two characteristics of the morphogen are 
defined: the signal has to act in a concentration-dependent manner to stimulate 
different responses at different thresholds, and that signal has to propagate 
toward a target tissue to affect over a long range from the source of its signal 
(Briscoe, 2009). 
 
Fig. 1.6. The French flag model. The signal is released from the source (S) 
and propagated through the tissue, resulting in different concentrations of signal. 
The signal gradient affects differently on the cells locating at different distance 
from the source of the signal, inducing distinct cell fates (A, B, C) from specific 
concentration thresholds (blue, white, and red) (adapted from (Wolpert, 1969).  
 
Below, I will review two examples of the morphogenic function of HH in 
invertebrates and vertebrates, which are in the wing disc of Drosophila and in 
the neural tube of vertebrates. 
Morphogenic role of HH in Drosophila wing imaginal disc 
Although, HH was first shown to act as a morphogen in the epidermis of the 
developing Drosophila embryo (Heemskerk and DiNardo, 1994), its 
morphogenic role is perhaps better illustrated in the patterning of the wing 
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imaginal disc, from which the fly wing is derived (Strigini and Cohen, 1999). In 
Drosophila wing imaginal disc, HH is produced by the cells in posterior 
compartment of the disc and it locally induces gene expression of the anterior 
compartment cells to pattern the anterior wing region adjacent compartment 
boundary (Fig 1.7). Moreover, HH functions distantly by inducing the expression 
of the BMP family morphogen, Decapentaplegic (Dpp). Dpp diffusing to both 
anterior and posterior compartments of imaginal disc plays a role in regulating 
the growth and patterning of the whole wing (Fig. 1.7). The different levels of HH 
expression activate different gene targets. It has been shown that dpp 
expression is activated by the low level of HH, whereas the activation of Patched 
(ptch) is stimulated by the high level of HH (Jiang and Hui, 2008). Thus, in 
invertebrates, HH can act as a morphogen eliciting different cellular responses 
according to its concentration. 
 
 
 
Figure 1.7. Signal gradient plays a role in patterning the Drosophila wing 
imaginal disc. The HH is secreted from the anteroposterior boundary of the 
Drosophila wing imaginal disc and stimulates Dpp (red), which spreads 
anteriorly and posteriorly (red arrow) to pattern the anterior and posterior 
compartments. The HH itself (green) spreads anteriorly (green arrow) and 
functions in patterning the anterior compartment (Left). Developed Drosophila 
wing shows the regions formed from the anterior (top) and posterior (bottom) 
compartments, and the regions affected by HH (green, between wing veins 3 
and 4) and Dpp (red arrows) (Right) (adapted from (Varjosalo and Taipale, 
2008). 
Morphogenic role of SHH in neural development 
Among those HH proteins in vertebrates, SHH has been shown to be the most 
broadly expressed mammalian HH signalling molecule. It plays a pivotal role in 
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regulating cell proliferation and differentiation in various types of tissue (Ingham 
and McMahon, 2001, McMahon et al., 2003). In nervous system as well as the 
other systems, it functions as a morphogen. SHH plays a role in patterning and 
cell fate specification in developing neural tube as well as in patterning of limbs. 
Here, I highlight only the morphogenic role of SHH signalling in neural tube 
development.  
During ventral spinal cord patterning of vertebrate embryos, SHH is secreted 
from notochord and floor plate at the ventral midline of neural tube and it 
regulates the neuronal cell specification in a concentration-dependent manner 
by generating a ventral-to-dorsal gradient to indicate the cell fate of neuronal 
progenitors at different locations in the dorsal-ventral axis. As shown in Fig. 1.8, 
an increase in the concentration of SHH determines the generation of distinct 
neuronal subtypes; interneurons (V0-V3) and motor neuron (MN) (Ingham and 
McMahon, 2001). Precisely how these different cell types are induced according 
to the SHH concentration remains unclear, but current models suggest that a 
gradient of GLI activity is set up by the amount and duration of SHH signal which 
in turn determines when and where genes are activated (Balaskas et al., 2012). 
 
 
Figure 1.8. SHH gradient in the early neural tube development. SHH is 
expressed at the notochord and floor plate of the neural tube and spreads from 
ventral to dorsal, forming a SHH gradient to regulate the cell fate of neuronal 
subtypes; interneurons (V0-V3) and motor neuron (MN) (adapted from (Briscoe, 
2009)).   
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1.4.4.1.2 HH functions as a mitogen 
In contrast to the morphogenic role of SHH in neural development, SHH acts 
apparently as a mitogen in cerebellum. During cerebellar development, it is 
required for the proliferation of GNPs (Wechsler-Reya and Scott, 1999, Wallace, 
1999, Dahmane and Ruiz i Altaba, 1999). 
Mitogenic role of SHH in in cerebellum 
In the cerebellum, SHH stimulates an increase in the number of dividing granule 
neurons (Dahmane and Ruiz i Altaba, 1999, Wallace, 1999, Wechsler-Reya and 
Scott, 1999) and loss of SHH in Purkinje cells leads to a failure of the granule 
cells layer to expand normally and a severe reduction in cerebellar size (Lewis 
et al., 2004). SHH is therefore an essential mitogen in growth of the cerebellar 
cortex.  
 
 
Figure 1.9. Role of SHH in cerebellar growth. Schematic representation of the 
mouse cerebellum in the first postnatal week, showing the position of neurons 
and glia in the cerebellar cortex. SHH is secreted and spreads towards the EGL, 
consequentially promoting the proliferation of GNPs in the EGL (modified from 
(Ruiz i Altaba et al., 2002). 
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As shown in figure 1.9, SHH is secreted in the Purkinje cell layer of cerebellum 
and it spreads upwards and causes proliferation of granule neurons. 
Interestingly, GNPs closest to where SHH presumably is secreted (ie those in 
the inner EGL; iEGL) proliferate less than GNPs in outer EGL (oEGL); indeed 
the iEGL is where GNPs become post-mitotic (Miyazawa et al., 2000). Even so, 
it is clear that SHH target genes are activated, even in the iEGL, where Ptch1 
expression is highest (Lewis et al., 2004), although activation of other SHH 
targets, notably Gli1, is greatest in the outer layers (Corrales et al., 2004). A key 
question that arises here, therefore, is how SHH activity is spatially restricted in 
cerebellar morphogenesis, and whether the response to SHH is solely 
mitogenic. One obvious possibility is that other molecules may modulate SHH 
signalling, either simply attenuating the mitogenic response to allow 
differentiation, or perhaps even qualitatively changing the signal to drive different 
responses in different contexts. 
To investigate the response of SHH signalling, based on proliferation response, 
as a readout is too far from the SHH signalling. Gli1 and Ptch1 are normally 
used as readouts of the SHH response (Wechsler-Reya and Scott, 1999, 
Humke et al., 2010, Hillman et al., 2011). Moreover, Nmyc and CyclinD1 are 
downstream gene targets of the SHH signal. It has been shown that Nmyc and 
CyclinD1 are direct targets of SHH signalling (Oliver et al., 2003, Kenney et al., 
2003, Martinez et al., 2013). Nmyc and CyclinD1 are expressed in proliferating 
GNPs of the developing cerebellum and upregulation of Nymc, resulting in the 
promotion of GNP proliferation following SHH stimulation (Kenney et al., 2003).  
Apparently, SHH does not play a morphogenic role to determine the cell fate 
specific in the cerebellum. Therefore, this raises the question of whether this is 
fundamentally different between morphogenic and mitogenic effects and how 
the signalling mechanisms are different. Although, SHH plays a distinct 
mitogenic role in the cerebellum, it is not known how morphogenic and 
mitogenic effects are related from one system to another system. One of the 
possible explanations is that the SHH signalling interacts with other molecules, 
which alters the signal from a concentration-dependent morphogen to a simple 
on-off mitogen. 
1.4.5 Modulation of SHH signalling during the development of GNPs 
1.4.5.1 Modulation of SHH signalling by other signals and molecules 
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Several signals have been suggested to control GNP proliferation in response to 
SHH. Bone Morphogenetic Protein 2 (BMP2) has been shown to turn SHH-
mediated proliferative response of GNPs into the differentiation of the granule 
neurons. Moreover, BMP2 treated GNPs demonstrate the down-regulation of 
SHH pathway gene components, such as SMO, GLI1 (Rios et al., 2004).  
Although it is clear that BMP signalling has a major role in antagonising SHH-
induced proliferation, it is not clear that BMP is the signal that initiates cell cycle 
exit. Although it can induce differentiation in culture, in vivo phospho-Smad – the 
readout of BMP2/4 signalling, does not appear in granule cells until they reach 
the Purkinje cell layer (Rios et al., 2004), by which time they are already post-
mitotic. This suggested that even though BMP signalling is playing an important 
role in inducing GNP differentiation, other signals are likely to be involved.  
In contrast to the effect of BMP2 on the SHH-induced proliferative response of 
SHH signalling on GNPs, Fernandez et al. (2010) proposed that Insulin-like 
Growth Factor 1 and 2 (IGF1 and IGF2) modulate SHH signalling by reinforcing 
the effect of SHH on inducing GNP proliferation. However the complete picture 
of such modulation, particularly in vivo has not been elucidated (Fernandez et 
al., 2010). 
1.4.5.2 Modulation of SHH signalling by cell contacts  
On the other hand, it has been known for some time that cell contact influences 
granule cell proliferation and differentiation (Gao et al., 1991, Baptista et al., 
1994). Contacts mediated by Notch interactions with Delta-like ligands appear to 
stimulate GNP proliferation (Solecki et al., 2001). Adhesive contacts with 
extracellular matrix (ECM) proteins also appear to modulate GNP proliferation. 
On the one hand, laminin (LN) is expressed in the meningeal layer and 
potentiates SHH-induced proliferation (Blaess et al., 2004). Since LN binds SHH 
directly, this may be one way that its activity is localised in the EGL, but this 
does not explain what causes cell cycle exit in the iEGL. On the other hand, 
vitronectin (VN) is found in the iEGL and regulates SHH activity in vitro by 
turning proliferation to differentiation (Pons et al., 2001). However, cerebellar 
development is not affected by VN loss (Zheng et al., 1995), and the VN 
receptor, integrin αvβ3, is apparently not expressed until the cells are already 
post-mitotic (Pons et al., 2001) 
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In contrast, adhesion molecules (CAMs) of the related L1 and contactin families 
(L1-CNTNs) are expressed throughout the EGL and have been shown to affect 
GNP proliferation when mis-expressed in the cerebellum (Bizzoca et al., 2003). 
The properties of this family are discussed in greater details as follow. 
 
1.5 L1-CNTNs 
1.5.1 L1-CNTN structures  
The L1-CNTNs are members of the immunoglobulin protein superfamily, and are 
part of a subfamily characterised by the presence of both Ig domains and 
fibronectin type III (FNIII) domains. Although this family includes an array of cell 
surface receptors, many of which are associated with neural development - such 
as Deleted in Colorectal Cancer (DCC), a Netrin receptor and Roundabout 
(Robo), a Slit receptor - the L1-CNTNs are a clearly related sub-group defined 
by a similar topology that suggests they arose by gene duplication 
(Brummendorf and Lemmon, 2001). They are further divided into the L1-like 
family, whose members are type1 transmembrane proteins and the CNTN-like 
family, whose members are anchored to the cell surface by 
glycosphosphoinositol (GPI) linkages (Brummendorf and Rathjen, 1995). As 
shown in Fig. 1.10, the transmembrane L1 family consists of L1 cell adhesion 
molecule (L1/L1CAM), neuronal cell adhesion molecule (NRCAM), cell adhesion 
molecule L1-like (CHL1) and neurofascin (NFASC). Except for NFASC, they all 
contain 6 Ig and 5 FNIII domains, connecting with an intracellular domain to 
transduce the intracellular signalling. The intracellular domains of all four L1-like 
molecules are highly conserved and include binding sites for ankyrin, FERM 
proteins, Doublecortin and PDZ-containing proteins. In immature neurons, L1, 
NFASC and NRCAM also include an alternatively spliced exons which encodes 
a binding site for Adaptor Protein 2 (AP2), which is required for their endocytosis 
(Herron et al., 2009). 
The GPI-linked CNTN family comprises of contactin 1 (CNTN1 or F3), contactin 
2 (CNTN2 or TAG-1), contactin 3 (CNTN3 or BIG-1), contactin 4 (CNTN4 or 
BIG-2), contactin 5 (CNTN5 or NB-2) and contactin 6 (CNTN6 or NB-3) and they 
all contain 6 Ig domains and 4 FNIII domains, anchored to the cell membrane by 
the GPI. 
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Figure 1.10. L1-CNTN protein structures. Schematic representation of the 
protein structures of L1-like and CNTN-like families. 
 
Classically, L1-CNTNs play a role in broad range of processes such as cell 
migration, axon growth and guidance, myelination and synaptogenesis (Maness 
and Schachner, 2007). L1 and β1-Integrins together play a role in potentiating 
neuronal migration to extracellular matrix proteins (Thelen et al., 2002). In 
addition, it has been demonstrated that L1 as well as NRCAM functions in 
promoting axon guidance. The L1-deficient mice showed defective corticospinal 
axon guidance (Cohen et al., 1998). Similarly, NRCAM-deficient mice also 
showed an error of retinal axon guidance (Williams et al., 2006). Below, 
however, I will focus on more recent studies that implicate L1-CNTNs in the 
earlier stages of neuronal differentiation. 
1.5.2 L1-CNTNs and modulation of proliferation 
In contrast to the post-mitotic roles of L1-CNTNs mentioned above, recent 
evidence links them with the earlier events in neurogenesis. It has been shown 
that L1 is implicated in modulating cell proliferation. Substrate-coated L1 
decreases the neural precursor cell proliferation in a dose-dependent manner 
(Dihne et al., 2003). TAG-1 binds to Amyloid β precursor protein (APP). This 
interaction stimulates secretase-dependent cleavage of APP and subsequently 
releases C-terminal APP intracellular domain (AICD), resulting in the 
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suppression of neurogenesis (Ma et al., 2008). In contrast to the role of F3 in 
cerebellum, which decreases neurogenesis by suppressing GNP proliferation 
when mis-expressed on progenitors (Bizzoca et al., 2003), F3 mis-expression in 
the developing cortex increases the number of proliferating ventricular zone 
precursors of TAGF3 transgenic mice and stimulates the proliferation of primary 
forebrain cells from WT mouse embryo in vitro (Bizzoca et al., 2012). Although 
the mechanisms involved in these effects remain unclear, together they suggest 
that L1-CNTNs do not only function in post-mitotic events but also play a role in 
modulating neuronal progenitor cell proliferation. 
1.5.3 Expression of L1-CNTNs and their roles in cerebellar development 
Loss-of-function experiments also support a role for L1-CNTNs in the 
cerebellum: individually, loss of NRCAM, CHL1, NFASC or L1 does not 
dramatically affect the size or morphology of the cerebellum, although the L1 
and NRCAM single mutants show slight size reductions in specific lobules 
(Sakurai et al., 2001, Heyden et al., 2008, Zonta et al., 2011). However, loss of 
NRCAM and L1 together leads to a severe reduction of the size and defects in 
foliation of the cerebellum (Sakurai et al., 2001), which is not seen in the other 
mutant combination that have been tried (Heyden et al., 2008) and which 
strongly suggests that NRCAM and L1 have redundant functions in the growth of 
the cerebellum. Cerebellar development is also severely disrupted when F3, a 
ligand of both of these L1-like molecules, is lost, leading to ataxia and early 
postnatal death (Berglund et al., 1999). F3 is normally expressed on post-mitotic 
granule neurons in the iEGL and IGL (Xenaki et al., 2011); however, our group 
and collaborators have shown that ectopic expression of F3 on mitotic GNPs in 
transgenic mice leads to a transient, but substantial reduction in cerebellar size 
(Bizzoca et al., 2003). Although these previous studies suggested that these 
molecules had their effects on cerebellar development through a role in post-
mitotic events, recent experiments from our laboratory suggest these L1-CNTNs 
may have a role in the modulation of SHH signalling, which I will review below. 
1.5.4 L1-CNTNs and SHH signalling 
The observation that F3 mis-expression in the cerebellum transiently inhibits 
cerebellar growth (Bizzoca et al., 2003) led our laboratory to test whether 
purified F3 protein (made soluble by fusion to human immunoglobulin fc domain: 
F3-fc) can inhibit SHH-induced proliferation and promote differentiation of 
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purified GNPs in vitro (Xenaki et al., 2011). Interestingly, not only was F3-fc able 
to inhibit SHH-induced proliferation, but also this inhibition was antagonised by 
the simultaneous addition of TAG-1. TAG-1 is normally expressed in the iEGL, 
but is present on both mitotic and post-mitotic GNPs, though not on granule 
neurons in the IGL. Moreover, immunolabelling revealed that F3-fc and TAG-fc 
bind to, and co-localise with NRCAM on granule neurons (Xenaki et al., 2011), 
consistent with their known abilities to bind NRCAM directly (Brummendorf and 
Rathjen, 1995). Furthermore, F3-fc is unable to suppress proliferation of purified 
GNPs of NRCAM null mice. These results indicate that F3 requires NRCAM for 
its function and that TAG-1 can act antagonistically to F3 activity, suggesting 
that F3 and TAG-1 compete for NRCAM as a receptor (Xenaki et al., 2011).  
The question that arises is how F3, TAG-1 and NRCAM modulate SHH 
signalling. One possibility is that regulation of cell proliferation through NRCAM 
is completely independent of SHH signalling pathway (Fig. 1.11A). Another 
possibility is that NRCAM is in some way directly involved in the SHH signalling 
pathway (Fig. 1.11B).  
 
Figure 1.11 Possibilities of how F3 and NRCAM function in SHH pathway. 
(A) The first possibility: F3 and NRCAM act independently through some 
unknown pathway. (B) The second possibility: they function somewhere in SHH 
pathway. 
 
To address this, our laboratory preliminarily tested whether GNPs from 
transgenic SmoA1 mice, expressing a constitutively activate SMO protein 
(Hatton et al., 2008), were responsive to F3 protein in culture. As expected, 
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purified SmoA1 GNPs proliferated without addition of SHH, but this proliferation 
was not suppressed by F3 protein (Xenaki, unpublished data). To confirm this 
result, Smoothened Agonist (SAG), which is a chlorobenzothiophen-containing 
compound that is known to bind SMO and activate SHH signalling (Chen et al., 
2002), was used to stimulate WT GNPs. Our preliminary data (Xenaki, 
unpublished data) showed that, as expected, SAG can induce the proliferation of 
WT GNPs, however, F3-fc was not able to inhibit this proliferation even though it 
could inhibit SHH-induced proliferation in the same experiment (in agreement 
with previous results; (Xenaki et al., 2011)). The inability of F3-fc to inhibit either 
genetically (SmoA) or pharmacologically (SAG) activated SMO, strongly 
suggests that F3 and NRCAM may regulate the SHH signalling pathway 
upstream of SMO (Figure 1.11B).  
1.5.5 Role of L1-CNTNs in modulating the signal of other membrane 
receptor by endocytosis or trafficking  
These preliminary results lead to the interesting question of how exactly F3 and 
NRCAM might be involved in inhibiting SHH signalling in cerebellar granule 
neurons. As noted above, classically these molecules are regarded as adhesion 
molecules. However, a number of lines of evidence suggest that they have a 
role in the localisation of other proteins to particular parts of the membrane, 
either at the cell surface or intracellular. Of particular interest is their role in the 
formation and maintenance of the node of Ranvier (Salzer, 2003). NFASC and 
NRCAM, both L1-like CAMs, have been demonstrated to facilitate node 
formation by recruiting ankyrin G, a cytoskeletal scaffold protein, and hence 
sodium channels to the node (Dzhashiashvili et al., 2007). Similarly, it has been 
shown that TAG-1 is required to localise contactin-associated protein 2 (Caspr2; 
CNTNAP2) and potassium channels to the juxtaparanodal region (Poliak et al., 
2003). F3 similarly associates with Caspr1 and together these are required to 
separate sodium channels from potassium channels by maintaining the integrity 
of the paranode axon-glia adhesion. Loss of either protein leads to a failure of 
the other to be trafficked to the cell surface and a breakdown of the paranodal 
complex (Boyle et al., 2001). This evidence clearly suggests that L1-CNTNs are 
important in organising the membrane into specific subdomains. 
From studies in other contexts, it is also clear that L1-CNTNs can modulate the 
signalling of other membrane receptors. A study in the context of neuronal 
responses to axon guidance cues found that L1 is required for receptor 
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endocytosis during growth cone responses to Semaphorin3A (Sema3A), one of 
the secreted semaphorins (Castellani et al., 2004). Importantly, L1 binds directly 
to neuropilin1 (NRP1), which in turn is required for the endocytosis of the 
signalling component of the receptor, PlexinA. NRP1 is also involved VEGF 
receptor endocytosis and may have a general role in trafficking. NRCAM is 
similarly involved in responses to Sema3F, though in this case it binds to 
neuropilin2 (NRP2), which associates with a different subset of Plexins (Falk et 
al., 2005). Recently our laboratory has shown that TAG-1 is also involved in both 
these responses (Law et al., 2008); Law, unpublished) and, in the case of 
Sema3A responses, is required for the intracellular separation of L1 from NRP1 
and PlexinA, which is necessary for Sema3A to elicit the full set of signalling 
components required for sensory neuron growth cone collapse (Dang et al., 
2012).  
These observations indicate that L1-CNTNs are required in a number of 
contexts to localise other membrane molecules to specific subcellular locations, 
raising the possibility that they could modulate SHH signalling by controlling the 
trafficking of the membrane-bound components of the pathway. The most 
obvious trafficking event is the translocation of SMO and/or PTCH1 into/out of 
the cilium. Therefore, in this study I set out to test whether NRCAM might be 
involved in this trafficking. 
How exactly SHH signalling is regulated during GNP proliferation is key to 
understanding both normal development and tumorigenesis. An understanding 
of the role of L1-CNTNs in controlling SHH-induced proliferation in cerebellar 
granule neurons therefore could provide a mechanism by which to modulate 
SHH function in the cerebellum and possibly lead to a novel therapeutic 
approach for the treatment of MB in the future. 
 
1.6 The hypothesis and aims of this study 
The inability of F3-fc to suppress SHH induced proliferation of GNPs when 
NRCAM is missing, suggests that NRCAM is involved in regulating SHH 
signalling. In this thesis, the main hypothesis is that this regulation is due to the 
ability of NRCAM to affect the trafficking of SHH signalling pathway components 
in the primary cilium. The specific aims are as follows.  
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1.6.1 To determine whether NRCAM, F3 or TAG-1 are located to the 
primary cilia of proliferating GNPs 
Our lab has previously shown that NRCAM is expressed on proliferating GNPs 
(Xenaki et al., 2011). However, it was not tested whether NRCAM is present in 
the primary cilium of these cells. If NRCAM is involved the trafficking of SHH 
pathway components to the cilium it seems likely that NRCAM or its interacting 
ligands, TAG-1 or F3 should be present in or around the primary cilium. 
1.6.2 To determine whether loss of NRCAM affects the localisation of 
SHH pathway components to the primary cilium 
If NRCAM is present in or around the primary cilium, it is more likely that 
NRCAM is involved in the ciliary translocation of the key protein components of 
SHH pathway, especially either PTCH1 or SMO. 
1.6.3 To test whether NRCAM interacts with SHH pathway protein 
components, specifically PTCH1 or SMO 
If NRCAM is involved in the trafficking of SHH pathway components, it is likely, 
though not necessary, that it is able to physically associate, directly or indirectly 
with these components.  
1.6.4 To investigate how loss of NRCAM affects SHH signalling 
Although we know that NRCAM is required to mediate the effects of F3-fc on 
SHH signalling (Xenaki et al., 2011), we do not know what role, if any; NRCAM 
is playing in SHH signalling in vivo. Even if the phenotype of NRCAM knockout 
mice (Sakurai et al., 2001) is not equivalent to that of SHH knockout mice 
(Chiang et al., 1996), it is still possible that NRCAM affect the level of SHH 
signalling, rather than being absolutely required for SHH. 
  
 
 
 
 
 
 
 
Chapter 2 
Materials and Methods 
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2.1  Animals 
All mice were maintained on a C57/BL6 strain background (≥10 generation 
backcross). NRCAM mutant mice were a kind gift from T. Sakurai. All mice were 
bred and maintained at the University of Sheffield animal facility, and all 
experiments performed, in accordance with UK Home Office regulations. All in 
vitro GNP experiments were performed at postnatal day 5 (P5).  
 
2.2  Genotyping 
0.5-1cm of mouse-tail was collected from individual mouse and its DNA was 
extracted using a quick extraction protocol (Truett et al., 2000). Briefly, 100µl 
extraction buffer (recipe in table 2.4) was added into an eppendorf tube 
containing mouse-tail and boiled at 95°C at least 30 minutes. Then 100µl 
neutralisation buffer (recipe in table 2.4) was added followed by spinning down 
at 13000 rpm for 5 minutes. The supernatant was transferred to a fresh tube and 
PCR reaction was set up using the primers listed in table 2.1. Each PCR 
reaction contains 10µl 2x Bio-Red mix (BIO-25005, Bioline), 5µl extract DNA, 1µl 
of each primer (20µM stock concentration), and the reaction volume was made 
up to 20µl using dH2O. The reaction tubes were run in a thermal cycler (Hybaid 
or PTC-200 Peltier Thermal Cycler, MJ research), using the programme as 
follows: 
NRCAM: 94°C for 3 minutes, 30 cycles of 94°C for 30 seconds, 60°C for 45 
seconds, 72°C for 1 minute, final extension at 72°C for 10 minutes and cooling 
at 4°C indefinitely.  
10µl of the PCR product then was resolved on a 2% agarose gel in Tris-acetate-
EDTA buffer (TAE buffer) (see recipe in table 2.4) containing 0.5µg/ml ethidium 
bromide. The gel was run at 85 volts for 50 minutes and visualised using a UV 
transilluminator (UVdoc, Uvitec). 
 
2.3  Primary granule cell culture 
2.3.1 Granule cell (GC) preparation 
Primary GC culture methodology was modified from a previous report (Hatten, 
1985), as described by Xenaki et al. (2011). P5 mice were sacrificed by 
 Oratai Weeranantanapan                                                              35 
overdose of IsoFlu (B506, Abbott) and their cerebella were dissected out. Their 
meninges were carefully removed in cold calcium- and magnesium-free PBS 
(CMF-PBS) media under a dissecting microscope (Stemi SV6, Zeiss). Each 
clean cerebellum was transferred to a 15ml conical tube filled with 10ml cold 
CMF-PBS until all cerebella were dissected. The CMF-PBS was carefully 
discarded from the tube, and 1ml 1% Trypsin-DNase solution (recipe in table 
2.2) was added to the cerebella which were then incubated in a 37°C water bath 
for 8 minutes to dissociate the cells from the remainder of brain tissue. The 
Trypsin-DNase solution was then replaced with 1ml DNase (recipe in table 2.2). 
The cells were gently dissociated by trituration with a 1ml-Gilson pipette, and 
then with fine and extra fine-bore fire-polished Pasteur pipettes, respectively, 
until cell clumps were not visible. 3ml CMF-PBS was added to the cells and 
which were then centrifuged at 700g for 5 minutes at 4°C. The supernatant was 
removed and the pellet was gently triturated in 1ml DNase again until a 
homogeneous solution was seen. A further 3ml CMF-PBS was added to the 
suspension, which was gently mixed and then carefully applied over a two step-
percoll gradient as described (Solecki et al., 2001) for a further granule cell 
purification step, as follows. 
2.3.2 Granule cell purification – gradient centrifugation   
The cell suspension was applied over two step-percoll gradients which were 
prepared as follows (see Figure 2.1): First, 10ml 35% Percoll (white) was added 
into a conical 50ml tube. A 10ml syringe with 18G needle was placed in the 
bottom of the tube, then 10ml 60% Percoll (with trypan blue) was added into the 
syringe and left to flow by gravity under the 35% percoll. Then, the syringe was 
carefully removed without disturbing the clear sharp line between the 35% and 
60% Percoll layers (see figure 2.1).  
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Figure 2.1. Preparation of Percoll gradients for granule cell purification. 
The Percoll gradients were prepared for granule cell purification by adding 10ml 
35% Percoll (white solution), followed by underlaying 10ml 65% Percoll (blue 
solution) through a syringe. The cerebellar cell suspension was then carefully 
added to the top without disturbing a sharp line between the gradients. After 
centrifugation, the granule cells were accumulated at the interface of the 
gradients. 
!
The cell suspension from the previous step was carefully applied on top of the 
Percoll gradient, then centrifuged at 3200 rpm (2378.96 × g) for 17 minutes in a 
swing out rotor (SX4750A swing out bucket, rmax = 207.8 mm) in a Beckman 
Coulter Allegra X-12R centrifuge and then allowed to slow to a stop with the 
brake off. During centrifugation, cells are selected by the different gradients 
according to their density, which broadly correlates with their size. The low 
density, large cell fraction, which contains cells such as glia cells, Purkinje cells, 
and interneurons, collects above the upper-phase of the gradient; whereas, high 
density, small cells, including cerebellar granule cells and fibroblasts, collect at 
the interface of the 35% and 60% Percoll solutions (Hatten et al., 1997, Lee et 
al., 2009). To purify the cells, the upper phase was carefully removed without 
disturbing the interface, where the small cells accumulated. The interface was 
transferred to a 50ml conical tube, containing 40ml cold CMF-PBS, and 
centrifuged at 700 × g for 5 minutes at 4°C to get rid of the Percoll, which can be 
toxic to the cells. The supernatant was removed and the pellet was transferred 
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to a new 15ml conical tube containing 15ml cold CMF-PBS, and centrifuged 
again at 700 × g for 5 minutes at 4°C. 
2.3.3 Granule cell purification – pre-plating step 
The pellet from the previous step was re-suspended in 1.5ml warm Granule Cell 
Medium with Serum (GCM+S), a pre-plating medium, (see recipe in table 2.2) 
on a 35mm plastic dish and incubated for 20 minutes at 37°C to get rid of 
fibroblasts. Then the cell suspension was transferred to a 35mm-tissue culture 
dish (153066, Nunclon®), which was previously coated with 0.1mg/ml Poly-D-
Lysine hydrobromide (PDL; P1024-50MG, Sigma) for at least 3 hours at room 
temperature and washed twice with 1.5ml water before cell suspension transfer 
(the stock concentration was 5mg/ml, was diluted 1:50 by sterile water). To 
remove glia cell contamination, the cell suspension were incubated again for 2 
hours at 37°C as glia cells are more likely able to adhere to the dish coated with 
the lower concentration of PDL than GCs (Lee et al., 2009).   
2.3.4 GC plating step and culture 
As serum contains glutamate causing neuronal death (Schramm et al., 1990), 
after the 2-hour pre-plating step, the cells were washed serum off by transferring 
to a new 15ml conical tube and CMF-PBS was added to 15ml total volume, then 
centrifuged at 1000g for 5 minutes. The GC cell pellet was resuspended in 1ml 
GC medium (GCM) (recipe in table 2.2). Then, the GC cells were plated on the 
circular glass 13mm diameter coverslips (631-0150, VWR), which were pre-
coated with PDL the day before using the following protocol: the glass coverslips 
were put in a glass beaker and flamed for 2-3 minutes with shaking every 30 
seconds to prevent overheating and bending. Flamed forceps were used to 
transfer the coverslips into each single well in a 4 well dish (176740, Nunclon®). 
Then, 90µl of 0.5mg/ml PDL (PDL stock concentration was 5mg/ml, which was 
diluted 1:10 with sterile water) was carefully transferred onto each coverslip to 
form a drop and incubated at 37°C overnight. The coverslips were then washed 
twice with 2ml sterile water directly before GC plating. The number of GCs was 
counted and plated at a cell density of 0.5x106 cells/coverslip in 300µl GCM, and 
incubated at 37°C in a standard 5% CO2 tissue culture incubator. All GC 
experiments were terminated at 6 hours post-plating, unless otherwise indicated. 
The cells were fixed either with 4% Paraformaldehyde (PFA) in 0.1M Phosphate 
buffer (PB buffer) (see recipe in table 2.4) or harvested for RNA collection at that 
time. Any treatment – for instance, SHH [Recombinant Human Sonic Hedgehog 
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(C24II), N-Terminus; 1845-SH, R&D Systems] or SAG (Smoothened Agonist; 
ALX-270-426, Enzo Life Sciences)  (see list of drugs in table 2.5) – was added 
to GCs, after plating for 1.5 hours. All reagents and medium recipes for GC 
preparation and culture are listed in table 2.2-2.3. 
 
2.4  Testing the optimal SHH concentration that giving maximal 
proliferation 
Before verifying that SHH can drive SMO into primary cilia, the dose of 
recombinant SHH (1845-SH, R&D Systems) was typically titrated to find what 
concentration gives maximal proliferation of GNPs. As shown in fig 2.2, 30nM 
SHH drove maximal proliferation of GNPs at 24 hours treatment. As a result of 
this, the 30nM SHH concentration was selected to use in all further experiments. 
 
Figure 2.2. 30nM SHH drove maximal proliferation of GNPs at 24 hours. 
The GNPs were plated for 1.5 hours and then the various concentrations of 
recombinant SHH (C24II), which is from E.coli-derived, Cys24-Gly197 
(Cys24Ile-Ile), with and N-terminal Met, were added to the cells for 24 hours. 
The cells were stained with anti-Ki67 antibody and the Ki67+ cells were 
quantified as a percentage of proliferative GNPs. 
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2.5  Immunolabelling 
After 6 hours in culture (4.5 hours after treatment), the GNPs growing on PDL-
coated coverslips were fixed with 4% PFA for 20 minutes at room temperature, 
followed by 3 washes with 0.05% Triton-X in PBS (PBT) for 15 minutes each 
time. Primary antibodies, diluted in 3% Donkey serum in PBT, were added to the 
cells overnight at 4°C. Next day, the cells were washed 3 times with PBT for 15 
minutes and then secondary antibodies were added to the cells for 40 minutes 
at room temperature. The cells were washed 3 times again with PBT for 15 
minutes, then mounted with Vectashield mounting medium with DAPI (H-1200, 
Vector). The primary and secondary antibodies used in this study were listed in 
table 2.6-2.7. 
 
2.6 NRCAM antibody pre-absorption 
The NRCAM 838 antibody, which was kindly provided by Prof. Martin Grumet, 
USA, was pre-absorbed with head tissue from E13.5 Nrcam-/- embryos to 
remove non-specific reactivities: The tissue was cut into small pieces, then fixed 
with 4%PFA in 0.1M PB buffer on the roller overnight at 4°C. Next day, the 
tissue was washed 3 times with PBS for 30 minutes. The 1x NRCAM 838 
antibody (see its concentration in table 2.6) was diluted with PBS to 0.4x and 
added to an appropriate amount of washed tissue, which was calculated so as 
to have 100x more protein. This mixture was put on a roller at 4°C overnight. 
Next day, the antibody was centrifuged twice at 13,000 rpm (Sigma centrifuges, 
Nr.12124) for 10 minutes to remove as much of the tissue as possible. The 
supernatant was collected and tested for an optimal concentration on WT and 
Nrcam-/- GNPs. The appropriate concentration was chosen by the maximal 
signal from pre-absorbed NRCAM staining on WT GNPs, while seeing no signal 
on Nrcam-/- GNPs. After pre-absorption, the antibody was named NRCAM 838- 
antibody. 
 
2.7  Immunofluorescence microscopy and image analysis 
All cilia images were obtained on an Apotome (Imager.Z1 Apotome, Zeiss) 
microscope. Unless otherwise noted, images were taken with a 100x objective 
lens. The initial exposure time of each channel was chosen from optimal 
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exposure, and then it was kept constant between the experiments. Only the 
cilium clearly protruded beyond the cell body and the whole shaft of cilium was 
clearly in focus so that ciliary labelling was not confused with labelling in the 
main body of the cell. Cilia were classified as either occupied or not occupied 
with the relevant protein according to whether fluorescence could be seen by 
eye anywhere along the shaft of the cilium, including the tip in a dark room. For 
each condition, thirty images were analysed for each of three independent 
experiments. An example of how the ciliary protein occupancies were quantified 
is illustrated in Fig 2.3. The puncta of relevant protein at the base of primary 
cilium was not included for quantification for several reasons. Firstly, the protein 
puncta became obscure by the background; therefore, it was very difficult to 
distinguish them against the background. Secondly, in case of SMO, although 
Milenkovic et al. proposed the model of how SMO trafficks from Golgi to primary 
cilium (Milenkovic et al., 2009), it has been shown that SMO localisation in the 
cilium is essential for the activation of the pathway (Corbit et al., 2005, Wilson et 
al., 2009). Moreover, Yoo et al. showed that the tip-base ciliary localisation of 
SMO is related to the SHH pathway activation (Yoo et al., 2012).  
To avoid bias during counting SMO, PTCH and NRCAM occupancy in primary 
cilia, blind quantifications were also done in parallel. The blind quantifications of 
the SMO/PTCH/NRCAM ciliary occupancy were performed by randomising data 
and quantitating for the protein ciliary occupancy again by a fellow PhD student 
at the same department who was not told which images were from untreated, 
SHH-treated or SAG-treated GNPs.  
All image analysis of GLI1 fluorescent intensity was performed using the 
Volocity programme, version 6.1.1 (Improvision). Mean fluorescent intensity of 
GLI1 on whole cell GNPs were measured and subtracted by background nearby 
the cells. Twenty fields of images (1,200-1,600 cells) were analysed for each 
condition of three independent experiments. 
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Figure 2.3. The principle of the quantification of interesting protein occupancy. Acquired images from Apotome-epifluorescent 
microscope were scored for protein occupancy in primary cilia by eye in a completely dark room. Only protein puncta from proximal to distal 
end of cilium (dashed line around the cilium) were scored as either absence (top panel) or presence (bottom panel). Arrow shows the presence 
of SMO along the shaft of the cilium.   
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2.8  Statistical methods 
Compiled data sets from each experiment were analysed for statistical 
significance in Prism software (GraphPad Prism version 6). Unless otherwise 
noted, all data are graphed showing the Standard Error of the Mean (SEM) and 
have been tested for statistically significant differences among the control and 
treated samples using one-way ANOVA, followed by Bonferroni’s post-test. 
Confidence interval was set to 95%, with a p-value less than 0.05 taken as 
statistically significant. Statistical significances are indicated as asterisks; *: 
p<0.05, **: p<0.01, ***: p<0.001 and N.S.: not significant. 
 
2.9  Immunoprecipitation 
2.9.1 Extraction of plasmid DNA 
50µl of subcloning efficiency competent DH5α cells (18265-017, Invitrogen) 
were thawed from -80°C on ice, to which 1µl of plasmid DNA (0.1-2µg) was 
added (see the list of plasmid DNA constructs in table 2.8). The same amount of 
dH2O was also added to the cells in another tube as a negative control, gently 
mixed and incubated on ice for 30 minutes. The mixture was heat-shocked at 
37°C for 20 seconds, then incubated on ice for 2 minutes. To allow the cells to 
recover, 1ml of Luria-Bertani (LB) medium (see the recipe table 2.4), without 
antibiotics was added to the mixture and incubated for approximately 2 hours 
with occasional mixing at 37°C. 500µl of the transformation mix was spread 
plated on LB agar (see the recipe table 2.4) containing appropriate antibiotic (50 
µg/ml ampicillin or kanamycin). The plates were incubated at 37°C overnight 
(12-16 hours) in a bacterial incubator. After 16 hours, 3 individual colonies were 
picked and used to inoculate 10ml starter cultures of LB supplemented with 
appropriate antibiotic, incubated at 37°C with agitation (200 rpm) overnight (12-
16 hours). Next day, 5ml of each starter culture was used to extract DNA using 
Miniprep kit (27104, QIAGEN) according to the manufacturer’s instructions. To 
verify the DNA construct, the DNA extracts from 3 individual colonies were 
tested by restriction enzymatic digestion. 
2.9.2 Restriction enzymatic digestion 
The digestion mix consisted of 500ng DNA construct, 2µl buffer (for the double 
digestion, the compatible buffer for each enzyme was checked from the 
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Promega-Restriction enzymes resource website), 2µl 10 × BSA, 0.5µl restriction 
enzyme (for double digestion, 0.5µl of each restriction enzyme was used), and 
dH20 to get 20µl total volume. These materials were combined and then the 
appropriate enzyme was added to the reaction. The uncut reaction was also 
prepared by mixing only 50ng DNA and dH20. The reactions were incubated at 
37°C for at least 1 hour. To verify the molecular weight of the vector and insert, 
the products were resolved on an 0.8% agarose gel containing 0.5µg/ml 
ethidium bromide at 80 volts for 50 minutes and then visualised on UV 
transilluminator (UVidoc, UVitec). The clone showing the correct inserts was 
selected for scaling up the DNA production by adding the remaining starter 
culture of this clone to 250ml LB medium containing selective antibiotics, and 
grown in the bacteria shaker incubator at 37°C, at 240 rpm overnight (12-16 
hours). Next day, the DNA was extracted from the bacterial culture using 
Maxiprep kit (12163, QIAGEN) following the manufacturer’s instructions. The 
concentration of the purified DNA was measured by ND-100 spectrophotometer 
(NanoDrop Technologies, USA) using programme NanoDrop 1000 3.7.1, 
Nucleic acids, DNA-50, averaged and adjusted to 1µg/ml.  
2.9.3 Transfection of Cos-7 cells and protein harvesting 
Cos-7 cells were plated in a 100mm tissue culture dish at 106 cells/dish in 10% 
FBS DMEM and incubated at 37°C, 5% CO2 for 24 hours. Next day, the cells 
were transfected with expression plasmids for indicated proteins (see the list of 
the DNA constructs in table 2.5). The medium was changed to Opti-MEM 
(31985, Invitrogen) without antibiotics. 15µl Lipofectamine 2000 (11668-019, 
Invitrogen) was added to the fresh-clean tube containing 250µl Opti-MEM per 
100-mm dish and incubated for 5 minutes at room temperature. 5µg DNA was 
directly added to the Lipofectamine 2000/Opti-MEM complex and mixed by 
pipetting gently and incubated for 20 minutes at room temperature. Then the 
complex was carefully dispersed on cells covered with 5ml Optimem. The cells 
were left in the incubator for 8 hours and then the medium was changed to 10% 
FBS DMEM. After 24 hours, the cells were washed twice with cold-PBS and 
then 150µl RIPA buffer (see the recipe in table 2.4), containing Complete 
ULTRA tablet protease inhibitor cocktail, EDTA-free (05 892 791 001, Roche) 
was added to the cells. The protein was collected using a cell scraper (83.1830, 
Sarstedt), and the cells were broken mechanically by passing through a 25G 
needle ten times and incubated on ice for 30 minutes. Then, the lysate was 
clarified by centrifugation at 13000 × g for 20 minutes at 4°C. The supernatants 
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were collected and separated into 3 tubes; the volume of the first tube was 
about 3-5µl for measuring protein concentration using Bradford protein assay 
(500-0006, BioRad). The second tube was prepared for performing Western blot 
to check protein input and the third portion was for immunoprecipitation.  
2.9.4 Immunoprecipitation 
In a pre-clearing step, 25µl protein A/G-PLUS agarose beads (sc-2003, 
Santacruz) were pre-washed with 100µl IpH buffer (see the recipe in table 2.4), 
without protease inhibitor. Then, 2 sets of 500µg of protein extract from each 
sample were added to pre-washed beads — labelled as ‘mock IP’ (protein 
extract and beads) and ‘IP’ (protein extract, beads and antibody), respectively — 
and pre-cleared at 4°C on rotation for 45 minutes. The protein-bead complex 
was then centrifuged at 12000g for 20 seconds and the supernatant was taken 
to a fresh tube. The relevant antibodies (listed in table 2.6) were then added to 
the ‘IP’ samples and all tubes were incubated for a further 45 minutes at 4°C. 
Then, both samples were transferred to new tubes containing pre-washed 
agarose beads and immune-precipitated on a roller for 1 hour at 4°C. The beads 
were then pelleted and washed 5 times with 500µl IpH buffer containing 
protease inhibitor for 25 minutes at 4°C. The samples were spun down and the 
supernatants were discarded. At room temperature, 6x sample buffer (see table 
2.4) was diluted to 1x strength with dH2O and 25µl was added to each sample to 
elute the precipitated protein from the beads. As SMO and PTCH1 are the 
multipass transmembrane proteins, which are more likely to aggregate in the 
loading buffer when boiled at high temperature because of their hydrophobic 
nature, the precipitated proteins and their input samples were run directly on an 
SDS-PAGE gel without boiling (Steves Morin, Pers. Comm.; see also (Hillman et 
al., 2011)), followed by immunoblotting with appropriate antibodies (Table 2.6-
2.7). 
 
2.10 SDS-PAGE and immunoblotting 
Protein samples from cell lysates and immunoprecipitations were loaded onto 
7.5% resolving gel (see the recipe in table 2.9) and run at a constant current of 
85 amps (BioRad PowerPAC 300, BioRad). This was followed by transferring to 
a Polyvinylidene fluoride (PVDF) membrane (IPVH00010, Millipore) at 85 volts, 
constant voltage for 90 minutes. To block the nonspecific proteins, the 
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membrane was incubated in 5% non-fat dry milk in 0.05% Tween-20 (P9416, 
Sigma) in TBS (TBST) (see the recipe in table 2.4), on a roller mixer for 2 hours 
at room temperature. The blocking solution was then replaced by fresh blocking 
solution in which an appropriate primary antibody was diluted (table 2.6), and 
then the membrane was incubated overnight at 4°C. Next day, the membrane 
was washed 3 times for 20 minutes in TBST, followed by incubation with an 
appropriate secondary antibody conjugated to horseradish peroxidase (HRP) 
(table 2.7), diluted in 5% non-fat dried milk in TBST, for 1 hour at room 
temperature. The membrane was again washed with TBST for 20 minutes 3 
times before processing for enhanced chemiluminescence (ECL) detection 
according to the manufacturers directions (RPN2109, Amersham). The protein 
signal was captured with different exposure times on X-ray film (28906837, 
Amersham), and then developed in an X-ray developer (Optimax2010 X-ray film 
processor).  
 
2.11 NIH3T3-GL cell culture and transfection 
NIH3T3-GL cells (a gift from Dr. Frederic Charron, Montreal, Canada) were 
cultured in 10% FBS DMEM. To begin transfection, the cells were plated in a 
60mm tissue culture dish at a density of 5.5x105 cells/dish in 10%FBS DMEM 
and incubated at 37°C, 5% CO2 for 24 hours. Next day, 3µg either of pIRES-neo 
empty vector or Nrcam-HA plasmid (kindly provided by Dr. Catherine Faivre-
Sarrailh, France), as well as, 9µl Lipofectamine-2000 were diluted in 250µl Opti-
MEM and incubated for 5 minutes at room temperature. The diluted plasmids 
were combined with the diluted Lipofectamine-2000 and incubated again for 20 
minutes at room temperature. Meanwhile, the cells were washed twice with 
10%FBS DMEM without Penicillin-Streptomycin (15140, Invitrogen) and 3ml 
10%FBS DMEM without Penicillin-Streptomycin was added to each well. Then 
the DNA-Lipofectamine-Opti-MEM complex was added to the cells and left in the 
incubator for 18 hours.  
Next day, the cells were serum starved with 0.5% FBS DMEM for 24 hours, and 
treated with 30nM SHH or 100nM SAG in 0.5% FBS DMEM for 24 hours (Karen 
Cholmondeley pers comm; see also (Rohatgi et al., 2007)). Then the cells were 
washed twice with cold-PBS, scraped and lysed in a lysis buffer (see the recipe 
in table 2.8), with Complete ULTRA tablet protease inhibitor cocktail, EDTA-free. 
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The cells were broken mechanically by passing through a 25G needle ten times 
and incubated on ice for 30 minutes. Then, the lysate was clarified by 
centrifugation at 13000g for 20 minutes at 4°C. The supernatants were collected 
and the protein concentration was measured using Bradford protein assay. The 
protein from each sample was supplemented with 4x SDS loading buffer (see 
the recipe in table 2.4), and boiled at 95°C for 10 minutes and briefly spun down. 
50mg total protein from each sample was loaded to 7.5% SDS-PAGE, followed 
by immunoblotting and probed with appropriate antibodies (table 2.6-2.7). 
 
2.12 Quantitative PCR (qPCR) 
2.12.1 RNA isolation 
RNA from the GNPs after SHH or SAG treatment was extracted by adding 500 
µl TRIzol Reagent (15596-018, Invitrogen) to each well (from 4 well-dish) and 
passing the cell lysate several times through a pipette. The homogenised 
samples were incubated for 2 minutes at room temperature to allow complete 
dissociation of nucleoprotein complexes, and then transferred to a fresh tube. 
100µl chloroform was added and mixed vigorously by shaking for 15 seconds 
and incubated at room temperature for 3 minutes. The samples were centrifuged 
at 12,000g for 15 minutes at 4°C. After centrifugation, to obtain RNA, the upper 
aqueous phase was taken to a fresh new tube (about 250µl). RNA was 
precipitated by adding 625µl 100% ethanol, 25µl LiCl and 1µl glycogen (901 
393, Boehringer) and incubated at -20°C overnight. Next day, the sample was 
centrifuged at 12,000 × g for 30 minutes at 4°C. The precipitated RNA was seen 
as a gel-like pellet from which the supernatant was carefully removed. The RNA 
pellet was washed once with 100µl 75% ethanol, and centrifuged at 7,500 × g 
for 10 minutes at 4°C. The supernatant was again removed and briefly air-dried. 
The pellet was not left until it completely dried as this can decrease its solubility. 
15µl DEPC water (see recipe in table 2.4) was added to the RNA and the 
solution was passed through a pipette tip several times to dissolve the RNA. 
Before starting cDNA synthesis, the concentration of RNA was measured by 
ND-100 spectrophotometer (NanoDrop Technologies, USA) using programme 
NanoDrop 1000 3.7.1, Nucleic acids, RNA-40. RNA purity was also taken into a 
consideration, as the pure RNA should have had an A260/A280 ratio above 1.6. 
The RNA was stored at -80°C. 
 Oratai Weeranantanapan                                                              47 
2.12.2 cDNA synthesis 
500ng RNA was reverse-transcribed with QuantiTect Reverse Transcription Kit 
(205311, Qiagen), following the manufacturer’s protocol. In addition, RT-control 
reactions were performed alongside using exactly the same conditions as for the 
experimental samples. However, the reverse transcriptase was not added to the 
RT-control samples to ensure that there was no genomic DNA contamination, 
which may affect later qPCR results. The cDNA samples were quantified by ND-
100 spectrophotometer (NanoDrop Technologies, USA) using programme 
NanoDrop 1000 3.7.1, Nucleic acids, DNA-50, and the concentration of each 
sample was made to 500ng/µl. Then, 1µl cDNA from all samples was checked 
for the expression of Gapdh by semi-quantitative PCR (PTC-200 Peltier Thermal 
Cycler, MJ research), before performing qPCR.  Only DNA, which had an 
A260/A280 ratio of 1.8-2.0, was allowed to continue to the next step. The cDNA 
samples were kept at -80°C after use. All reagents and kits for RNA isolation 
and cDNA synthesis were listed in table 2.10. 
2.12.3 Protocol optimisation 
As the accuracy of qPCR depends on proper protocol optimisation, according to 
manufacturer’s direction (qPCR technical guide, Sigma), the guidelines to 
optimise to qPCR are follows; the primer concentration optimisation, experiment 
validation with a standard curve and investigation of melt curves. I will explain 
these guidelines in details below. 
2.12.3.1 Primer concentration 
The optimal concentrations of forward and reverse primers were determined by 
testing the following combinations of primer concentrations: 1000 nM, 500 nM, 
250 nM, 125 nM and 62.5 nM, to determine which was the most efficient. The 
qPCR primers used in this study are listed in table 2.1. Each concentration was 
run in triplicate on an E13.5 mouse cDNA sample, which was used as a positive 
control. Thermal cycling was performed at an optimal temperature for each pair 
of primers (the optimal temperature was obtained according to the optimal 
temperature from gradient PCR) with iCycler iQ system. The lowest primer 
concentration with the combination of the lowest threshold cycle (Ct) and the 
highest fluorescence was chosen for subsequent experiments.  
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2.12.3.2 Standard curve 
The optimal concentrations for each primer pair were again tested on 5 fold-
dilutions of the positive control (E13.5 mouse cDNA), which are 1000ng, 100ng, 
10ng, 1ng, 0.1ng DNA to investigate their efficiencies. The threshold cycle (Ct) 
values and the log of DNA dilutions were plotted as a standard curve and the 
reaction efficiency was automatically calculated by iCycler iQ Optical system 
software, version 3.1 (BioRad) or using the equations below: 
Amplification efficiency = 10(-1/slope) 
% Efficiency = (Amplification efficiency-1) × 100 
The accepted range of %efficiency was 80-110% (Schmittgen and Livak, 2008).  
2.12.3.3 Melt curve 
The melt curve of each set of primers was analysed individually with a single 
peak to indicate that there was a single specific product. In addition, PCR 
products of each set of primers were also resolved on 1.2% agarose gel to 
check there was no primer dimer formation and non-specific product. 
2.12.4 qPCR experimental design  
The qPCR experimental design and methodologies used in this study were the 
Relative Standard Curve Method, which involves using a set of known standards 
relative to which unknown samples can be quantitated. The cDNA sample from 
WT GNP-cDNA at 4.5 hours post-treatment was set as a calibrator, a sample 
used as the basis for comparing results.  
2.12.5 qPCR reaction optimisation 
All qPCR reactions were performed with iCycler iQ system using 96 well plate 
(NS-96-CC/CP, Cell Projects) (see table 2.10). Each individual reaction was 
performed in triplicate and was made up as follows: 10µl SYBR Green 
JumpStart Taq Ready Mix (S4438, Sigma-Aldrich), 1µl each FW and RV primers 
purchased from Eurofins MWG Operons (see table 2.11 for concentrations), 2µl 
of 1/10 diluted cDNA, which the started concentration are 500ng/µl (=100ng), 
and nuclease-free water (AM9937, Ambion) to get total volume 20 µl/reaction. 
Standard curves of Gli1/Ptch1 and Gapdh were generated for each qPCR 
reaction using serial dilutions of the calibrator (WT GNP control at 4.5 hours 
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post-treatment cDNA sample; 1000ng, 100ng, 10ng, 1ng and 0.1ng of cDNA.). A 
set of primers for the gene of interest (Gli1 or Ptch1) was used alongside in the 
same reaction with a set of primers for a reference control (Gapdh). As the 
quantification was normalised to the endogenous control (Gapdh), the standard 
curves were performed for both the target and the endogenous reference in the 
same plate. The reactions were performed using the following protocol; 94°C. 
for 2 minutes (preincubation); 50 cycles of 94°C. for 15 seconds (denaturation), 
optimal annealing temperature (as indicated in table 2.11) for 1 minute and 
72°C. for 1 second (amplification); 95°C. for 1 seconds, 50°C. for 1 minute 
(melting curve); and 40°C. for 10 minutes (cooling). The optimal temperature 
and primer concentration were used as listed in table 2.11. 
All qPCR reactions were also run with a no reverse transcriptase (RT) control, 
an E13.5 positive control and a no cDNA negative control in the same plate. The 
melt curve from each sample was examined to verify that amplification resulted 
in just one product. 
2.12.6 qPCR analysis 
All qPCR results were analysed using iCycler iQ Optical system software. For 
each experimental sample, the amounts of the target genes and the 
endogenous housekeeping genes were each determined by their own standard 
curve. As each individual sample was performed the reaction for three 
replicates, the average quantity (avg) of each sample, the standard deviation of 
the average (stdev) and the coefficient of variation (CV) were calculated. 
%!"!!!!!!! = !!!!!!! !"#$%!"# !!100 
 
Any outlier points giving greater than 21.8% CV was identified and removed 
(Bookout et al., 2006), following by recalculating the avg, stdev and CV. 
However, only one point per replicate can be removed.  
Then the avg quantity of each sample was normalised to its respective 
endogenous housekeeping gene control in order to calculate a normalised target 
value according to the following equation. The recalculated value was used if an 
outlier point was removed.  
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Then the normalised target values of the test samples were divided by the 
normalised target value of the WT control sample (a calibrator) to calculate the 
fold difference in target quantity between the samples and the calibrator. 
!"#$!!"##$%$&'$!!"!!"#$%!!!!!! = !!!!!!!! !"#$%&'()*!!"#$%!!(!"#!!!"#$%&)!"#$%&'()*!!"#$%!!(!"#$%&"'(&!!"#$%&) 
 
Each experimental sample was averaged from its triplicate and also repeated to 
3 biological replications. A one-way ANOVA were then tested to determine 
significance in gene expression change between control and experimental 
groups.  
 
2.13 Tables of antibodies, media and reagents using in this study 
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Table 2.1. List of Primers used in this study !
Gene 
Name 
Primer Source Gene 
Bank 
Access
ion No. 
Primer Sequence (5′ – 3′) Product Sizes 
(bp) or 
Amplicon (bp) 
Purpose Annealing 
Temperature 
(◦C) 
References 
Nrcam NRCAM Dr. Andrew 
Furley, UK 
- 1. Nr1 Int 3: GCTCAGGATGGTTGCGCC 
2. NrMP1: CTTCCTGTGCCAGATGATCA 
3. NEO F1: 
TGGAGAGGCTATTCGGCTATGAC 
4. PAF11 B2 (NEO B5): 
AGCAAGGTGAGATGACAGGAGATC 
NRCAM (+/+) 
340 bp 
NEO (-/-) 260 bp 
Genotyping 60 - 
Gli1 mGli1  Dr. Andrew 
Furley, UK  
NM_01
0296.2 
FW: GCTTGGATGAAGGACCTTGTG 
RV: GCTGATCCAGCCTAAGGTTCTC 
78 bp qPCR 64 (Romer et al., 
2004) 
Ptch1 mPtch1 Dr Anne-
Gaelle 
Borycki, UK 
NM_00
8957.2 
FW: CAACACCTGGACTCAGCACTCC 
RV: GCAAGGGTAAAGGTATTC TATTATCTG 
150 bp qPCR 59 Dr Anne-Gaelle 
Borycki, UK 
Gapdh mGapdh Dr Anne-
Gaelle 
Borycki, UK 
NM_00
8084.2 
FW: ACTCCACTCACGGCAAATTC 
RV: GACTCCACGACATACTCA GCACC 
145 bp qPCR 58-64 (Lepper et al., 
2009) and Dr 
Anne-Gaelle 
Borycki, UK  
Gapdh mGapdh  
 
Dr Anne-
Gaelle 
Borycki, UK 
NM_00
8084.2 
FW: ACTCCACTCACGGCAAATTC 
RV: ACTGTGGTCATGAGCCCTTC 
385 bp Semi-
quantitative 
PCR 
59 (Lepper et al., 
2009) 
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Table 2.2. List of Buffer and Reagents for GC preparation and culture 
Reagent 
 
CMF-PBS 500 
ml 
Volume Catalogue 
Number 
Supplier 
1. CMF-PBS 
500 ml 
 
1. D-PBS 
(Without 
Ca2+ and 
Mg2+) 
500ml 14190-094 Gibco, 
Invitrogen 
2. 45% 
Glucose 
2.22ml 101174Y BDH 
Laboratory 
Supplies 
3. 7.5% 
Sodium 
Bicarbonate 
0.27ml 25080 Gibco, 
Invitrogen 
4. Phenol Red 0.25ml P0290 Sigma 
Mixed and kept at 4°C 
2. Trypsin-
DNase100ml 
1. DNase 
(2000u/mg) 
100 mg 2139 Worthington 
2. Trypsin 1g 3703 Worthington 
3. CMF-PBS 99.4 ml 
4. 1N NaOH 0.6 ml 102524X BDH 
Laboratory 
Supplies 
Filtered and aliquoted 1 ml/tube and kept at 20°C 
3. DNase 200 
ml 
1. DNase 
(2000u/mg) 
100 mg 2139 Worthington 
2. 30% 
Glucose 
2.26ml 101174Y BDH 
Laboratory 
Supplies 
3. BME, no 
Glutamine 
197.7ml 41010 Gibco, 
Invitrogen 
Filtered and aliquoted 2 ml/tube and kept at 20°c 
4. 4xCMF-PBS-
EDTA (for 
making Percoll 
solutions) 
1. NaCl 32g S7653-1KG Sigma 
2. KCl 1.2g P-9541 Sigma 
3. Glucose 8g 101174Y BDH 
Laboratory 
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Reagent 
 
CMF-PBS 500 
ml 
Volume Catalogue 
Number 
Supplier 
Supplies 
4. NaH2PO4H20 2g 102454R BDH 
Laboratory 
Supplies 
5. KH2PO4 1g P-0662 BDH 
Laboratory 
Supplies 
6. 7.5% 
Sodium 
Bicarbonate 
2.13ml 25080 Gibco, 
Invitrogen 
7. 1M EDTA, 
pH8 (final 
EDTA 
concentratio
n = 2.5 mM) 
10ml - - 
8. Sterile water 900ml 
pH 7.35, then made up to 1L, filtered and kept at  4°C 
5. 35% Percoll 
(White solution) 
1. 4xCMF-
PBS-EDTA 
25ml 
2. Percoll 35ml P1644-1L Sigma 
3. Autoclaved 
water 
40ml - - 
Filter sterilise 
6. 60% Percoll 
(Blue solution) 
1. 4xCMF-
PBS-EDTA 
25ml 
2. Percoll 60ml P1644-1L Sigma 
3. Autoclaved 
water 
15ml - - 
4. Trypan Blue 
0.4% 
0.3ml 15250-061 
 
Gibco, 
Invitrogen 
Filter sterilise 
7. GCM+S 
(Pre-plating 
1. L-Glutamine 
200mM 
0.1ml 25030 Gibco, 
Invitrogen 
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Reagent 
 
CMF-PBS 500 
ml 
Volume Catalogue 
Number 
Supplier 
media) 2. Penicillin-
Streptomyci
n 
0.1ml 15140 Gibco, 
Invitrogen 
3. 30% 
Glucose 
0.3ml 101174Y BDH 
Laboratory 
Supplies 
4. Horse serum 
(Heat 
inactivated) 
1ml - - 
5. BME, no 
Glutamine 
8.5ml 41010 Gibco, 
Invitrogen 
Filter 
* This medium should be prepare freshly for each experiment 
8. GCM 1. L-Glutamine 
200mM 
0.1ml 25030 Gibco, 
Invitrogen 
2. Penicillin-
Streptomyci
n 
0.1ml 15140 Gibco, 
Invitrogen 
3. 30% 
Glucose 
0.16ml 101174Y BDH 
Laboratory 
Supplies 
4. N-2 
supplement 
(100x), 
Liquid 
0.1ml 17502-048 Gibco, 
Invitrogen 
5. BME, no 
Glutamine 
9.54ml 41010 Gibco, 
Invitrogen 
Filter 
* This medium should be prepare freshly for each experiment !!!!!
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Table 2.3. List of Culture Media 
Reagent Catalogue Number Supplier 
1. DMEM, high glucose, 
Pyruvate, no glutamine 
21969-035 Gibco, Invitrogen 
2. DPBS, no calcium no 
magnesium 
14190-094 Gibco, Invitrogen 
3. BME, no Glutamine 41010 Gibco, Invitrogen 
4. Leibovitz’s L-15  11415-049 Gibco, Invitrogen 
5. Opti-MEM 31985 Gibco, Invitrogen 
6. FBS-Fetal Bovine 
Serum 
10270 Gibco, Invitrogen 
7. Chicken serum C5405 Sigma 
8. 0.25% Trypsin-EDTA 
(1x), Phenol Red 
25200-056 Gibco, Invitrogen 
9. L-Glutamine 200mM 
solution 
25030 Gibco, Invitrogen 
10. Penicillin-
Streptomycin 
15140 Gibco, Invitrogen 
11. N-2 supplement 
(100x), Liquid 
17502-048 Gibco, Invitrogen 
 !!!!!!!!!!
 Oratai Weeranantanapan                                                              56 
Table 2.4. List of Buffers and Fixative used in this study 
Buffers Formula Amount/Volume 
1. 10x Extraction buffer  1. 250mM NaOH - 
2. 2mM EDTA - 
2. Neutralisation buffer 1. 40mM Trisma - 
Adjust the pH to 5.5 with conc. HCl 
3. 50x TAE buffer 1 liter 1. Tris-base 242g 
2. 0.5M EDTA, pH 8.0 100ml 
3. Glacial acetic acid 57.2ml 
4. dH2O 750ml 
Stirrer until it is completely dissolved and added up with 
dH2O to bring final volume to 1000ml, stored at room 
temperature 
4. 4%PFA 1 liter 1. Paraformaldehyde (PFA) 40g 
2. dH2O 500ml 
Add NaOH 2-3 drops and warm up on a hotplate with 
stirrer bar until it dissolves completely, then adjust the pH 
to 7.2 
3. 0.2M PB buffer, pH 7.2 500ml 
Filter and make aliquots and store at -20°c 
5. 0.2M PB buffer (pH 
7.2) 1 liter 
1. Na2HPO4 21.8g 
2. NaH2PO4 6.4g 
3. dH2O 900ml 
Stirrer until it is completely dissolved, then adjust the pH to 
7.2 with conc. HCl, then adjust the volume to 1 liter with 
dH2O 
6. 10x PBS 1 liter 1. NaCl 80g 
2. KCl  2g 
3. Na2HPO4  14.4g 
4. KH2PO4  2.4g 
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Buffers Formula Amount/Volume 
5. dH2O                                                          800ml 
Adjust the pH to 7.4 with conc. HCl, then adjust the volume 
to 1liter with dH2O 
7. 10x TBS washing 
buffer (pH 7.4) 1 liter 
1. Tris base  30g 
2. NaCl  80g 
3. KCl 2g 
4. dH2O                                        800ml 
Adjust the pH to 7.4 with conc. HCl, then adjust the volume 
to 1 liter with dH2O 
8. 4x sample buffer (for 
WB) 10ml 
1. 0.5M Tris-HCl pH 6.8  2.5ml 
2. 20% SDS  2ml 
3. Glycerol  4ml 
4. Bromophenol Blue (1% in ethanol)  200µl 
Add 10% Mercapto-ethanol later just before using 
9. 6x sample buffer 
(Maniatis) for Co-IP 
1. 4x Tris-Cl/SDS, pH 6.8 (take 0.5M 
Tris Cl, pH 6.8 10ml and add 40mg 
SDS) 
7ml 
2. Glycerol (30% final concentration)  3.8g/3ml 
3. SDS (10% final concentration) 1g 
4. Bromophenol Blue  1.3mg 
5. Beta Mercaptoethanol (5% final 
concentarion) 
0.5ml 
Make 0.5ml aliquots and store at -20°c 
10. 10x Leammli 
running buffer 1 liter 
1. Tris base  30.3g 
2. Glycine 144.2g 
3. SDS  10g 
Add dH2O to 1 liter 
11. 1x Transfer buffer 1. 1x running buffer  800ml 
 Oratai Weeranantanapan                                                              58 
Buffers Formula Amount/Volume 
2. Methanol  200ml 
12. 1x TE buffer 1 liter 1. 1M Tris-HCl, pH 7.5 (final 
concentration 10mM) 
10ml 
2. 0.5M EDTA, pH 8 (final concentration 
1mM) 
2ml 
Add dH2O to 1 liter 
13. Stripping buffer 
(500ml) 
1. β-Mercaptoethanol (final 
concentration 100mM) 
3.5ml 
2. SDS 10g 
3. 1.35M Tris-HCl, pH 6.7  25ml 
4. dH2O 471.5ml 
14. Lysis buffer for WB 
(200ml), store at 4°C 
1. 1M Tris-HCl, pH 8.0 (final conc = 
50mM) 
10ml 
2. 0.5M EDTA (final conc = 1mM) 0.4ml 
3. NaCl (final conc = 150mM) 1.74g 
4. NaF (final conc = 50mM) 0.42g 
5. 1% Triton X-100 2ml 
6. 10% Glycerol 20ml 
15. RIPA buffer for Co-
IP (100ml), store at 4°c 
1. 1M HEPES, pH 7.4 (final conc = 
50mM) 
5ml 
2. NaCl (final conc = 150mM) 0.87g 
3. 10% Glycerol 10ml 
4. 1M MgCl2 (final conc = 1.5mM) 150µl 
5. 1% Triton X-100  1ml 
6. 0.5% Sodium deoxycholate 
(Deoxycholic acid) 
0.5g 
7. dH2O 84ml 
16. IpH buffer for Co-IP 
(100ml) 
1. 1M Tris-HCl, pH 8 (final conc = 
50mM) 
5ml 
 Oratai Weeranantanapan                                                              59 
Buffers Formula Amount/Volume 
2. 400mM NaCl 2.32g 
3. 0.5M EDTA, pH 8 (final conc = 5mM) 1ml 
4. 0.1% Np40 (Nonidet-P40) (560092L, 
BDH) 
0.1ml 
5. dH2O 91.68ml 
17. LB Broth 1 liter 1. Bacto-tryptone (T9410, Sigma) 10g 
2. Yeast extract (Y1625, Sigma) 5g 
3. NaCl 5g 
Make up to 1 liter with dH2O and autoclave 
18. LB Agar 1 liter 1. Bacto-tryptone (T9410, Sigma) 10g 
2. Yeast extract (Y1625, Sigma) 5g 
3. NaCl 5g 
4. Agar (A5306, Sigma) 15g 
Make up to 1 liter with dH2O and autoclave 
19. DEPC water 100ml 1. DEPC (D5758, Sigma) 0.1ml 
2. dH2O 100ml 
Shake vigorously and incubate for 12 hours at 37°C, then 
autoclave for 15 minutes to remove any trace of DEPC 
 
 
Table 2.5. List of Recombinant Proteins and Small Molecules!
Recombinant Proteins 
and Small Molecules 
Catalogue Number Supplier 
1. Recombinant Human 
Sonic Hedgehog (C24II), 
N-Terminus 
1845-SH R&D Systems 
2. SAG, Smoothened 
ligand 
ALX-270-426 Enzo Life Sciences 
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Table 2.6. List of Primary antibodies used in this study 
Primary antibody Type Concentration Application and Dilution Source 
1. Anti-Acetylated α-tubulin Mouse, monoclonal IgG2b 1.5mg/ml IF 1:1000 Sigma (T6793) 
2. Anti-γ-tubulin Rabbit, IgG fraction of antiserum 15mg/ml IF 1:1000 Sigma (T3559) 
3. Anti-SMO Rabbit, polyclonal antibody - IF 1: 1000 Prof. Kathryn Anderson’s lab 
3. Anti-SMO (H-300) Rabbit, polyclonal antibody raised 
against amino acids 488-787 
mapping at the C-terminus of 
Smo of human origin 
0.2mg/ml IF 1:25 Santa Cruz (sc-13943) 
4. Anti-PTCH (H-267) Rabbit, polyclonal antibody raised 
against amino acids 1181-1447 of 
patched of human origin 
0.2mg/ml IF 1:25 Santa Cruz (sc-9016) 
5. Anti-NRCAM (N-18) Goat, polyclonal antibody raised 
against a peptide mapping within 
an internal region of NRCAM of 
human origin 
0.2mg/ml IF 1:25 Santa Cruz (sc-18958) 
6. Anti-BOC Goat, polyclonal IgG (mouse Boc 
extracellular domain) 
0.2mg/ml IF 1:100, WB 1:1000 R&D systems (AF2385) 
7. Anti-GAS1 Goat, polyclonal IgG 0.2mg/ml IF 1:200, WB 1:500 R&D systems (AF2644) 
8. Anti-NRCAM 838- Rabbit polyclonal 12µg/ml IF 1:1200 (after pre-
absorption) 
Prof. Martin Grumet’s lab 
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Primary antibody Type Concentration Application and Dilution Source 
9. Anti-NRCAM 838 Rabbit polyclonal 38µg/ml WB 1:1500, IP 2.5 µl Prof. Martin Grumet’s lab 
10. Anti-GFP Rabbit polyclonal serum Not applicable IF 1:4000, WB 1:1000 Invitrogen (A6455) 
11. Anti-GFP Chicken polyclonal IgY 10mg/ml WB 1:500 Abcam (ab13970) 
12. Anti-HA Rat monoclonal (clone 3F10) 
recognized the HA peptide 
sequence [YPYDVPDYA] 
0.1mg/ml IF 1:1000, WB 1:1000, IP 
8 µl 
Roche (11 867 423 001) 
13. Anti-Flag (anti-DDDDK 
tag antibody) 
Rabbit polyclonal to DDDDK tag 1mg/ml WB 1:4000, IP 2 µl Abcam (ab21536) 
14. Anti-TIE 2 Goat polyclonal Not applicable WB 1:500 Prof. Elizabeth Smythe’s Lab 
15. Anti-GLI1 Mouse monoclonal Not applicable WB 1:500, IF 1:200 Cell signaling (L42B10) 
16. Anti-TUJ1 Mouse monoclonal 1mg/ml IF 1:1000 Covance (MMS-435P100) 
17. Anti-KI67 Rabbit polyclonal Not applicable IF 1:250 Leica (NCL-Ki67p) 
18. Anti-PAX6 Mouse monoclonal Not applicable IF 1:50 Hybridoma Bank 
19. Anti-GFAP Rabbit polyclonal 2.9mg/ml IF 1:1000 Dako (Z0334) 
20. Anti-α-Tubulin Mouse monoclonal 1mg/ml WB 1:10000 Sigma (T6199) 
 
 
 Oratai Weeranantanapan                                                              62 
Table 2.7. List of Secondary antibodies used in this study 
Secondary antibody Application and Concentration Source 
1. Goat Anti-Mouse IgG1-HRP WB 1:5000 Santa Cruz (sc-2060) 
2. Goat Anti-Rabbit IgG-HRP WB 1:5000 Jackson ImmunoResearch (111-035-144) 
3. Rabbit Anti-Goat IgG-HRP WB 1:2000 Everest (EB2ND-001-HRP) 
4. Donkey Anti-Chicken-HRP WB 1:5000 Jackson ImmunoResearch (703-036-155) 
5. Goat Anti-Rat-IgG-HRP WB 1:5000 Sigma (A9037) 
6. Alexa Fluor 647 Donkey Anti-Rabbit IgG IF 1:800 Jackson ImmunoResearch (711-606-152) 
7. DyLight 488 Donkey Anti-Mouse IgG IF 1:900 Jackson ImmunoResearch (715-486-151) 
8. Rhodamine Red-X-Donkey Anti-Mouse IgG IF 1:200 Jackson ImmunoResearch (715-296-150) 
9. Rhodamine Red-X-Donkey Anti-Rabbit IgG IF 1:200 Jackson ImmunoResearch (711-296-152) 
10. Rhodamine Red-X-Donkey Anti-Rat IgG IF 1:200 Jackson ImmunoResearch (712-296-153) 
11. Rhodamine Red-X-Donkey Anti-Goat IgG IF 1:200 Jackson ImmunoResearch (705-296-147) 
12. Rhodamine Red-X-Goat Anti-Mouse IgM IF 1:200 Jackson ImmunoResearch (115-295-020) 
13. Alexa Fluor 488 Goat Anti-Chicken IgG IF 1:500 Invitrogen (A-11039) 
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Table 2.8. List of DNA constructs used in this study 
Construct name Vector/vector size Insert/Site/Size Resistance Restriction endonuclease/ 
Expected band size 
Source 
1. Nrcam-FL (#272 
in the lab 
database) 
pcDNA3 (5.5 kb) NRCAM/EcoRI/4 kb Amp EcoRI Dr. Fleur Davy (University 
of St Andrews) 
2. Rat Nrcam-HA pIRES1 neo (5.3 
kb) 
NRCAM/EcoRI/4.04kb 
HA/ NotI-BstEI/0.3kb 
Note: HA epitope was inserted by 
PCR 5 amino acids downstream 
of the signal peptide in 
NRCAM12 subcloned in 
pIRESIneo (see Falk et al., 2004) 
Amp ClaI and EcoRI/5.3, 4.04 and 0.3 kb Dr. Catherine Faivre-
Sarrailh (France) 
3. Ptch1-GFP pEGFP-C1 mPtc1 ORF/BglII-KpnI/4305 bp Kan BglII and KpnI/4.7 and 4.3 kb Dr. Frederic Charron 
(Montreal, Canada)-
Original from C.C. Hui 
4. Smo-GFP pEGFP-N (4.7 kb) mSmo/EcoRI-SACII/2468 bp Kan EcoRI/ 4.7 and 2.468 kb Dr. Frederic Charron 
(Montreal, Canada)- 
Original from C.C. Hui 
5. Boc-FLAG pcDNA3.1 (5.4 kb) mBoc/EcoRI-ApaI/3 kb 
FLAG/259 bp 
Note: Flag-tagged at C-terminus 
Amp ApaI and EcoRI/ 3, 0.259 and 5.4 
kb 
Dr. Frederic Charron 
(Montreal, Canada) 
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Table 2.9. Recipes for SDS-PAGE 1.5mm mini 
Reagents Resolving gel Stacking gel 
5% 6% 7.5% 10% 12.5% 
1. dH2O    5.65ml 5.3ml 4.8ml 3.95ml 3.15ml 2.8ml 
2. 30% Acrylamide/Bis 
solution (161-0156, 
BioRad) 
1.65ml 2ml 2.5ml 3.35ml 4.15ml 0.85ml 
3. 1.5M Tris-HCl, pH 8.8 2.5ml 2.5ml 2.5ml 2.5ml 2.5ml - 
4. 0.5M Tris-HCl, pH 6.8 - - - - - 1.25ml 
5. 10% SDS (444464T, 
BDH) 
100µl 100µl 100µl 100µl 100µl 50ml 
6. 10% Ammonium 
Persulphate (APS) (161-
0700, BioRad)* 
100µl 100µl 100µl 100µl 100µl 50ml 
7. TEMED (T-9281, 
Sigma)* 
10µl 10µl 10µl 10µl 10µl 5µl 
*Add APS and TEMED last when ready to pour gel. 
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Table 2.10. List of Kits and Special Materials 
Product Name Catalogue Number Supplier 
1. TRIzol Reagent 15596-018 Invitrogen 
2. Glycogen 901 393 Boehringer Mannheim 
3. QuantiTect Reverse 
Transcription Kit 
205311 Qiagen 
2. SYBR Green 
JumpStart Taq Ready 
Mix 
S4438 Sigma-Aldrich 
3. PCR Sealers 
Microseal ‘B’ Film 
MSB1001 Bio-Rad 
4. Non Skirted PCR 90 
Well Plates 
NS-96-CC/CP Cell Projects 
5. BioRad 500-0006 BioRad 
6. Roche Complete 
protease inhibitor cocktail 
without EDTA 
05 892 791 001 Roche 
7. Lipofectamine-2000 11668-019 Invitrogen 
8. DMSO 05879 Sigma 
9. Quick-load 1kb DNA 
ladder 
N0468S New England Biolabs 
10. Quick-load 100bp 
DNA ladder 
N0467S New England Biolabs 
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Table 2.11. List of optimal annealing temperature and concentration of 
primers used in this qPCR experiment 
Gene of interest Optimal Annealing 
Temperature 
Primer concentrations 
Gli1 64°C. FW Gli primer: 250 nM 
RW Gli primer: 1000 nM 
GAPDH FW GAPDH primer: 500 nM 
RV GAPDH primer: 125 nM 
Ptch1 59°C. FW Ptc primer: 250 nM 
RV Ptc primer: 250 nM 
GAPDH FW GAPDH primer: 125 nM 
RV GAPDH primer: 100 nM 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Chapter 3 
Investigation of how  
NRCAM is involved  
in SHH pathway 
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3.1 Introduction 
The proliferation of granule neuron progenitors (GNPs) during cerebellar 
development is induced by Sonic Hedgehog (SHH) signaling (Dahmane and 
Ruiz i Altaba, 1999, Wallace, 1999, Wechsler-Reya and Scott, 1999). Recent 
work from our lab has demonstrated that neural adhesion molecules belonging 
to L1-CNTN family are involved in SHH signalling (Xenaki et al., 2011). Soluble, 
cross-linked F3 protein (F3-fc) suppresses SHH-induced GNP proliferation. 
NRCAM, to which F3 is known to bind (Faivre-Sarrailh et al., 1999) (F3 chicken 
homolog, F11 (Morales et al., 1993)) is expressed in GNPs and F3-fc co-
localises with it on the surface of cultured GNPs. However, F3 fails to suppress 
SHH-induced proliferation when NRCAM is missing. Together these data 
suggested that F3 suppresses SHH-induced proliferation by binding to NRCAM 
on the GNP cell surface. However, exactly how F3 and NRCAM impinge on the 
effects of SHH signalling was not clear. As the effect of F3-fc on GNP 
proliferation appeared to act through NRCAM, in this study we aimed to 
understand how NRCAM is involved in SHH signalling.  
Recently, it has been shown that SHH requires a tiny cell surface protrusion 
called the primary cilium to mediate its signal (Michaud and Yoder, 2006, 
Simpson et al., 2009, Goetz and Anderson, 2010). Briefly, signalling occurs 
when SHH binds to PTCH and causes it to translocate out of the cilium, which in 
some way allows SMO to then translocate into the cilium, which activates SHH 
signalling (Rohatgi et al., 2007) (see greater details in the main introduction, 
Chapter 1, section 1.4.3). Exactly how these translocations occur is not known, 
but evidence suggests that this may require endocytosis and intracellular 
trafficking (Michaud and Yoder, 2006, Goetz and Anderson, 2010, Simpson et 
al., 2009). Since studies in other contexts have demonstrated that L1-CNTNs 
are involved in trafficking and endocytosis (Falk et al., 2005, Dang et al., 2012), 
our hypothesis is that NRCAM may be playing a role in the trafficking of SHH 
pathway components, particularly SMO or PTCH, into or out of the primary 
cilium of GNPs. Therefore, the main aim of this chapter is to investigate whether 
there is any evidence that loss of NRCAM may affect these events.  
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3.2 Results 
3.2.1 Investigation of primary cilia in the cerebellar section 
To begin to address whether NRCAM might be involved in the trafficking of SHH 
pathway components, we had first to be able to demonstrate whether we could 
visualise primary cilia on granule neuron progenitors. Although the first studies 
of cilia on GNPs were ultrastructure studies of the rat cerebellum using electron 
microscopy (Del Cerro and Snider, 1972), more recent studies have described 
primary cilia on mouse cerebellar sections using immunofluorescence (Spassky 
et al., 2008). Therefore, I began the study by attempting to verify whether 
primary cilia could be seen on GNPs in cryostat sections of the postnatal day 5 
(P5) mouse cerebellum, as it was during this period that our previous studies 
had documented differences between WT and Nrcam-/- mice (Xenaki et al., 
2011). P5 cerebellum was cryo-sectioned to 15µm and stained with antibody to 
acetylated α-tubulin, a primary cilia marker (Poole et al., 1997). However, it was 
very difficult to discern where the primary cilia were, because the number of 
GNPs and the number of axons at P5, which also stain for acetylated α-tubulin, 
is substantially higher than at E18.5, the time point at which previous studies 
were undertaken (Spassky et al., 2008). Even when I attempted to stain thinner 
sections at P5 (ie with fewer cells), I was still not able to clearly visualise primary 
cilia on the GNPs (data not shown). 
3.2.2 Development of a protocol to visualise primary cilia of GNPs in 
vitro 
Since I could not visualise primary cilia of GNPs on cerebellar sections, I also 
looked at cultured P5 GNPs, with which many of our previous observations had 
been made (Xenaki et al., 2011). GNPs were purified from P5 mice using our 
established protocol (Xenaki et al., 2011) (see Methods, section 2.3.2) and 
cultured for 24 hours without SHH. To establish the purity of the cultures, cells 
were labelled with antibodies to PAX6 [granule neuron marker; (Engelkamp et 
al., 1999)] and Glial Fibrillary Acidic Protein [GFAP; astrocyte marker; (Bignami 
et al., 1972)]. Greater than 95% of cells were PAX6+ cells (97.02±1.91%), while 
less than 1% (0.6±0.32%) was GFAP+ (Fig 3.1, consistent with previous results 
(Xenaki et al., 2011, Hatten et al., 1997). 
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Figure 3.1. Percentage of GNP populations after GNP preparation. After GNP preparation, the cells were plated for 24 hours and fixed with 
4%PFA. The cells were stained with PAX6 and GFAP and quantified percentage of GNP population. Arrow indicates the GFAP positive cell. 
Scale bar = 20µm. 
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Although our previous work had examined the downstream effects of SHH on 
GNP proliferation at 24 hours and 48 hours after plating (Xenaki et al., 2011), 
our hypothesis was that loss of NRCAM would affect the trafficking of SHH 
pathway components into or out of the primary cilium, most likely during the 
initial response to SHH addition. Since such responses, including translocation 
of PTCH and SMO to and from primary cilia, can be seen at least as early as 4 
hours after SHH addition to NIH3T3 cells (Rohatgi et al., 2007), and since we 
normally add SHH to our GNP cultures soon after plating (+1.5 hours), this 
suggested that we should attempt to visualise primary cilia as early as possible 
after this. Cultures were therefore analysed 6 hours and 24 hours after plating 
with antibodies to acetylated α-tubulin. As shown in fig 3.2, at 6 hours a number 
of cells could be seen with single α-tubulin positive protrusions that appeared to 
be primary cilia (Fig 3.2A: a and b; arrow heads). However, more widespread 
labelling was apparent in other cells (Fig 3.2A: a and b; arrows), consistent with 
the initiation of axonal processes, and by 24 hours a complex network of axons 
covered the culture and obscured most cell bodies (Fig 3.2A: c and d).  
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Figure 3.2. Comparison of visualization of primary cilia of cultured WT 
GNPs at 2 different time-points: 6 and 24 hours. (A). Primary cilia staining of 
WT GNPs cultured at 6 hours (a) at low magnification (40x). The 6 hour-cultured 
GNPs were stained with anti acetylated α-tubulin antibody and visualised at 40x. 
The primary cilium (arrow head) and the initiating axons (arrow) were shown. 
Scale bar = 20µm (b) At high magnification (100x), primary cilium (arrow head) 
and the initiating axons (arrow) on GNPs were more clearly shown. Scale bar = 
10µm (c) Primary cilia staining of WT GNPs cultured at 24 hours at low 
magnification (40x). The 24 hour-cultured GNPs were stained with anti 
acetylated α-tubulin antibody and visualised at 40x. As there were many axons 
crossing over on 24 hour-cultured GNPs, it was hard to indicate where primary 
cilium was. Scale bar = 20µm (d) At high magnification (100x) Scale bar = 10µm 
(B) At 6 hours culture, the GNP shows primary cilium (arrowhead) and axon 
(arrow) on the same cell. Scale bar = 10µm 
 
I then used antibodies to acetylated α- and γ-tubulin in combination to allow 
unambiguous identification of the primary cilium (acetylated α-tubulin+) overlying 
the basal body (γ-tubulin+) (Poole et al., 1997, Alieva and Vorobjev, 2004) on 
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purified GNPs in vitro. As shown in Fig 3.3, this allows the unambiguous 
identification of primary cilia, which are present on dissociated GNPs after 6 
hours of culture. The percentage of primary ciliated untreated GNPs 
(83.41±10.67%) was not significantly different from 4.5 hours SHH treated 
GNPs (85.81±10.95%). Although the percentage of primary ciliated GNPs was 
quite high, the number of primary cilia that I could quantitate was far fewer 
because of the cell orientation (a typical field is shown in Fig 3.2A:a). To be able 
to unambiguously demonstrate whether SMO or PTCH are present in primary 
cilia, I selected for analysis cells in which the primary cilium clearly protruded 
beyond the cell body, so that ciliary labelling was not confused with labelling in 
the main body of the cell. At this time point, 30-35% of the cells had more 
extensive labelling, consistent with this indicating the initiation of axon formation 
(Fig. 3.2A) and 15-20% of cells have labelling suggesting they have both 
primary cilia and axons (Fig. 3.2B). The number of cells having axons was not 
obviously affected by addition of SHH for 4.5 hours (data not shown). 
From these preliminary experiments, I concluded that it was considerably easier 
to identify primary cilia in GNPs at 6 hours than at 24 hours of culture. Although I 
also attempted to perform the experiment earlier than at 6 hours I found that the 
cells were more likely to detach from coverslips. Since 6 hours of culture is 
actually 4.5 hours after addition of SHH, corresponding to the point at which 
SMO and PTCH translocations are almost maximal in NIH3T3 cells (Rohatgi et 
al., 2007), this seemed a reasonable time point to use for further experiments.  
After establishing that primary cilia are present in GNPs by double labelling with 
anti-acetylated α-tubulin and γ-tubulin antibodies (Fig 3.3), in the rest of this 
study, I stained only with anti-acetylated α-tubulin antibody; the intensity of 
labelling and the unique morphology of the primary cilium when stained with this 
antibody are typically sufficient for accurately differentiating the primary cilium 
from nascent axons (see also Fig 3.2B). 
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Figure 3.3. Primary cilium is present on GNP. GNPs from WT P5 mice were purified and cultured for 6 hours and immunolabelled with anti-
acetylated α-tubulin (green) and anti-γ-tubulin antibodies (red). The localizations of basal body (arrow) and primary cilia (arrow head) on GNP 
were shown. Scale bar = 10 µm 
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3.2.3 Demonstration of PTCH and SMO localisation in primary cilia of 
cultured GNPs in response to SHH or SAG  
Recently, the stimulation of PTCH and SMO translocations in primary cilia by 
SHH signalling has mostly been demonstrated in cultured fibroblasts (Rohatgi et 
al., 2007, Milenkovic et al., 2009). To determine if this can also be seen in 
cultured GNPs, double labelling with acetylated α-tubulin and anti-SMO (a gift 
from Prof. Kathryn Anderson) or anti-PTCH (Santacruz) antibodies were 
performed. The SMO agonist, SAG (Chen et al., 2002) was used as a positive 
control, since both SMO and PTCH are known to be found in primary cilium after 
SAG treatment in other cell types (Rohatgi et al., 2007, Milenkovic et al., 2009). 
The images were visualised using a Zeiss Apotome epifluorescence 
microscope. 
Under control conditions, labelling in both cases (anti-SMO and anti-PTCH) 
could be seen throughout the cell, consistent with the fact that the cells were 
permeabilised. Some of this labelling could be attributed to non-specific labelling 
by the secondary antibody, but brighter labelling was evident with primary 
antibodies in vesicle-like structures in both cases. However, differences were 
seen between labelling with the two antibodies in and around the primary cilium: 
in the absence of SHH or SAG, while SMO labelling was strongly evident in 
vesicle-like structures around the base of the cilium (arrow heads in Fig 3.4), it 
was never seen overlapping acetylated α-tubulin labelling in the cilial 
protrusions. This changed significantly when either SHH or SAG was added. 
SMO immunoreactivity now became obvious along the primary cilium as puncta. 
In the SAG-activated condition, SMO was present along the shaft and the tip of 
the cilium in 80–90% of cilia. This was less obvious in the cilium of SHH-
activated GNPs, but was still present in 45%–50% of the cases. This is 
consistent with quantitative fluorescent imaging in SHH- activated NIH3T3 cells, 
which demonstrated that there are different SMO distribution patterns in primary 
cilia and that SMO accumulating at the tip of the cilium is correlated with SHH 
transcription activation (Yoo et al., 2012).  
By contrast, puncta of PTCH labelling were frequently seen along the length of 
the cilium, including at the cilial tip (Fig 3.5; arrow), in untreated GNPs. This cilial 
labelling was never seen with secondary antibody alone (Fig 3.6). This labelling 
changed significantly upon addition of SHH, with PTCH disappearing from the 
cilium of a significant proportion of the cells. By contrast, and in agreement with 
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the observations of others (Rohatgi et al. 2007; Milenkovic et al., 2009), the 
PTCH distribution did not change upon SAG treatment. 
Presentation of the images of fluorescently labelled proteins in primary cilia is 
very challenging, even though when the data were collected in the dark 
microscope room, the results were obvious. For this reason, I tried to image this 
in a different way to verify if I got similar results. GNPs were immunolabelled 
with anti-SMO and anti-PTCH and fluorescence was visualised using the ‘grid 
projection’ (or ‘structured illumination’) function of the Apotome microscope 
(Gustafsson, 2000). This gave similar results for both SMO and PTCH (compare 
Figs 3.4 and 3.5, with Fig 3.7). Unfortunately, although in some cases the grid 
image was clearer, in many cases grid lines appear in the images. Therefore, 
only the epifluorescent images were used for quantitation. For illustration 
however, either epifluorescent or grid visualisation is used in the subsequent 
experiments, depending on which image made the results clearer. 
Although I could not control for the specificity of the antibodies in the strictest 
sense (we did not have GNPs lacking either PTCH or SMO) several lines of 
argument suggest that the changes in anti-PTCH and anti-SMO labelling that we 
see in the primary cilia reflect changes in the distribution of the PTCH and SMO 
proteins. First, these changes were not seen with secondary antibodies alone. 
Second, both antibodies are rabbit polyclonals, yet the changes seen in cilia 
labelling are specific to each antibody under each condition. Third, in the case of 
SMO, similar changes were seen with two different sources of antibodies (Fig 
3.4 and 3.7A). The GNPs were labelled with anti-SMO antibody, which was 
kindly provided by Prof. Kathryn Anderson, USA (Fig. 3.4) and this experiment 
was repeated with anti-SMO antibody (sc-13943, Santa Cruz) (Fig. 3.7A), and 
still showed that the localisation of SMO in primary cilia is increased in addition 
to SHH and SAG. Finally, the changes seen are similar to those seen in NIH3T3 
cells in response to SHH and SAG (Rohatgi et al., 2007). 
For the quantification of these effects, I decided to quantitate the percentage 
‘occupancy’ of the cilia by the relevant protein (see the principle of how to 
quantify the SMO and PTCH ciliary occupancy in Methods, section 2.7) rather 
than measure fluorescence intensity of the labelling in the cilium. The reason for 
this was that measurements of fluorescence intensity are difficult in such a tiny 
structure (average diameter is 0.5-0.9 µm and average length is 2-3 µm) and 
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particularly complicated when the staining is punctate rather than smoothly 
distributed along the cilium.  
After SHH treatment, the percentage of primary cilia containing SMO labelling 
increases (Fig 3.4 and 3.7A; see Fig.3.8A for quantification), whereas, that of 
cilia containing PTCH is decreased when compared with control (Fig. 3.5 and 
3.7B; see Fig.3.8B for quantification). However, both SMO and PTCH are found 
in the primary cilia after addition of SAG (Fig. 3.4, 3.7A for SMO and Fig. 3.5, 
3.7B), which is consistent with previous reports (Milenkovic et al., 2009, Rohatgi 
et al., 2007) 
In summary, I have shown for the first time that PTCH and SMO proteins can be 
visualised in the primary cilia of cultured GNPs and that their behavior in 
response to SHH and SAG is similar to that seen in NIH3T3 cells (Rohatgi et al., 
2007). 
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Figure 3.4. The localisation of SMO in primary cilia is increased upon addition of SHH and SAG. Immunofluorescence of 6 hour-cultured 
GNPs (4.5 hours SHH or SAG treatment) from P5 WT mice stained with anti-acetylated α-tubulin (green), anti-SMO (kindly provided by Prof. 
Kathryn Anderson) (red) antibodies and nuclei (blue) with DAPI staining. Arrows show the presence of SMO in primary cilia in SHH and SAG 
conditions and arrowheads show the accumulation of SMO vesicle-like structure around the base of the primary cilia. To clearly see if SMO is 
present in primary cilium, insets were made to show the area marked around the primary cilium and the fluorescent intensities were 
manipulated to the same extent. The fluorescent intensity of primary cilia labelling was decreased for 25% and the fluorescent intensity of SMO 
labelling was enhanced for 100%.  Scale bar = 10µm  
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Figure 3.5. The localisation of PTCH in primary cilia is decreased upon addition of SHH or SAG. Immunofluorescence of 6 hour-cultured 
GNPs (4.5 hours SHH or SAG treatment) from P5 WT mice stained with anti-acetylated α tubulin (green), anti-PTCH (red) antibodies and nuclei 
(blue) with DAPI staining. Arrows show the presence of PTCH in primary cilia in control and SAG conditions. To clearly see if PTCH is present 
in primary cilium, insets were made to show the area marked around the primary cilium and the brightness and contrast were enhanced to the 
same extent. The fluorescent intensity of primary cilia labelling was decreased for 25% and the fluorescent intensity of PTCH labelling was 
enhanced for 100%.  Scale bar = 10µm  
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Fig. 3.6. No nonspecific binding in secondary antibody labelling control. Without adding primary antibody, the secondary antibody control 
was performed in parallel with every experiment. With the same exposure when imaging the GNPs using Apotome, nonspecific binding of 
secondary antibody was not able to be detected. Scale bar = 10µm 
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Fig. 3.7. Grid-Apotome visualisation of the localisation of SMO and PTCH 
in primary cilia of GNPs when the cells were treated with SHH or SAG. (A) 
The experiments were performed similar to Fig 3.4; however, the images were 
taken with the grid-apotome. Briefly, immunofluorescence of 6 hour-cultured 
GNPs from P5 WT mice stained with anti-acetylated α tubulin (green), anti-SMO 
(red) antibodies (SantaCruz) and nuclei (blue) with DAPI staining. Arrows show 
the presence of SMO in primary cilia in control and SAG conditions. To clearly 
see if SMO is present in primary cilium, insets were made to show the area 
marked around the primary cilium and the brightness and contrast were 
enhanced to the same extent. Scale bar = 10µm (B) The experiments were 
performed similar to Fig 3.5; however, the images were taken with the grid-
apotome. Briefly, immunofluorescence of 6 hour-cultured GNPs from P5 WT 
mice stained with anti-acetylated α tubulin (green), anti-PTCH (red) antibodies 
(Santa Cruz) and nuclei (blue) with DAPI staining. Arrows show the presence of 
PTCH in primary cilia in control and SAG conditions. To clearly see if PTCH is 
present in primary cilium, insets were made to show the area marked around the 
primary cilium and the brightness and contrast were enhanced to the same 
extent. Scale bar = 10µm 
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Fig. 3.8. Quantification of SMO and PTCH occupancies in primary cilia of 
GNPs after addition of SHH or SAG. (A) Acquired images of 4.5 hours SHH 
and SAG stimulated GNPs after labelling with anti-acetylated α tubulin, anti-
SMO antibodies and nuclei with DAPI were quantified the SMO ciliary 
occupancy. After addition of SHH or SAG to GNPs, the percentage of SMO 
occupancy in primary cilia is increased in SHH and SAG conditions when 
compare with control. Thirty GNPs were quantified the occupancy of SMO in 
primary cilium, from each 3 independent experiments. The data are graphed 
showing the Standard Error of the Mean (SEM) and tested for statistically 
significant differences among the control and treated samples using one-way 
ANOVA, followed by Bonferroni’s post-test. The bar graphs show Mean±SEM. 
Confidence interval was set to 95%, with a p-value less than 0.05 taken as 
statistically significant. Statistical significances are indicated as asterisks; *: 
p<0.05, **: p<0.01, ***: p<0.001, ****: p<0.0001 and N.S.: not significant. (B) 
Acquired images of 4.5 hours SHH and SAG stimulated GNPs after labelling 
with anti-acetylated α tubulin, anti-PTCH antibodies and nuclei with DAPI were 
quantified the PTCH ciliary occupancy. After addition of 30nM SHH for 4.5 
hours, the percentage of PTCH occupancy in primary cilia is decreased, 
however, this occupancy is not affected by addition of SAG when compare with 
control. Thirty GNPs were quantified the occupancy of PTCH in primary cilium, 
from each 3 independent experiments. The data are graphed showing the 
Standard Error of the Mean (SEM) and tested for statistically significant 
differences among the control and treated samples using one-way ANOVA, 
followed by Bonferroni’s post-test. The bar graphs show Mean±SEM. 
Confidence interval was set to 95%, with a p-value less than 0.05 taken as 
statistically significant. Statistical significances are indicated as asterisks; *: 
p<0.05, **: p<0.01, ***: p<0.001, ****: p<0.0001 and N.S.: not significant. 
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3.2.4 NRCAM, TAG-1 but not F3 are present in primary cilia of GNPs  
Our hypothesis is that NRCAM is involved in the trafficking of SHH pathway 
components, particularly PTCH or SMO, into or out of the cilium. If this is the 
case, we might expect that NRCAM should be present, either in the primary 
cilium or somewhere around base of primary cilia, where it is thought that PTCH 
and SMO can be found in trafficking vesicles (Pazour and Bloodgood, 2008, 
Martin et al., 2001, Petralia et al., 2012)  
To investigate the localisation of NRCAM in primary cilia of GNPs, double-
labeling with acetylated α-tubulin and NRCAM antibodies was performed on 6 
hour-cultured GNPs. Anti-TAG-1 and anti-F3 labelling was also included: anti-
TAG-1 as a positive control, because the majority of GNPs should express it 
(Xenaki et al., 2011), and anti-F3 as a matched negative control which should 
not be present; like anti-NRCAM, anti-F3 is a rabbit polyclonal (see Methods).  
As shown in Fig. 3.9A, anti-NRCAM immunoreactivity is clearly present in 
primary cilia as well as in the body of the cell. I was able to see similar TAG-1 
labelling, including labelling in the cilium. Perhaps surprisingly, anti-F3 
immunoreactivity was also seen on vesicle-like structures within the body of the 
cell, notably around the base of the primary cilium, however, reactivity of anti-F3 
in the primary cilia was not seen. 
Because both antibodies are rabbit polyclonals, the lack of F3 labelling in 
primary cilium strongly suggests that the anti-NRCAM immunoreactivity in the 
cilium is due to the presence of NRCAM. However, given that NRCAM shares 
35-40% identity with its sister molecules, L1, CHL1 and NFASC (Holm et al., 
1996), I was concerned that there may be cross-reactivity. To test this, I labelled 
GNPs from Nrcam-/- mice with the anti-NRCAM antibody (838). Although the 
labelling was significantly weaker than on WT GNPs (compare with Fig 3.9A), 
some signal could still be detected (Fig 3.9B:a). I therefore performed an 
antibody pre-absorption on tissues from E13.5 Nrcam-/- embryos (see protocol in 
Materials and Methods, section 2.6). The resulting antibody, designated ‘838-’, 
was then titrated until no signal could be detected on Nrcam-/- GNPs (Fig. 
3.9B:b). At these concentrations, this pre-absorbed antibody still gave a strong 
signal on WT GNPs (for example, Fig 3.13A) and was then used for all 
subsequent GNP labelling in this study. 
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Figure 3.9. NRCAM, TAG-1 but not F3 are present in primary cilia of WT GNPs. (A) Immunofluorescence from 6 hour-cultured GNPs from 
P5 WT mice, which were purified and cultured for 6 hours and immunolabelled with anti-acetylated α-tubulin (green) and anti-NRCAM 838, 
TAG-1 or F3 antibodies (red). To clearly see if NRCAM, TAG-1 or F3 is present in primary cilium, insets were made to show the area marked 
around the primary cilium and the brightness and contrast were enhanced to the same extent. Arrows show the presence of NRCAM and TAG-
1 in primary cilia. (B) Testing NRCAM 838 and NRCAM 838- antibodies on Nrcam-/- GNPs. (a) Before NRCAM 838 antibody pre-absorption. 
GNPs from P5 Nrcam-/- mice were purified and cultured for 6 hours and immunolabelled with anti-acetylated α-tubulin (green) and anti-NRCAM 
838 antibodies (red). The NRCAM 838 antibody staining shows signal on Nrcam-/- GNPs (arrow). (b) After NRCAM 838 antibody pre-
absorption, which was named as NRCAM 838- antibody. NRCAM signal is not detected on Nrcam-/- GNPs. Scale bar = 10 µm  
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3.2.5 Loss of NRCAM affects the localisation of SMO and PTCH in 
primary cilia 
The results above clearly indicate that NRCAM is present in the primary cilia of 
6 hour-cultured GNPs. Therefore, NRCAM is in the right place at the right time 
to be involved in the translocations of SMO and PTCH to or from the primary 
cilium. Therefore, I started testing the main hypothesis by investigating whether 
loss of NRCAM affects these translocations. To achieve this, immunolabelling 
with anti-SMO or anti- PTCH was performed with acetylated α-tubulin antibodies 
after SHH or SAG treatment of WT or Nrcam-/- GNPs.  
Loss of NRCAM did not significantly affect the number of cilia found on cultured 
GNPs at 6 hours (83.41±10.67% in untreated WT GNPs and 87.72±9.24% in 
untreated Nrcam-/- GNPs), nor was the proportion of cilia that were scored 
positive for SMO immunofluorescence changed under basal (untreated) 
conditions (Fig. 3.10B). However, in the presence of SHH, SMO localisation in 
primary cilia was significantly reduced in Nrcam-/- GNPs when compared with 
WT GNPs (Fig. 3.10B, p<0.0001, one-way ANOVA, followed by Bonferroni’s 
post-test). Interestingly, however, SAG induction of SMO translocation to 
primary cilia is unaffected by loss of NRCAM (Fig. 3.10B). 
These results suggested that NRCAM plays a role in localising SMO to primary 
cilia after SHH treatment. However, I considered the alternative possibility that 
SMO fails to enter the primary cilium in Nrcam-/- GNPs because NRCAM is 
required for PTCH to leave the primary cilium. To verify this, I tested whether 
loss of NRCAM affects the translocation of PTCH out of primary cilia in 
response to SHH. If NRCAM is required for PTCH removal, PTCH should 
remain in primary cilia whether or not SHH is added to Nrcam-/- GNPs. Similar to 
SMO, the proportion of primary cilia containing PTCH protein under control 
conditions was unaffected by NRCAM loss (77.5±1.44% in untreated WT GNPs 
and 78.63±4.64% in untreated Nrcam-/- GNPs). However, addition of SHH to 
Nrcam-/- GNPs had no affect on occupancy (87.55±1.41%), whereas this was 
reduced to ~45% in WT GNPs (40.97±0.56%), suggesting that PTCH is not able 
to leave primary cilia when NRCAM was missing (Fig. 3.11).  
We also attempted to investigate if loss of NRCAM alters the overall levels SMO 
and PTCH protein expressions of GNPs by performing western blot, 
unfortunately however our antibodies did not work properly. However, the SMO 
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and PTCH ciliary occupancies in SAG-activated WT and Nrcam-/- GNPs were 
not significantly different between WT and Nrcam-/- GNPs, and the general level 
of immunofluorescence in the cells appeared similar, suggesting that loss of 
NRCAM does not obviously affect the pools of SMO and PTCH in the cells. 
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Figure 3.10. Loss of NRCAM affects SMO localisation in primary cilia of GNPs after addition of SHH or SAG. (A) Immunostaining of 
cultured GNPs of P5 mice with anti-acetylated α-tubulin (green) and anti-SMO antibodies (kindly provided from Prof. Kathryn Anderson) (red) 
compared between wild type and Nrcam-/- GNPs in control, SHH and SAG (100nM) conditions. To clearly see if SMO is present in primary 
cilium, insets were made to show the area marked around the primary cilium and the brightness and contrast were enhanced to the same 
extent. Arrows show SMO inside primary cilia. In Nrcam-/- GNPs, SMO localization in primary cilia is not affected by addition of SHH; however, 
SAG can still increase SMO localisation in primary cilia. Scale bar = 10µm (B) Quantification of 30 fields in each condition (3n) shows the 
percentage of primary cilia containing SMO protein (3 independent experiments). The data are graphed showing the Standard Error of the 
Mean (SEM) and tested for statistically significant differences among the control and treated samples using one-way ANOVA, followed by 
Bonferroni’s post-test. The bar graphs show Mean±SEM. Confidence interval was set to 95%, with a p-value less than 0.05 taken as 
statistically significant. Statistical significances are indicated as asterisks; *: p<0.05, **: p<0.01, ***: p<0.001, ****: p<0.0001 and N.S.: not 
significant. (C) The experiments were performed similar to (A) but GNPs were stained with anti-SMO antibody from Santacruz and the images 
were taken with the grid-apotome 
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Figure 3.11. Loss of NRCAM also affects PTCH exit from primary cilia. (A) Immunostaining in cultured GNPs of P5 mice with anti-
acetylated α-tubulin (green) and anti-PTCH antibodies (red) compared between wild type and Nrcam-/- GNPs in control (no additions), SHH and 
SAG (100nM) conditions. To clearly see if PTCH is present in primary cilium, insets were made to show the area marked around the primary 
cilium and the brightness and contrast were enhanced to the same extent. Arrows show PTC inside primary cilia. In Nrcam-/- GNPs, PTCH 
localization in primary cilia is not changed in addition of SHH as well as in addition of SAG. Scale bar = 10µm (B) Quantification of 30 fields in 
each condition (3n) shows the percentage of primary cilia containing PTCH protein (3 independent experiments). The data are graphed 
showing the Standard Error of the Mean (SEM) and tested for statistically significant differences among the control and treated samples using 
one-way ANOVA, followed by Bonferroni’s post-test. The bar graphs show Mean±SEM. Confidence interval was set to 95%, with a p-value less 
than 0.05 taken as statistically significant. Statistical significances are indicated as asterisks; *: p<0.05, **: p<0.01, ***: p<0.001, ****: p<0.0001 
and N.S.: not significant. (C) The experiments were performed similar to (A); however, the images were taken with the grid-apotome.  
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3.2.6 Loss of NRCAM does not affect the percentage of GNP with primary 
cilium whether or not SHH is added 
The results above seem to suggest that the ability of PTCH and SMO to 
translocate in primary cilia in response to SHH is affected by loss of NRCAM. 
However it is possible that the number of primary cilia may have changed which 
might affect the results. If loss of NRCAM affects the percentage of primary cilia 
of GNPs, this might affect the way we interpret data. I therefore compared the 
percentage of ciliated cells between WT and Nrcam-/- GNPs. Cultured WT and 
Nrcam-/- GNPs were treated with SHH, fixed and stained with acetylated α-
tubulin antibody and quantitated for the percentage of primary cilia with and 
without addition of SHH. As shown in Fig. 3.12, the percentage of primary cilia 
of WT and Nrcam-/- GNPs were not significantly different in either condition. 
Therefore, I came to the conclusion that loss of NRCAM does not affect the 
number of primary cilia of GNPs, however, it does affect the ability of PTCH and 
SMO to translocate within primary cilia in response to SHH at 4.5 hours.  
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Figure 3.12. No significant difference in the percentage of WT and Nrcam-/- 
GNPs with primary cilium after addition of SHH for 4.5 hours. The P5 WT 
and Nrcam-/- GNPs were cultured and treated with SHH for 4.5 hours. Then the 
cells were fixed with 4% PFA and immunolabelled with anti-acetylated α-tubulin 
antibody to the primary cilium. 20 image fields from 3 independent experiments 
were quantified for the percentage of GNPs with primary cilium. There were no 
significant differences between the percentages of WT and Nrcam-/- GNPs with 
primary cilium with or without addition of SHH. The data are graphed showing 
the Standard Error of the Mean (SEM) and tested for statistically significant 
differences among the control and treated samples using one-way ANOVA, 
followed by Bonferroni’s post-test. The bar graphs show Mean±SEM. 
Confidence interval was set to 95%, with a p-value less than 0.05 taken as 
statistically significant. Statistical significances are indicated as asterisks; *: 
p<0.05, **: p<0.01, ***: p<0.001 and N.S.: not significant.  
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3.2.7 The occupancy of NRCAM in primary cilia is not affected in addition 
of SHH or SAG 
The results above showed that NRCAM is present in the primary cilium and that 
the loss of NRCAM affects the translocations of SMO and PTCH in primary cilia 
after SHH treatment. Therefore we speculated that if NRCAM is involved in 
trafficking of either PTCH removal or SMO entry to primary cilia of GNPs, 
NRCAM might itself be translocated in response to SHH treatment. However, as 
shown in fig. 3.13, the occupancy of NRCAM in primary cilia is not significantly 
changed by addition of SHH or SAG (p>0.9999, one-way ANOVA, followed by 
Bonferroni’s post-test), at least not at 4.5 hours post-treatment. 
 
 
 
 
 
 
 
 
 Oratai Weeranantanapan 
 
102 
 
 
 
 
 Oratai Weeranantanapan 
 
103 
 
 
 
 
 
_________________________________________________________________________________________________________________ 
Figure 3.13. The occupancy of NRCAM in primary cilia is not significantly affected by addition of SHH or SAG. (A) Immunofluorescence 
of cultured GNPs from P5 WT mice which were cultured and treated with SHH or SAG for 4.5 hours and immunolabelled with anti-acetylated α-
tubulin (green), anti-NRCAM 838- (red) antibodies and nuclei (blue) with DAPI staining. To clearly see if NRCAM is present in primary cilium, 
insets were made to show the area marked around the primary cilium and the brightness and contrast were enhanced to the same extent. 
Arrows show the presence of NRCAM in primary cilia. Scale bar = 10µm (B) After addition of 30nM of SHH or 100NM SAG to GNPs for 4.5 
hours, the percentage of NRCAM occupancy in primary cilia is not significantly changed when compare with control. 30 GNPs were quantified 
the occupancy of SMO in primary cilium, from each 3 independent experiments. The data are graphed showing the Standard Error of the Mean 
(SEM) and tested for statistically significant differences among the control and treated samples using one-way ANOVA, followed by 
Bonferroni’s post-test. The bar graphs show Mean±SEM. Confidence interval was set to 95%, with a p-value less than 0.05 taken as 
statistically significant. Statistical significances are indicated as asterisks; *: p<0.05, **: p<0.01, ***: p<0.001 and N.S.: not significant.  
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3.3 Discussion 
Primary cilia are required for the SHH signalling in vertebrate, a key pathway 
controlling cell proliferation and differentiation (Michaud and Yoder, 2006, 
Simpson et al., 2009, Goetz and Anderson, 2010). PTCH, which is a receptor for 
SHH localises in primary cilium in the absence of SHH. When SHH binds PTCH, 
the complex leaves primary cilium and this allows SMO to translocate to the 
cilium and activate downstream signalling events (Rohatgi et al., 2007, Corbit et 
al., 2005). However, the mechanism that regulates PTCH and SMO 
translocation in primary cilia is not clearly understood. Since F3 can suppress 
SHH-induced proliferation of GNPs via binding to NRCAM (Xenaki et al., 2011), 
and given that we know from studies in other contexts that L1-CNTNs play a 
role in trafficking and endocytosis (Falk et al., 2005, Dang et al., 2012), we 
hypothesised that NRCAM might be involved in trafficking of either PTCH or 
SMO in primary cilium. In this chapter, we established for the first time that 
NRCAM is present in primary cilia and that loss of NRCAM affects the 
localisation of PTCH and SMO in primary cilia of GNPs after addition of SHH for 
4.5 hours. This suggests that NRCAM might play a role in either PTCH or SMO 
trafficking in the primary cilia of GNPs. 
3.3.1 Primary cilia of GNPs 
Primary cilia of GNPs from cerebellar sections 
Previous studies have demonstrated the presence of primary cilia on GNPs in 
cerebellar sections from rodents (Spassky et al., 2008). I initially started my 
study by trying to verify this using anti-acetylated α-tubulin antibody on sections 
of P5 mouse cerebellum. However, as anti-acetylated α-tubulin antibody also 
labels axons, I had difficulty to identify where exactly primary cilia are, whereas 
Spassky et al. were able to do this (Spassky et al., 2008). Although Spassky et 
al. also used anti-acetylated α-tubulin antibody, their study was conducted at 
E18.5, at which stage the number of axons is considerably reduced compared to 
P5. Other studies have been able to identify primary cilia at later stages by using 
antibodies against adenylate cyclase type III, which labels cilia more specifically 
(Chizhikov et al., 2007). Therefore, if I were to repeat these studies, I might 
attempt to try other primary cilia makers such as anti- Arl13b, anti-Sstr3, anti-
adenylyl cyclase III antibodies, which are also shown that they are able to use 
as primary cilia markers (Berbari et al., 2007, Cantagrel et al., 2008, Chizhikov 
et al., 2007).  
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Primary cilia of cultured GNPs 
Despite the importance of the primary cilium to GNP development (Spassky et 
al., 2008), it mostly has been described in cerebellar sections and only once on 
acutely dissociated GNPs (Cantagrel et al., 2008). So for the first time we have 
established that cilia can be visualised on cultured GNPs. Interestingly, about 
20% of the GNPs in our cultures appeared not to have cilia (Fig 3.12). This 
could be for a number of reasons: the first reason may be simply the practical 
limits of my method of visualisation: since GNPs are quite spherical in culture, 
cilia can be hidden behind the body of the cell quite easily and therefore easily 
missed. However, it is also possible that some cells do not have cilia because 
they are in a specific stage of the cell cycle: primary cilia start decreasing in 
length in G2 phase and are disrupted when the cells go into M phase of the cell 
cycle (Plotnikova et al., 2009). Consistent with this possibility, we know that our 
cultured GNPs are a heterogeneous cell population: At 6 hours, we know that 
~98% of the GNP population expresses the cell cycle marker Ki67+ (Xenaki et 
al., 2011). Although we did not measure the proportion of cells in G2 and M 
phase, previous studies of P10 rat cerebellum suggest that this may be as much 
as 14% of cells (Bodenant et al., 1997) Therefore, it is possible that I was not 
able to see the primary cilia of some cells because they were in G2/M or M-
phase of the cell cycle.   
This study also provides the first evidence demonstrating that changes in SMO 
and PTCH localisation can be analysed in primary cilia of cultured GNPs in 
response to SHH and SAG and this is consistent with the previous study which 
was demonstrated in NIH3T3 cells (Rohatgi et al., 2007, Milenkovic et al., 2009). 
Apart from NIH3T3 and mouse embryonic fibroblasts (MEFs) cells, which are 
widely used for studying SMO and PTCH activity in primary cilia (Rohatgi et al., 
2007, Milenkovic et al., 2009, Tukachinsky et al., 2010), as far as I am aware, 
the only other such study shows that undifferentiated human embryonic stem 
cell (hESC) lines possess primary cilia and the SMO and PTCH ciliary 
localisations are changed in response to SAG (Kiprilov et al., 2008). My study is 
therefore the first evidence of SMO and PTCH translocations in primary cells. 
This study then not only provides an alternative cell type to dissect SHH 
pathway but also verifies the relevance of the studies on cell lines to primary 
cells. 
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3.3.2 L1-CNTNs in primary cilia 
NRCAM and TAG-1 are present in primary cilia  
In this chapter I showed the presence of NRCAM and TAG-1 in primary cilium, 
which, as far as we are aware, is the first time that members of the L1 and 
contactin families have been shown to be present in cilia. Interestingly, a C. 
elegans L1 homolog, LAD-2 does appear in an online database of cilia-
associated genes (http://www.sfu.ca/~leroux/ciliome_database.htm), but the 
significance of its inclusion in the original study, which used a functional 
genomics approach to identifying ciliary proteins, is unclear (Blacque et al., 
2005). Indeed, some aspects of an L1-linked human neurological syndrome 
(CRASH/SPG1) bear some resemblance to ciliopathies (hydrocephalus, mental 
retardation;(Yamasaki et al., 1997)), but to date no link with cilia has been 
described. 
We also showed that NRCAM is present in the right place and at the right time 
and this raises the possibility that NRCAM could play a role in either PTCH or 
SMO trafficking in primary cilium. If this is the case, we speculated that the 
change of NRCAM occupancy in primary cilia should positively correlate with the 
occupancy of PTCH or SMO in primary cilia in response to SHH. However, the 
percentages of cilia containing NRCAM were not altered after the treatment of 
either SHH or SAG for 4.5 hours. The first possible explanation of this result 
could be that NRCAM might not be involved with either PTCH or SMO trafficking 
event in primary cilia, whereas, the second possibility is that NRCAM could be 
recycled while trafficking PTCH or SMO in primary cilia and this clearly need to 
be further investigated. A study in the context of neuronal responses to axon 
guidance cues found that L1, another member of L1-CNTN family, is required 
for receptor endocytosis during growth cone responses to Semaphorin3A 
(SEMA3A), one of the secreted Semaphorins (Castellani et al., 2004). Indeed, 
NRCAM has also been shown to be associated with Neuropilin2 (NRP2) and to 
mediate its endocytosis and SEMA3B signalling (Falk et al., 2005).  
3.3.3 The localisation of SMO and PTCH in primary cilia 
Interestingly, we found that there was 7.75±1.28% SMO occupancy in primary 
cilia of WT GNPs even in the absence of SHH. This is consistent with the results 
of Yoo et al. who saw that 10%-20% of NIH3T3 cells accumulated SMO in their 
cilia without addition of SHH (Yoo et al., 2012). It is possible that SMO is 
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capable of trafficking to the cilium to maintain a low level of SMO so that upon 
SHH binding to PTCH, SHH signalling is fired immediately. It is also possible, of 
course, that the small percentage of cells I see with SMO in their cilia reflect the 
remnant of cells that were already receiving SHH signal at the time that the 
cerebellum was being dissected. 
In this chapter, we also found SMO and PTCH localisations in the primary cilia 
of SAG-stimulated GNPs. This indicates that it is not necessary for PTCH to 
leave the primary cilium for SMO to enter. The result is consistent with the study 
in NIH3T3 cells (Rohatgi et al., 2007), however, it contradicts to study in hESc 
lines, which showed that SMO moves in and PTCH moves out when the cells 
expose to SAG (Kiprilov et al., 2008). Interestingly, the difference between these 
studies is that Kiprilov monitored PTCH from 1 – 4 hours after SAG treatment, 
whereas Rohatgi only looked at 4 hours and 24 hours and found much higher 
levels of PTCH in the cilium at the latter time point, suggesting that perhaps an 
initial removal of PTCH from the cilium of NIH3T3 cells was missed because it 
was followed by a subsequent replenishment at later time points. 
Unexpectedly, we could see whole GNP cell labelling with SMO and PTCH (Fig 
3.4 and 3.5, respectively), which were different from the study in NIH3T3 cells 
(Rohatgi et al., 2007). Although the cells were permeablised before 
immunolabelling in both studies, it would be interesting to investigate whether 
the labelling I see in the GNP cell body is surface labelling or internal labelling. 
In the case of SMO, a possible explanation of why we found SMO whole cell 
labelling would be that there are 2 pools of SMO, surface membrane and 
endosomal pools. It is not clear yet how SMO transport to primary cilia but 
Milenkovic et al. proposed a model of how SHH-induced SMO transport to the 
primary cilium (Milenkovic et al., 2009). The first way is a direct trafficking from 
Golgi to ciliary base. The second way is transport to the cell surface followed by 
lateral transport to the cilium and the last way is surface localisation followed by 
internalisation to recycling pathway. Therefore it would be possible that all of 
these dynamic events are happening all the time, resulting in the SMO labelling 
shows all over the whole cells. The result of seeing SMO and PTCH labelling all 
over the cells is also consistent with the immunofluorescent study in P2 rat 
hippocampal neurons that showed that PTCH and SMO were positive in soma 
and tips of neuronal cell processes (Petralia et al., 2011). 
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Interestingly, the vesicle-like structures of SMO were also found accumulated at 
the base of cilium (Fig 3.4, arrow heads). Although it is not clear how SMO and 
PTCH traffick to the cilium, immune-gold labelling of PTCH and SMO in 
immature rat cerebellum showed that they were present either within or near 
endosomes (Petralia et al., 2012). 
3.3.4 Loss of NRCAM affects the localisation of SMO and PTCH in 
primary cilia 
Having revealed the presence of NRCAM in primary cilia of GNPs, I then asked 
the question whether its presence was important. I showed that loss of NRCAM 
did not affect the percentage of GNPs with primary cilia, nor did it affect the 
localisation of SMO or PTCH in control conditions (Fig 3.10, 3.11). However, 
NRCAM loss did affect the translocation of SMO into cilia that normally occurs in 
response to SHH (Rohatgi et al., 2007, Milenkovic et al., 2009). In principle, this 
could be a direct effect on SMO translocation or it could be due to an effect of 
NRCAM loss on other components of the SHH pathway. We speculated that 
NRCAM somehow controls the translocation of PTCH out of primary cilia rather 
than SMO entry into primary cilia. Consistent with this, loss of NRCAM also 
affected the ability of PTCH to translocate out of the cilium as well as the ability 
of SMO to localise in the cilium after SHH treatment. Rohatgi et al. showed in 
NIH3T3 cells that the localisation of PTCH in primary cilia inhibits SMO entry to 
the primary cilia (Rohatgi et al., 2007). It seems likely; therefore, that the reason 
loss of NRCAM also affects SMO is because it is a consequence of the failure of 
PTCH to leave the primary cilia. Consistent with this idea, I found that SAG-
induced translocation of SMO into the cilium is not affected by loss of NRCAM. 
SAG, which binds directly to SMO (Chen et al., 2002), is known to affect SMO 
translocation irrespective of whether PTCH leaves the cilium (Rohatgi et al., 
2007). This is also consistent with previous observations in the lab that F3-fc is 
unable to suppress the proliferation induced by SAG, or the constitutive 
proliferation seen in GNPs expressing a constitutively active SMO (SMOA) 
(Xenaki, unpublished data). Together, all of these observations suggest that 
NRCAM is acting upstream of SMO affecting PTCH rather than SMO trafficking 
in primary cilia of GNPs.  
However, clearly there could be other possibilities that directly or indirectly affect 
the localisation of PTCH and SMO. For example, we can not clearly rule out that 
NRCAM affects the trafficking of SMO into an intracellular sub-compartment, 
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which may be required before PTCH is able to leave the primary cilium. Indeed, 
recent studies suggest that SMO activation may be a multi-step process 
involving the localisation of SMO to different ciliary-subregions (Wilson et al., 
2009). Therefore, the second possibility is that NRCAM affects SMO entry or 
both PTCH removal and SMO entry into primary cilia. 
The next possibility is that NRCAM affects other SHH pathway components 
such as BOC, GAS1. It has been shown that BOC and GAS1 each are required 
for SHH to form a complex with PTCH (Izzi et al., 2011). We therefore 
speculated that NRCAM might be required for either BOC or GAS1 trafficking 
and this indirectly has an effect on the trafficking of PTCH out of primary cilia. 
However, when I tested this, I did not see that loss of NRCAM alters the 
localisation of neither BOC nor GAS1 in primary cilia (data not shown).  
In fact, the other protein components that have been demonstrated to be 
involved in SHH signalling are Neurophilins (NRPs). They act as positive 
regulators of SHH signalling (Hillman et al., 2011). Moreover, Falk et al. showed 
that NRCAM interacts with NRP2 on the same membrane to act as a co-
receptor for SEMA3B (Falk et al., 2005). Taken together, this suggests NRPs 
are possibly involved in SHH signalling via NRCAM. In fact, Nrcam-/- GNPs still 
proliferate in response to SHH (Xenaki et al., 2011). This is currently being 
investigated in our lab. 
Despite these alternatives, the most obvious way that NRCAM could affect the 
translocations of SMO and PTCH would be through a direct interaction. Since 
this had not been tested before, this became the focus of the work described in 
the next chapter. 
The other question that arises is why, if PTCH and SMO translocations are 
disrupted in Nrcam-/- GNPs, this does not apparently dramatically disrupt SHH 
signalling in Nrcam-/- mice, which are viable as homozygotes and show only 
minor cerebellar defects (Sakurai et al., 2001). This may be because L1 has a 
redundant function with NRCAM (Sakurai et al., 2001). In fact L1 has also been 
implicated in controlling the proliferation of normal cells (Sakurai et al., 2001, 
Dihne et al., 2003) and tumor cells (Agic et al., 2010, Arlt et al., 2006). However, 
Xenaki et al. showed that F3, which is known to bind NRCAM to suppress SHH-
induced proliferation of GNPs, was not colocalised with L1 when NRCAM is 
missing and L1 is not normally expressed on proliferating GNPs (Xenaki et al., 
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2011). Even so, Nrcam-/- GNPs apparently still proliferate in response to SHH, 
although this was not directly compared to the response of WT cells (Xenaki et 
al., 2011). However, because proliferation is measured 24 hours or longer after 
SHH treatment, it is possible that there are subtle changes to the kinetics of 
SHH signalling. To address this more directly, in Chapter 5 I look at effects on 
immediate early responses to SHH. 
 
 
  
 
 
 
 
 
 
 
Chapter 4 
Investigation of  
the interaction of  
PTCH1 and NRCAM
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4.1 Introduction 
The results from the previous chapter seems to suggest that NRCAM is required 
for the removal of PTCH from the primary cilium of granule neuron progenitors 
4.5 hours after SHH treatment. Our hypothesis is that this is because NRCAM is 
required for the trafficking of one or more components of the SHH signalling 
pathway into or out of the cilium. This could be a direct or an indirect effect on 
PTCH and/or SMO. The simplest explanation of our data would be that NRCAM 
interacts directly with PTCH and is required for its trafficking out of the cilium. 
However, I am not be able to rule out that NRCAM affects the trafficking of SMO 
into an intracellular sub-compartment, which may be required before PTCH is 
able to leave the cilium. Indeed, recent studies suggest that SMO activation may 
be a multi-step process involving the localisation of SMO to different ciliary sub-
regions (Wilson et al., 2009). Thus, formally NRCAM might affect either PTCH 
or SMO. Moreover, this may be a direct or an indirect effect, for instance, 
NRCAM could be required for the trafficking of accessory molecules such as 
BOC or GAS1 to the primary cilium, or indeed NRCAM may be required more 
generally for the trafficking of vesicles to or from the cilium. To put this into 
context, below I briefly review what is known of the trafficking of PTCH and SMO 
and their interactions with other proteins. 
4.1.1 Known interactions of PTCH and SMO with other proteins 
Upon SHH pathway activation, SHH binds PTCH and the complex translocate 
out of the primary cilium, followed by internalisation to the cytoplasm (Rohatgi et 
al., 2007, Incardona et al., 2000, Incardona et al., 2002). However, it has not 
been clearly shown how PTCH moves out from the cilium and whether there are 
other proteins physically interacting or facilitating its translocation. PTCH1 is 
known to associate individually with three accessory proteins - growth arrest-
specific 1 (GAS1), CAM-related/down-regulated by oncogenes (CDO), and 
brother of CDO (BOC) - that appear to act as co-receptors with PTCH1 to 
facilitate HH binding and to be necessary for SHH activity (Izzi et al., 2011). 
Although ciliary localisation of these proteins has not been demonstrated, this 
raises the formal possibility that NRCAM could play a role in their trafficking and 
thus indirectly affect the ability of PTCH to leave the cilium. 
By contrast, rather more proteins have been found to interact with SMO and 
regulate SHH signalling pathway, β-Arrestins, multifunctional adaptors that 
mediate the desensitisation and internalisation of seven-transmembrane protein 
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receptors (Shenoy et al., 2009), interact with SMO that has been 
phosphorylated by G-protein-coupled receptor kinase 2 (GSK2), which facilitates 
SMO endocytosis (Chen et al., 2004). β-Arrestins also appear to be required for 
the localisation of SMO to the primary cilium apparently by forming multimeric 
complex with the kinesin motor protein, KIF3A (Kovacs et al., 2008). β-Arrestins 
and SMO also appear to be closely associated with Integrin-linked kinase (ILK), 
an essential effector of β1 integrin signalling, and ILK-depleted intermedullary 
collecting duct cells (IMCD3) and 10T1/2 cells had an effect on SMO ciliary 
translocation when the cells were activated by either SHH or SAG (Barakat et 
al., 2013). Myc-interacting Zinc finger protein 1 (MIZ1), a member of the POZ 
domian/zinc finger transcription factor family, has been also found to co-
precipitate with SMO and GLI2 and positively regulates SHH signalling by 
playing a role in GLI2 nuclear translocation (Lu et al., 2013). In addition, the 
study in chondrocytes has been demonstrated that EVC and EVC2, genes 
which responsible for the recessive skeletal dysplasia Ellis-van Creveld 
Syndrome (EvC), regulate IHH activity by interacting with SMO but not 
regulating SMO translocation. Instead EVC/EVC2 appear to control SuFu/GLI3 
dissociation and GLI3 translocation in primary cilium of chondrocytes (Caparros-
Martin et al., 2013).  
Although, the data above seems to suggest that several proteins have been 
associated with SMO, only β-Arrestins have been shown to be directly involved 
in SMO ciliary trafficking. Since β-Arrestins have been shown to be involved in 
the trafficking of several seven transmembrane receptors (Shenoy et al., 2009), 
and there are several seven transmembrane proteins localising in primary cilia 
such as Somatostatiin (SSTR3) (Handel et al., 1999), Serotonin receptor 
(Brailov et al., 2000), Angiotensin II receptor (Woost et al., 2006), it is possible 
that additional proteins may be required to specify the ciliary localisation of 
SMO. To date, however, there is no evidence to suggest that cell adhesion 
molecules are involved in SMO ciliary localisation. Given the results from 
previous chapter, in this chapter, I therefore investigate whether NRCAM is 
involved in SHH signalling through direct interactions with SHH pathway 
components. 
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4.2 Results 
4.2.1 Choice of transfected cell systems  
Our objective was to test whether there are direct interactions of NRCAM with 
SHH signalling components. In principle, we would have liked to look for these 
interactions in primary GNPs by performing immunoprecipitaion, however there 
are a number of limitations to achieving this: the main limitation was that the 
amount of protein obtained from cultured purified GNPs was very low even 
when I combined collected protein from several wells. Consistent with this, we 
had difficulty detecting an anti-PTCH immunoreactive band in P5 GNP lysates 
on a western blot, even though a 140kD band (the predicted size) was detected 
in embryonic brain lysates (not shown).  
In order to perform immunoprecipitation using A/G-PLUS agarose beads (sc-
2003, Santacruz), 500µg of lysate protein is required, according to the 
manufacturers directions. However, the amount of protein from cultured purified 
GNPs that I obtained was only 10-20µg/cerebellum. Moreover, it was not clear 
where the interactions were likely to occur or how abundant they would be. If 
NRCAM is involved in removing PTCH from the cilium, for example, perhaps 
only those NRCAM and PTCH proteins present in the cilium would be 
associated. Given that there is only one cilium per cell and its volume represents 
≤0.2% of the total cell volume, the amounts of associated protein may be very 
small. We therefore began by looking for interactions in transfected cells, where 
the amounts of protein that can be produced are considerably higher and 
constructs with epitope tags were available. 
I decided to use heterologous expression cell line as a protein expression 
system for studying these protein-protein interactions. First, I started by finding 
the cell lines of choice for transient protein expression. Two key criteria of 
selecting expression cell line were considered. The first criterion was that the 
cells should have high level of protein expression so that the protein interaction, 
testing by Co-Immunoprecipitation (Co-IP), can be detected easily. To also 
investigate the protein colocalisation by immunofluorescence particularly in 
primary cilia of that cell line, the second criterion was that the cells should 
possess primary cilia. I therefore began to test those criteria. Typically, Cos-7 
cells (Gluzman, 1981) or HEK-293 cells (Graham et al., 1977) were used for 
heterologous DNA expression based on SV40-based vectors. However, more 
recent studies of the SHH pathway have utilised NIH3T3 cells, derived from 
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mouse fibroblasts, as these cells respond to SHH and are capable of forming 
primary cilia when serum starved (Rohatgi et al., 2007, Milenkovic et al., 2009).  
As NIH3T3, kindly provided by Dr. Verdon Taylor, and Cos-7 cells were both 
available in the lab, I began by using these cells to compare the levels of 
Nrcam-full length (Nrcam-FL) produced. Importantly, as shown in fig 4.1, neither 
cell line expresses endogenous NRCAM at detectable levels (lane 2 and 4). 
When the Cos-7 cells (lane 5) were transfected by Nrcam-FL, they were able to 
be over-expressed larger amount of NRCAM than NIH3T3 cells (lane 3) were 
after Nrcam-FL transfection. The full-length NRCAM expression was also 
present in NRCAM transfected NIH3T3 (lane 3) and Cos-7 cells (lane 5), which 
normally hardly detected unless the cells were transfected with Nrcam (Sakurai 
et al., 1997). Moreover, I also performed immunolabelling to visualise primary 
cilia in both cell types so that I can investigate later whether NRCAM co-
localises either endogenous PTCH or SMO in their primary cilia. As shown in fig 
4.2A and B, the primary cilia were hardly seen on either cell types; however, the 
NIH3T3 cells have relatively more percentage of primary cilia than Cos-7 cells 
(Fig 4.2C). Given the widespread use of NIH3T3 cells to investigate SHH 
pathway in recent studies (Rohatgi et al., 2007, Milenkovic et al., 2009, Hillman 
et al., 2011), I therefore decided to choose NIH3T3 cells to perform further 
experiments. 
 !!!!!!!!
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Figure 4.1.  Comparative Nrcam-FL over-expression in NIH3T3 and Cos-7 
cells. Immunoblot with antibody to NRCAM was used to investigate the amount 
of NRCAM over-expression protein in NIH3T3 cells, kindly provided by Dr. 
Verdon Taylor, and Cos-7 cells. The expression of NRCAM from the lysate of 
NIH3T3 cells, which were not transfected or transfected by Nrcam-FL, were 
shown in lane 2 and 3, respectively. The expression of Nrcam from the lysate of 
Cos-7 cells, which were not transfected or transfected by Nrcam-FL, were 
shown in lane 4 and 5, respectively. The E13 mouse brain lysate (lane 1) was 
also loaded to serve as a positive control. The NRCAM antibody also detected 
nonspecific (*) bands, which were present in every condition except the E13 
mouse brain lysate (lane 1). 
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Figure 4. 2. NIH3T3 and Cos-7 cells possess primary cilia. NIH3T3 cells and Cos-7 cells were serum starved for 24 hours after plated for 24 
hours. Then the cells were fixed with 4% PFA, immunolabelled by anti-acetylated α-tubulin antibody (green) and their nuclei (blue) were 
detected by DAPI staining. Scale bar = 10 µm (A) Primary ciliated NIH3T3 cell (arrow). (B) Primary ciliated Cos-7 cell (arrow). (C) Comparison 
of the percentage of primary ciliated NIH3T3 and Cos-7 cells. 20 image fields from 3 independent experiments were quantified the percentage 
of cells with primary cilium. The data are graphed showing the Standard Error of the Mean (SEM) and tested for statistically significant 
differences among the control and treated samples using one-way ANOVA, followed by Bonferroni’s post-test. The bar graph shows 
Mean±SEM. Confidence interval was set to 95%, with a p-value less than 0.05 taken as statistically significant. Statistical significances are 
indicated as asterisks; *: p<0.05, **: p<0.01, ***: p<0.001, ****: p<0.0001 and N.S.: not significant.  
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4.2.2 Testing PTCH and SMO antibodies by western blot 
The ability of our SMO and PTCH antibodies to label mouse proteins in lysates 
of NIH3T3 cells has not been tested.  In addition, since NIH3T3 cells have been 
reported to express endogenous PTCH and SMO (Rohatgi et al., 2007), I first 
assessed whether it was feasible to look for SMO and PTCH expressions in 
NIH3T3 cells so that the interactions between the endogenous proteins and 
heterologously expressed NRCAM can be investigated later. I therefore 
performed western blots on such lysates. As shown in Fig 4.3, I was able to 
detect the expression of SMO (lane 1) but not PTCH (lane 2).  
 
 
Figure 4.3. Testing SMO and PTCH1 antibodies on NIH3T3 cell lysate. 
Immunoblot with antibodies to SMO and PTCH1 were used to investigate the 
endogenous SMO and PTCH1 proteins, respectively, in NIH3T3 cells, kindly 
provided by Dr. Verdon Taylor. The SMO expression can be detected by the 
SMO antibody (lane 1), whereas, the PTCH1 expression can not be detected by 
the PTCH1 antibody (lane 2). 
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4.2.3 Optimisation of Ptch1-YFP and Smo-YFP transfection protocol 
Given how poorly the PTCH antibody detected endogenous protein in NIH3T3 
cell lysates; we decided to investigate the protein interaction from 
overexpressed PTCH, SMO and NRCAM. Ptch1 and Smo expression 
constructs were obtained from Prof. Matthew P. Scott’s laboratory. I performed 
single transfections of either Ptch1-YFP or Smo-YFP into NIH3T3 cells using 
Lipofectamine 2000 (11668-019, Invitrogen) as a transfection reagent. The 
transfection efficiencies of both plasmids were also evaluated by 
immunocytochemistry. The SMO and PTCH1 transfection efficiencies were very 
low compared to GFP transfected control (table 4.1), which I confirmed using 
anti-GFP antibody by western blot (anti-GFP is known also to detect YFP; 
(Veening et al., 2004). As shown in Fig 4.4, GFP transfected protein, which was 
used as a positive control, was shown on the blot (lane 3), however, the bands 
of SMO-YFP (lane 1) and PTCH1-YFP (lane 2) transfected proteins could not be 
detected.  
 
Table 4.1. Smo-YFP, Ptch1-YFP and GFP transfection efficiencies in 
NIH3T3 cells 
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Figure 4.4. Immunoblot of SMO-YFP and PTCH1-YFP protein over-
expression in NIH3T3 cells. The Smo-YFP, Ptch1-YFP and GFP (positive 
control) constructs were transfected to NIH3T3 cells and their proteins were 
extracted after transfection for 24 hours.  Immunoblot was performed and 
probed with antibody against GFP. The GFP expression (lane 3) was detected, 
whereas, SMO-YFP (lane 1) and PTCH1-YFP (lane 2) expressions were hardly 
seen.  
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For these reasons, I began to optimize the transfection protocol by varying the 
DNA and Lipofectamine- 2000 ratio, however, the transfection efficiencies were 
not improved. I also attempted to use other transfection reagents such as 
Fugene HD (Promega), TransFectin (Bio-Rad), TransIT-2020 (Mirus) and also 
tried a different method by performing NIH3T3 cell electroporation using 
Microporator MP-100. As shown in table 4.2, the transfection efficiencies were 
not much different from that using Lipofectamine 2000. 
 
Table 4.2. Comparison of methods to overexpress Smo-YFP and Ptch1-
YFP in NIH3T3 cells 
 
Therefore, I turned to transfect Ptch1-YFP or Smo-YFP in Cos-7 cells using 
Lipofectamine 2000 as the transfection reagent. As shown in table 4.3, the 
transfection efficiencies were slightly more in Cos-7 cells than that in NIH3T3 
cells.  
I then started optimising the transfection protocol again, as I had done with 
NIH3T3 cells. Despite these efforts, the transfection efficiencies were only 
slightly increased and the levels of PTCH1 and SMO proteins seemed unlikely 
to be sufficient for performing Co-IP as the bands of PTCH1 and SMO were 
invisible on the western blot. 
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Table 4.3. Comparison of the transfection efficiencies of NIH3T3 and Cos-7 
cells 
 
Table 4.4. Smo-GFP and Ptch1-GFP transfection efficiencies in Cos-7 cells 
 
As a result, I decided to change plasmids to Ptch1-GFP and Smo-GFP (kindly 
provided by Frederic Charron, with permission from Prof. Chi-chung Hui), as I 
know that these plasmids have been shown to work in Cos-7 cells (Izzi et al., 
2011). As shown in table 4.4, the PTCH1-GFP and SMO-GFP transfection 
efficiencies were dramatically increased when compare to the transfection 
efficiencies of the previous constructs (Smo-YFP and Ptch1-YFP) (see table 
4.1). The PTCH1-GFP and SMO-GFP expression levels were also evaluated by 
western blot using anti-GFP antibodies. The anti-GFP immunoreactive bands 
corresponding to the predicted molecular weights of PTCH1-GFP and SMO-
GFP were seen (fig 4.5). As expected, the transfected NRCAM expression was 
not detected by the anti-GFP antibody under either condition. 
Although, we finally sorted out that Cos-7 cells were appropriately to use as a 
transfected cell system, actually their numbers of primary cilia were very low 
(Fig 4.2C). Therefore the experiments that follow address interactions in whole 
cell lysates rather than in cilia.  !!
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!
Figure 4.5. Overexpression of PTCH1-GFP and SMO-GFP in Cos-7 cells. 
Immunoblot with antibody to GFP was used to assess the amount of PTCH1-
GFP and SMO-GFP transfected protein extracts from Cos-7 cells. The GFP 
(positive control; lane 1), PTCH1-GFP (lane 4, 6) and SMO-GFP (lane 5, 7) 
expressions were obviously shown. Note that because the aim of this 
experiment was to also test protein co-precipitation in the co-transfected cells, 
the Nrcam-FL transfection (lane 3) was included to determine whether Nrcam 
transfection at the same time affects the level of co-expression in the cells (lane 
6, 7). !!!!!
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4.2.4 Evaluation of protein-protein interaction 
Having achieved detectable expression of the SMO and PTCH fusion proteins, I 
started investigating the interaction of NRCAM and PTCH1-GFP, NRCAM and 
SMO-GFP by Co-IP. First, I immunoprecipitated NRCAM and looked for co-
precipitation of the SMO and PTCH1 fusion proteins with anti-GFP antibody. As 
shown in Fig.4.6A, NRCAM seems to interact with PTCH1 (Lane 1, Fig. 4.6A) 
but not SMO (Lane 2, Fig. 4.6A). However, I did not have any control showing 
whether antibody specifically works. I therefore performed Co-IP again using the 
protein extracts from SMO-GFP transfected (Lane 1, Fig. 4.6B) and PTCH1-
GFP transfected (Lane 3, Fig. 4.6B) Cos-7 cells as controls, immunoprecipitated 
with anti-NRCAM antibody. Again, I can see the band (Lane 4, Fig. 4.6B), 
suggesting that NRCAM may interact with PTCH1 but not SMO (Lane 2, Fig. 
4.6B). However, a band was also present when NRCAM was not co-transfected 
(Lane 3, Fig. 4.6B), suggesting that non-specific interaction was occurring.  
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Figure 4.6. NRCAM seems to interact with PTCH1, but not SMO. Cos-7 cells were transfected with the indicated constructs and (A) lysates 
were immuno-precipitated (IP) with anti-NRCAM antibody and immunoblotted (IB) with anti-GFP antibody. (B) The experiment was performed 
as (A), however, the controls, the protein lysates from single Smo-GFP (lane 1) and Ptch1-GFP (lane 3) transfected Cos-7 cells, were included 
to demonstrate how specificity of Co-IP protocol was.  
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To begin to dissect the source of the non-specific interactions, I began to test 
the different components of the assay. To test whether this could reside in the 
polyclonal anti-NRCAM antibodies, I substituted a hemagglutinin (HA)-tagged 
construct (Nrcam-HA), kindly provided by Dr. Catherine Faivre-Sarrailh 
(France), in place of NRCAM-FL and repeated the experiments (Fig. 4.7A). In 
addition, I included as a positive control, FLAG-tagged BOC (Boc-FLAG), kindly 
provided by Dr. Frederic Charron (Canada), because PTCH1 and BOC have 
been shown to interact specifically (Izzi et al., 2011). To test the specificity of 
any interaction further, I asked whether a similar membrane protein, which like 
NRCAM also contains Ig domains, shows an interaction with PTCH1. Therefore, 
I used Fibroblast Growth Factor Receptor 3 (FGFR3), a single pass-membrane 
protein (Keegan et al., 1991), kindly provided by Prof. Marysia Plazek (United 
Kingdom) as a putative negative control. I performed co-transfection of Ptch1-
GFP and Boc-FLAG, Ptch1-GFP and Fgfr3 construct, which contains HA-tag 
(Fgfr3-HA) as well as Nrcam-HA, in Cos-7 cells and co-immunoprecipitated as 
above. As shown in Fig 4.6C, although GFP-reactive bands were apparent in 
the IPs of PTCH1-GFP and NRCAM-HA transfections (Lane 4, Fig. 4.7A), 
similar, though weaker bands were also present in the antibody control (Lane 3, 
Fig. 4.7A) and the negative control (FGFR3) lanes (Lane 6, Fig. 4.7A), again 
suggesting non-specific interactions.  
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Figure 4.7. NRCAM seems to interact with PTCH1 but the non-specific interactions are also present. Cos-7 cells were transfected with 
the indicated constructs and (A) lysates were IP with an anti-HA/FLAG antibodies as indicates and IB with anti-GFP. The interaction of PTCH1-
GFP and BOC-FLAG was used as a positive control (Izzi et al., 2011), whereas, the lysate from the co-transfection of PTCH1-GFP and 
FGFR3-HA was used as a negative control. (B) To investigate the cause of non-specific interaction, the mock experiment (no antibody adding 
in IP step) was also performed in parallel. The lysates were IP with anti-NRCAM antibody followed by IB with anti-GFP antibody.  
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Since these bands were present whenever Ptch1-GFP was transfected, I 
considered whether this protein could be directly interacting with components of 
the immunoprecipitation other than the primary antibody (anti-HA or anti-
NRCAM). I therefore tested whether these bands appeared in the absence of 
anti-HA or anti-NRCAM antibodies. As shown in Fig 4.7B, in mock condition (no 
antibody), the lysate from PTCH1-GFP showed the non-specific interactions 
(lane 1 and 3), whereas, that from SMO-GFP (lane 2 and 4) did not. This 
demonstrated that PTCH1-GFP does indeed interact directly with the 
ProteinA/G beads under my standard conditions. 
Therefore, I started optimizing the Co-IP protocol to get rid of this background 
interaction as much as possible and to see if there is the real PTCH1 and 
NRCAM interaction. I added a pre-clearing step before performing Co-IP as 
incubation of protein lysate with A/G-PLUS agarose beads first can remove the 
possibility of non-specific binding in the later stage of the IP. I also adjusted the 
recipes of RIPA buffer, which was used for extracting protein, and wash buffer 
called IpH buffer (see the final recipes in table 2.3). For example, NaCl 
concentration was increased in IpH buffer as this helps to reduce ionic and 
electrostatic interaction. Sodium deoxycholate, which is ionic detergent that is 
useful for disrupting and dissociating interactions, was added to RIPA buffer. In 
addition, the time for the washing step was increased, whereas, I decreased 
incubation time of proteins, beads and antibodies (see the full final Co-IP 
protocol in chapter 2, section 2.8.4).  
After including all these changes, the background band from the antibody-only 
control was removed (Lane 4, Fig. 4.8A), whereas anti-GFP-reactive bands from 
the NRCAM-HA with PTCH1-GFP co-IP (Lane 5, Fig. 4.8A) and also from the 
positive control (Lane 6, Fig. 4.8A) were still detected, suggesting that PTCH1 
can indeed be seen to co-precipiate with NRCAM.  
Of some concern, is that a weak anti-GFP reactive band was detected in a co-IP 
of the Angiopoeitin receptor 2 (TIE2), a single-transmembrane protein 
containing Ig domains (Partanen and Dumont, 1999), kindly provided by Prof. 
Elizabeth Smythe (United Kingdom), with PTCH1-GFP, which was included as a 
negative control (Lane 7, Fig. 4.8A). This leaves some doubt as to the specificity 
of the NRCAM and PTCH1 interaction detected.  
Importantly, however, under these more stringent conditions, SMO-GFP was not 
seen to co-precipitate with NRCAM (lane 2 and 3 Fig 4.8A), making it unlikely 
that NRCAM regulates SMO through direct interactions between the proteins. 
To confirm this result, the protein lysates were precipitated again but in an 
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inversed order. NRCAM appeared to be co-precipitated with PTCH1-GFP (lane 
3, Fig 4.8B), as well as BOC-FLAG and PTCH1-GFP (lane 4, Fig 4.8B). Again, 
NRCAM and SMO co-precipitation was not seen. Therefore these results 
suggested that NRCAM might interact with PTCH1 but not SMO. 
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Figure 4.8. NRCAM may interact with PTCH1 but not SMO. Cos-7 cells were transfected with the indicated constructs. (A) After optimising 
the Co-IP protocol to eliminate non-specific interaction, the lysates were IP with an anti-HA/FLAG/TIE2 antibodies and IB with anti-GFP. The 
co-transfection of Ptch1-GFP and Tie2 was also used as a negative control. After Co-IP protocol optimisation, the band suggesting that PTCH1 
may or may not interact with NRCAM whereas SMO does not was shown. The experiments were repeated 3 times (3 biological replications). 
(B) To confirm the result above, the lysates were also IP with anti-GFP and IB with anti-HA antibody. The interaction of PTCH1 and BOC was 
again used as a positive control. 
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4.3 Discussion 
I showed in the previous chapter that NRCAM can be visualised in the primary 
cilium of GNP and its loss affects SMO and PTCH ciliary localisation. Although, 
we were not able to distinguish whether NRCAM plays a role PTCH leaving the 
cilium or SMO entering the primary cilium in the previous chapter, Co-IP results 
from this chapter seem to suggest that NRCAM may physically associate with 
PTCH1 but not SMO.  
4.3.1 NRCAM may directly interact with PTCH1 but not SMO  
The clear result from the experiments in this chapter, is that NRCAM does not 
interact with SMO under any of the conditions that were tried (Fig. 4.6, 4.7, 4.8), 
suggesting that it is highly unlikely that there is an interaction between NRCAM 
and SMO. However, although after optimisation of my Co-IP conditions I was 
able to see some evidence of an interaction of PTCH1 with NRCAM (Fig. 4.6, 
4.7, 4.8), this data must be treated with caution, because the proteins that we 
included as putative negative controls, TIE-2 and FGFR3, also co-precipitated 
PTCH1. As far as we are aware, nothing has previously been reported to 
suggest that interactions might exist between the SHH pathway and these 
proteins, although there is some evidence showing that FGFR2 is involved in 
SHH pathway (Mukhopadhyay et al., 2013). Nonetheless, these apparent 
interactions inevitably give us some concern that non-physiological kinetics may 
result from over-expression of proteins in the Cos-7 cell system. 
Nonetheless, the interactions with TIE-2 and FGFR3 appear weaker than that 
with NRCAM, which, by contrast, appears to be at least as strong as the 
interaction of PTCH1 with BOC, which has been verified independently (Izzi et 
al., 2011). Moreover, I was able to demonstrate the NRCAM-PTCH1 interaction 
in ‘both directions’, i.e. anti-GFP (PTCH1-GFP) precipitated NRCAM as well as 
anti-NRCAM (or anti-HA for the NRCAM-HA experiments) was able to 
precipitate PTCH1. Finally, it seems unlikely that the interaction is due simply to 
the hydrophobicity of PTCH1 because NRCAM clearly does not interact with 
SMO, which also a multi-transmembrane receptor. Therefore, I tentatively 
conclude that NRCAM may interact with PTCH1. 
Importantly, of course, even without the above caveats, co-immunoprecipitation 
would not be definitive evidence of a direct binding between NRCAM and 
PTCH1. Co-immunoprecipitation may happen due to indirect binding through 
associated in the same protein complex, or even because two proteins are 
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present in the same intracellular vesicles. In fact it was originally argued that 
PTCH and SMO bound together on the basis that they could be co-
immunoprecipitated from co-transfected HEK-293 cells (Carpenter et al., 1998) 
and also Cos-1 cells (Murone et al., 1999). Evidence of direct binding requires a 
demonstration of binding between the purified proteins which, given the size and 
hydrophobicity of PTCH, may require substantial genetic or proteolytic 
subfractionation of the protein to prove. Nonetheless, corroborative evidence 
could be obtained, for instance, if PTCH1 and NRCAM could be demonstrated 
to be present in the same intracellular vesicles of GNPs, by immunostaining or 
perhaps by Proximity Ligation Assay (Soderberg et al., 2006), which our lab is 
now determining. 
Clearly the possible interaction of NRCAM and PTCH1 is consistent with the 
main hypothesis of this thesis, which is NRCAM might play a role in trafficking 
SHH components in primary cilia. If, however, the co-localisation studies noted 
above do not demonstrate evidence of NRCAM association with PTCH1 within 
cells, it remains possible that NRCAM may indirectly be involved in trafficking of 
the other molecules required for SHH pathway activation, for example BOC and 
GAS1 (Izzi et al., 2011).  
4.3.2 Differences in expression of different PTCH1 and SMO constructs 
Although, finally the problem of expression PTCH1 and SMO protein in the 
transfected cells were solved, I still wonder what factors causing different 
plasmids gave different transfection efficiencies. In spite of the fact that the 
Smo-YFP and Ptch1-YFP constructs were already used in published papers 
(Rohatgi et al., 2007, Milenkovic et al., 2009), the results in this chapter still 
show low transfection efficiencies for both of them. This could be due to several 
reasons, first; the methods used a different. The method that Rohatgi et al. and 
Milenkovic et al. used was retroviral infection, whereas, we attempted to used 
transfection reagents or electroporation. In addition, although the cells used 
were similar which is NIH3T3 cells, they are still different, as our NIH3T3 cells 
were discovered later that they were not respond well to either SHH or SAG 
(see Chapter 5). Therefore, these could be the reasons why we were not able to 
use both Smo-YFP and Ptch1-YFP to perform the experiment. 
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4.3.3 Investigation of colocalisation of PTCH1 and NRCAM in primary 
cilia and investigation of protein interaction 
In this chapter, I was not able to visualise the colocalisation of PTCH1 and 
NRCAM in the cilia of Cos-7 cells, as the percentage of primary ciliated cells 
was very low. Although I know that NIH3T3 cells have a higher percentage of 
ciliated cells, I did not perform SMO-GFP and PTCH1-GFP transfection in the 
cells. In the next chapter, the NIH3T3 cells that we initially attempted to use at 
the beginning of this chapter are revealed not to respond well to SHH and SAG 
(see chapter 5). For this reason, as a part of the future work, the investigation of 
PTCH1 and NRCAM colocalisation could be studied in GNPs or in NIH3T3-GL 
cells, kindly provided by Dr. Fredderic Charron (Canada). In addition, I recently 
attempted to co-transfect Ptch1-GFP and Nrcam-HA into the NIH3T3-GL cells 
and the preliminary results showed high percentage of co-transfected cells and 
a high percentage of cells with primary cilia in this cell type (data not shown). 
Unfortunately, I have not had time to complete this study to look at co-
localisation. 
To conclude from the previous chapter to this chapter, we have shown that 
NRCAM is present in primary cilium of GNP and loss of NRCAM affects the 
ciliary localisation of PTCH and SMO. We initially hypothesised that NRCAM is 
required for PTCH trafficking out of primary cilia rather than SMO entry to the 
cilium as we think that the inability of SMO ciliary trafficking could be due to the 
consequence of PTCH ciliary localisation. In this chapter, we discovered that 
NRCAM might interact with PTCH1 but not SMO, which is consistent with the 
hypothesis that we have made in the previous chapter. However, at the very 
least I would need to demonstrate colocalisation of the proteins in cells, perhaps 
using the PLA assay, to confirm the validity of this result.  
 
 
 
 
  
 
 
 
 
 
 
 
Chapter 5 
Investigation of  
how loss of NRCAM  
affects SHH signalling
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5.1 Introduction 
A variety of studies support the idea that the SHH signal transduction pathway 
plays a key role in GNP proliferation and patterning of the cerebellum (Dahmane 
and Ruiz i Altaba, 1999, Wallace, 1999, Wechsler-Reya and Scott, 1999, Lewis 
et al., 2004, Corrales et al., 2006). Although SHH null mutants (Shhn) are early 
embryonic lethal (Chiang et al., 1996), Lewis et al, 2004 and Corrales et al, 
2006 used a LoxP-flanked conditional mutant of the gene (Shhc) to provide 
evidence that SHH signalling is required not only for GNP expansion, but that 
the level of signalling regulates the complexity of cerebellar foliation (Lewis et 
al., 2004, Corrales et al., 2006). Lewis et al used Shhc/Shhn, Pax2-Cre mutant 
mice, in which the promoter of Pax2 drives Cre recombinase expression from as 
early as E8 leading to loss of SHH in almost all cells of the EGL and Purkinje 
Cell Layer (PCL). In these mice, cerebellar fissures failed to develop and the 
EGL was decreased in thickness at E18.5 and, by P5, the number of lobes was 
severely reduced and a visible EGL was absent, although some TAG-1+ granule 
neurons are present (Lewis et al., 2004). Similarly, reduction of SHH signalling 
level by removal of both GLI1 and GLI2, or of SMO, also diminished cerebellar 
foliation (Corrales et al., 2006).  
Previous work from our lab, and the evidence presented in the previous two 
chapters, suggests that L1-CNTNs are able to modulate the SHH signalling 
pathway. F3/contactin suppresses SHH-induced proliferation of GNPs in vitro 
and the cerebellum of TAG-F3 mice is reduced in size during the early postnatal 
period (Bizzoca et al., 2003, Xenaki et al., 2011). F3 appears to act by binding to 
NRCAM to suppress SHH-induced proliferation of GNPs (Xenaki et al., 2011). 
Moreover, we found that NRCAM is present in the primary cilium of GNPs and 
loss of NRCAM suppresses the translocation of SMO to this structure after 4.5 
hour-SHH treatment of GNPs (Chapter 3). In addition, we are able to co-
immunoprecipitate NRCAM with PTCH1 in transfected Cos-7 cells (Chapter 4).  
Although, all of these evidences suggest that NRCAM plays a role in SHH 
signalling pathway, it is clear that loss of NRCAM is not equivalent to loss of 
SHH. Complete loss of SHH leads to early embryonic lethality due to multiple 
defects such as incorrect brain, heart, lung and skeleton developments. 
Particularly for the nervous system defect, a decrease in the size of the brain 
and the spinal cord was obvious in E9.5 SHH mutant embryos, when compared 
with their normal littermates and an abnormal of cephalic flexure was present 
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(Chiang et al., 1996). Moreover, at E11.5, progressively severe abnormalities 
were demonstrated in hindbrain, midbrain and forebrain and bilateral eye 
structures were absent.  
By contrast, Nrcam knockout mice are viable and fertile, and show only a slight 
reduction of cerebellar size with no dramatic effect on other systems (Sakurai et 
al., 2001). In agreement with this, Moré et al. also reported no major 
abnormalities in independently created NRCAM-deficient mice, except cataract 
formation and a mild motor defect (More et al., 2001). Thus, NRCAM is unlikely 
to be playing a general role in SHH signalling, although it is striking that some of 
its expression mirrors that of SHH, notably along the midline (Lustig et al., 
2001). Even in the cerebellum, GNPs lacking NRCAM still show some 
proliferative response to SHH in vitro (Xenaki et al., 2011). This may be 
explained by NRCAM being redundant with L1 in this function (Sakurai et al., 
2001); loss of NRCAM and L1 leads to a dramatic reduction in cerebellar size 
and complexity. However, even the double knockout mutant (Nr/L1) phenotype 
(Sakurai et al., 2001) is not as severe as the total loss of SHH shown by 
Shhc/Shhn, Pax2-Cre mutant mice (Lewis et al., 2004) or loss of Smo (Corrales 
et al., 2006), although it is similar in effect to the targeted loss of Shh from 
Purkinje cells (Lewis et al., 2004) and the loss of Gli2. Therefore, both these in 
vivo and our in vitro results suggest that NRCAM may affect the amount of SHH 
signalling, rather than being absolutely required for the signal generation. 
To begin to address whether loss of NRCAM does indeed have a quantitative 
effect on SHH signalling, in this chapter I attempted to acquire a quantitative 
readout of SHH signalling by assaying immediate early responses in both GNPs 
and in NIH3T3 cells, which are known to respond to SHH (Wechsler-Reya and 
Scott, 1999, Dahmane and Ruiz i Altaba, 1999, Rohatgi et al., 2007, Hillman et 
al., 2011). Our previous studies used GNP proliferation as a readout of SHH 
signalling (Xenaki et al., 2011). However, cell division is considerably 
downstream of the initial signal and may not be a direct readout of the amount of 
SHH signal. Indeed, in other contexts, varying the amount of SHH signal has 
qualitative as well as quantitative consequences for cell proliferation and 
differentiation (Plaisant et al., 2011, Bermudez et al., 2013). Moreover, I also 
investigate the effect of loss or gain of NRCAM expression in these systems. 
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5.2  Results 
5.2.1 Quantitative investigation of mRNA expression of Gli1 and Ptch1 
An immediate early response to SHH signalling is increased Gli1 and Ptch1 
gene transcription (Wechsler-Reya and Scott, 1999). GLI1 is an activator of the 
pathway and induction of Gli1 transcription forms part of a positive feedback 
loop (Lee et al., 1997), whereas PTCH1 is a negative regulator of SHH 
signalling (Stone et al., 1996, Goodrich et al., 1996). Increases in Ptch1 and Gli1 
transcription can be seen obviously within 4 hours of SHH addition (Humke et 
al., 2010, Hillman et al., 2011). Since SMO translocation to primary cilia after 
SHH treatment occurs on a similar timescale in WT but not Nrcam-/- GNPs 
(Chapter 3), I set out to investigate whether loss of NRCAM also affected Gli1 
and Ptch1 transcriptional activation using Real Time quantitative PCR (qPCR). 
 
5.2.1.1 qPCR protocol optimisation 
The principle of both qPCR and traditional PCR is similar, which is an 
amplification of a DNA fragment. However, the difference is that the traditional 
PCR measures the amount of PCR products when the amplification process is 
ended, whereas, the qPCR does that after each round of amplification during 
exponential phase. The amplification products from the qPCR are measured 
when they are generated using a fluorescent label. When the fluorescence is 
increased to the point that is first detected as statistically significant above the 
background, that point is called the threshold cycle or Ct value, which is an 
inverse correlation of the logarithm of the initial DNA copy number. The higher 
initial amount of DNA, the lower the Ct value as the amplification product is 
detected sooner. The Ct value is used to quantify the amount of DNA in the 
samples.  
There are 2 main qPCR detection systems, which are a dye-based detection 
and a probe-based detection. Both of them use a fluorescent signal to quantify 
the amount of DNA in a sample. The dye-based detection system is based on 
an incorporation of a DNA binding dye to double-stranded DNA (dsDNA), which 
is generated during the PCR amplification, leading to the emission of the 
fluorescent signal. The probe-based detection is performed using sequence 
specific DNA-based fluorescent reporter probes, which contain a fluorescent 
reporter molecule, a quencher molecule and sequence-specific primers. The 
reporter molecule and the quencher molecule are closely located in order to 
allow the quencher to prevent fluorescence and they are separated when the 
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probe hybridises to the complementary target, resulting in the increase in 
fluorescent signal of the reporter.  
The local availability of an iCycler iQ qPCR system (BioRad) dictated that the 
dye-based detection system was used in the study. SYBR green was chosen as 
the DNA binding dye of detection for qPCR analysis. The qPCR protocol was 
firstly optimised so that the qPCR conditions can be acquired to enable accurate 
in later actual qPCR reactions. The guidelines of optimising qPCR and the 
criteria to determine the optimal condition of performing qPCR are previously 
shown in Methods, section 2.12.3. 
5.2.1.1.1 Optimal primer annealing temperature 
In this chapter, I describe the use of 3 pairs of qPCR primers, called Gli1, Ptch1 
and Gapdh (see primer sequences in table 2.1), to detect transcripts from the 
Gli1, Ptch1 and Gapdh genes respectively; transcription from Gapdh gene, 
which encodes glyceraldehyde-3-phosphate dehydrogenase, is included as a 
reference gene for the total amount of mRNA, as its transcription is considered 
broadly invariant from cell to cell (Radonic et al., 2004). Ptch1 and Gapdh 
primers were kindly provided by Dr. Anne-Gaelle Borycki and I adopted the 
conditions for these used routinely in her lab on the same equipment. The Gli1 
primer sequences were as described by (Romer et al., 2004) and therefore 
optimal conditions needed to be established on our PCR equipment.  
To approximately estimate the optimal annealing temperatures of Gli1 primers, I 
started by using gradient PCR (PTCH-200 Peltier Thermal Cycler, MJ 
Research). Clearly the characteristics of this machine might be different from the 
iCycler qPCR machine. However, the iCycler qPCR machine had a fault in its 
gradient qPCR function. As shown in Fig 5.1, PCR reactions of the Gli1 primer 
set, which was performed from E13.5 mouse cDNA (see Methods, section 
2.12.3), seemed to give the least non-specific products in the temperature range 
62°C-64°C. Initially, the lowest temperature in the range, 62°C, was selected in 
order to maximise yield of the diagnostic band. However, when the experiment 
was repeated using the iCycler the qPCR reaction analysis showed non-specific 
product (Fig 5.2A). Therefore I raised the temperature and determined that 
qPCR reactions of Gli1 primer set at 64°C showed the highest primer specificity 
(Fig 5.2B). This temperature was used throughout this study.  
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Fig 5.1. Optimal annealing temperature. Electroporesis of PCR products from 
E13.5 mouse cDNA using gradient PCR showed that the optimal annealing 
temperature of Gli1 primers used in this study is 62°C-64°C, where only the 
specific target products can be amplified. This range of annealing temperatures 
had to be tested again by performing qPCR reaction to ensure that there is no 
primer-dimer formation with that annealing temperature.  
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Fig 5.2. Primer dimer is not shown in the qPCR reaction that performs with 
optimal annealing temperature of Gli1 primer. The melt curves are plotted by 
temperature (°C) (X-axis) the first negative derivative of the fluorescence as a 
function of temperature (-dF/dT) (Y-axis) (A) The melt curve of Gli1 primers 
showed non-specific product in the reaction that perform with the 62°C 
annealing temperature, whereas, (B) when increase the annealing temperature 
to 64°C, the melt curve showed single peak, indicating the high primer 
specificity. 
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5.2.1.1.2 Optimal primer concentration 
Performing qPCR using sub-optimal concentrations of primer reduces the rate of 
PCR amplification, whereas using excessive concentrations of primers will 
increase the amount of non-specific binding. Therefore, the optimal primer 
concentration for each pair of primers used in this study was determined. After 
varying the concentration of forward and reverse primers and running the qPCR 
reactions (see Methods, section 2.12.3) using the optimal annealing 
temperature acquired in the previous section, the primer combinations with the 
lowest Ct value and highest fluorescence were selected. The optimal annealing 
temperatures and the optimal primer concentrations of each pair of primers are 
shown in Table 2.11.   
To ensure the primer specificity, the melt curve of each set of forward and 
reverse primer combination concentration was also analysed individually to 
ensure the production of a single peak, indicating that there was a single 
specific product (Fig 5.3A). In addition, PCR products for each set of primers 
were also run on agarose gel to confirm there were no primer-dimer formation 
and no obvious non-specific products (Fig 5.3B).  
5.2.1.1.3 Standard curve and PCR efficiency 
To validate the qPCR reaction, the PCR efficiency, which is the rate at which a 
PCR product is generated (see Methods, section 2.13.3), was investigated. The 
qPCR reactions of 5 fold-dilutions of the positive control (E13.5 mouse cDNA) 
were run at the optimal concentration for each pair of primers, at the respective 
optimal annealing temperature, to create a standard curve (see Methods, 
section 2.12.3). Examples of standard curve of each set of primers are shown in 
Fig. 5.4. The accepted range of PCR efficiency is 80-110% (Schmittgen and 
Livak, 2008). A summary of the selected set of primers used in this study and 
their average percentage of efficiencies are shown in Table 5.1. 
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Fig 5.3. Specificity of primers used in this study. (A) The melt curves are 
plotted by temperature (°C) (X-axis) the first negative derivative of the 
fluorescence as a function of temperature (-dF/dT) (Y-axis). The melt curves of 
each pair of forward and reverse primer combination concentration showed 
single peak indicating specificity of primers (a): Gli1, (b): Gapdh, (c): Ptch1 (B) 
Electroporesis of random qPCR products from (A). After performing qPCR 
reaction, the graphical traces were confirmed visually by resolving qPCR 
products on agarose gel to demonstrate that the primers used in this study were 
amplified only their specific target sequences. Lane 2: random qPCR product 
from Gli1 primer, Lane 4: Gapdh, Lane 6: Ptch1, Lane 3, 5, 7 are negative 
control reactions (Nuclease-free water). 
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Fig 5.4. Examples of standard curves using primers used in this study. The 
graphs are plotted with threshold cycle (Y-axis) number versus log DNA dilution 
(X-axis). To determine a standard curve, the 5 fold-dilution of E13.5 mouse 
cDNA are set as the standard (blue dots) and the PCR amplification efficiency is 
calculated from the curve. (A) Gli1 and (B) Gapdh at annealing temperature 
64°C, (C) Ptch1 and (D) Gapdh at annealing temperature 59°C 
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Table 5.1. A summary of the efficiencies of qPCR primers were used in this 
study 
qPCR 
primers 
Gli1 Gapdh Ptch1 Gapdh 
Optimal 
annealing 
temperatur
e (°C) 
64 64 59 59 
Average 
percentage 
of 
efficiencies 
99.46%±8.15
% 
92.95%±4.65
% 
95.93%±4.01
% 
86.93%±7.26
% 
 
As shown in table 5.1, the PCR efficiencies of the primer pairs of the genes of 
interest (Gli1 and Ptch1) are different to that of the reference gene primer pair 
(Gapdh) under each condition; therefore, the standard curve method (see 
Methods, section 2.12.6) was used instead of ΔΔCt method since the ΔΔCt 
method can be used only when both primer sets have similar PCR efficiencies 
(slopes = -3.3±0.1 with R2 = 0.99) (Bookout et al., 2006).   
5.2.1.2 Quantitative analysis of the mRNA expression of Gli1 and Ptch1 
in WT and Nrcam-/- GNPs in response to SHH or SAG 
To investigate if SHH signalling is affected by loss of NRCAM, I looked at the 
mRNA expression of Gli1 and Ptch1, transcriptional targets of SHH signal 
transduction, after addition of SHH to GNPs for 4.5 and 24 hours. I looked at 4.5 
hours SHH addition time point because it is the same time point as used in 
chapter 3, where the results suggested that the localisations of PTCH and SMO 
in primary cilia of GNPs were affected when NRCAM is missing, and Ptch1 and 
Gli1 transcription are known to be affected as early as 4 hours after SHH 
treatment (Wechsler-Reya and Scott, 1999). However, since I could not be 
certain when NRCAM loss would have its effect, I investigated also at 24 hours, 
which is known to give maximal expression of Gli1 and Ptch1 after SHH 
induction (Wechsler-Reya and Scott, 1999). GNPs were therefore, as usual; 
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cultured 1.5 hours followed by SHH addition for 4.5 hours or for 24 hours. RNA 
was then extracted and reverse-transcribed to cDNA to perform qPCR. SAG 
was again used to treat GNPs as a positive control.  
As shown in Fig 5.5, as expected, Gli1 mRNA levels of WT GNPs were 
significantly increased when compared with control at 4.5 hours and 24 hours 
addition of SHH. Levels of Gli1 mRNA in Nrcam-/- GNPs were also significantly 
higher than control after 4.5 hours of SHH treatment. However, unlike in WT 
cells, Gli1 levels were not sustained after 24 hours of SHH treatment. 
Interestingly, 4.5 hours after addition of SHH, Nrcam-/- GNPs have significantly 
more Gli1 mRNA expression than WT GNPs, whereas by 24 hours Nrcam-/- 
GNPs significantly have less Gli1 mRNA expression.  
By contrast, the response of Nrcam-/- GNPs to SAG, which directly activates 
SMO (Fig 5.6), was similar to WT. Although the response of WT cells at 4.5 
hours was just sub-threshold (p = 0.0689), there was a clear elevation in Gli1 
mRNA levels which became highly significant by 24 hours (p = 0.0014). For 
Nrcam-/- GNPs, both time points showed a significant induction of Gli1 mRNA 
levels compared to controls. However, in contrast to the response to SHH, 
although there appeared to be a slight elevation compared to WT at 4.5 hours, 
and perhaps a slightly lower response at 24 hours, these differences were not 
significantly different to WT at either 4.5 or 24 hours.  
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Fig 5.5. Quantitative PCR measurement of Gli1 transcripts after addition of 
SHH for 4.5 and 24 hours to WT and Nrcam-/- GNPs. The WT and Nrcam-/- 
GNPs were cultured for 1.5 hours, then treated with SHH for 4.5 or 24 hours. 
The RNA was extracted and reverse-transcribed to cDNA to perform qPCR. The 
graph shows as the fold change of Gli1 expression level normalised to those of 
Gapdh from each of 3 independent experiments. The data are graphed showing 
the Standard Error of the Mean (SEM) and tested for statistically significant 
differences among the control and treated samples using one-way ANOVA, 
followed by Bonferroni’s post-test. The bar graphs show Mean±SEM. 
Confidence interval was set to 95%, with a p-value less than 0.05 taken as 
statistically significant. Statistical significances are indicated as asterisks; *: 
p<0.05, **: p<0.01, ***: p<0.001, ****: p<0.0001 and N.S.: not significant. The 
different data groups were analysed using 1-way ANOVA and statistic details 
are shown in the tables. 
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Fig 5.6. Quantitative PCR measurement of Gli1 transcripts after addition of 
SAG for 4.5 and 24 hours to WT and Nrcam-/- GNPs. The WT and Nrcam-/- 
GNPs were cultured for 1.5 hours, and then treated with SAG for 4.5 or 24 
hours. The RNA was extracted and reverse-transcribed to cDNA to perform 
qPCR. The graph shows as the fold change of Gli1 expression level normalised 
to those of Gapdh from each of 3 independent experiments and then the data 
were treated as in Fig 5.5.  
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To try to find corroborative evidence that loss of NRCAM affects SHH signalling 
at 4.5 and 24 hours, Ptch1 mRNA transcription levels were also evaluated. 
However, as shown in Fig 5.7, although there was a trend towards higher levels 
of Ptch1 transcripts when SHH was added to WT GNPs for 4.5 hours, this 
change was not significant nor was it different in Nrcam-/- GNPs. Surprisingly, 
although Ptch1 mRNA transcription levels at 24 hours were higher than at 4.5 
hours, this occurred irrespective of SHH addition or Nrcam genotype. Similar 
results were obtained for Ptch1 induction when the GNPs were treated with 
SAG for 4.5 or 24 hours in both WT and Nrcam-/- GNPs (Fig 5.8).   
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Fig 5.7. Quantitative PCR measurement of Ptch1 transcripts after addition 
of SHH for 4.5 and 24 hours to WT and Nrcam-/- GNPs. The WT and Nrcam-/- 
GNPs were cultured for 1.5 hours, then treated with either SHH or SAG for 4.5 
or 24 hours. The RNA was extracted and reverse-transcribed to cDNA to 
perform qPCR. The graph shows as fold change of Ptch1 expression level 
normalised to those of Gapdh from each 3 independent experiments. The data 
are graphed showing the Standard Error of the Mean (SEM) and tested for 
statistically significant differences among the control and treated samples using 
one-way ANOVA, followed by Bonferroni’s post-test. The bar graphs show 
Mean±SEM. Confidence interval was set to 95%, with a p-value less than 0.05 
taken as statistically significant. Statistical significances are indicated as 
asterisks; *: p<0.05, **: p<0.01, ***: p<0.001, ****: p<0.0001 and N.S.: not 
significant. The different data groups were analysed using 1-way ANOVA and 
statistic details are shown in the tables. 
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Fig 5.8. Quantitative PCR measurement of Ptch1 transcripts after addition 
of SAG for 4.5 and 24 hours to WT and Nrcam-/- GNPs. (A) The WT and 
Nrcam-/- GNPs were cultured for 1.5 hours, and then treated with SAG for 4.5 or 
24 hours. The RNA was extracted and reverse-transcribed to cDNA to perform 
qPCR. The graph shows as fold change of Ptch1 expression level normalised to 
those of Gapdh from each 3 independent experiments and then the data were 
treated as in Fig 5.7.  
 
 
 
 
 Oratai Weeranantanapan 
 
155 
Although this data clearly showed that the Gli1 transcription levels were 
significantly affected by loss of NRCAM, it is not confirmed by the Ptch1 
transcription result.  Although I can still see the trends in the Ptch1 induction, 
which are consistent with the Gli1 induction results – i.e. suggesting that there is 
more SHH signaling at 4.5 hours when NRCAM is missing compare to WT 
GNPs and the signal in Nrcam-/- GNPs is lower when compared with WT GNPs 
at 24 hours post-SHH treatment – the high levels of Ptch1 in the control cells at 
24 hours makes this difficult to interpret. In addition, I noticed that the variability 
among the triplicates was noticeably high (the Ct variance: SD = 0.14-0.48). 
Even after removing outliers in some replicates (see chapter 2, section 2.12.6 
for the criteria applied in outlier removal), the Ct variance in some replicated 
samples was still higher than 0.3, which according to the manufacturer’s 
guidelines, indicates that there may be a problem with the precision of the assay 
particularly in Ptch1 induction results (see also Discussion).     
5.2.2 Investigation of Gli1 fluorescent intensity in the staining of GNPs in 
response to SHH or SAG 
As an alternative to looking at Gli1 and Ptch1 gene transcriptions, I considered 
whether instead protein levels could be followed. However, preliminary 
experiments (not shown) suggested that obtaining sufficient numbers of purified 
GNPs to assay protein levels by Western blotting for each condition would be 
difficult. Therefore, instead I attempted to quantitate GLI1 protein levels in WT 
and Nrcam-/- GNPs after addition of SHH and SAG using GLI1 fluorescence 
intensity (see Methods, section 2.7).  
As shown in Fig 5.9, after 4.5 hours SHH treatment, the GLI1 fluorescence 
intensity of WT GNPs as well as Nrcam-/- GNPs, was significantly increased 
when compared to the control.  Interestingly, however, the GLI1 fluorescence in 
Nrcam-/- GNPs was significantly increased compared to the WT controls. By 
contrast, after 4.5 hour SAG treatment, although GLI1 protein levels were 
significantly increased in WT GNPs, when NRCAM is missing there was 
apparently no increase in GLI1 fluorescence relative to the untreated cells.  
Thus, the increase in GLI1 protein level when NRCAM is missing at early time 
point is consistent with the qPCR result from the previous section, which 
suggested that Gli1 and possibly Ptch1 transcripts are elevated in Nrcam-/- 
GNPs compared to WT GNPs after SHH treatment for 4.5 hours (Figs 5.5 and 
5.7). Curiously, however, the GLI1 fluorescent intensity in SAG induced Nrcam-/- 
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GNPs hardly changed when compare with that in control Nrcam-/- GNPs, which 
contrasts with the results from the qPCR experiments (see Fig 5.6). 
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_________________________________________________________________________________________________________________ 
Fig 5.9. Mean fluorescent intensity of GLI1 in WT and Nrcam-/- GNPs treated with SHH or SAG for 4.5 hours. (A) Immunostaining in 
cultured GNPs of P5 mice with anti-GLI1 antibody (green) compared between wild type and Nrcam-/- GNPs after addition of SHH and SAG 
(100nM) for 4.5 hours. Scale bar = 20µm (B) The graph shows relative mean fluorescent intensity of GLI1 (a.u.) from each of 3 independent 
experiments (3n). The data are graphed showing the Standard Error of the Mean (SEM) and tested for statistically significant differences 
among the control and treated samples using one-way ANOVA, followed by Bonferroni’s post-test. The bar graphs show Mean±SEM of 
fluorescence from 1,200-1,600 GNPs/condition/experiment. Confidence interval was set to 95%, with a p-value less than 0.05 taken as 
statistically significant. Statistical significances are indicated as asterisks; *: p<0.05, **: p<0.01, ***: p<0.001, ****: p<0.0001 and N.S.: not 
significant. (C) The different data groups were analysed using 1-way ANOVA and statistic details are shown in the tables. 
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5.2.3 Investigation of GLI1 protein in NRCAM over-expressed NIH3T3-GL 
cells in response to SHH 
To obtain corroborative evidence that NRCAM is affecting SHH signalling in 
GNPs, ideally an experiment should be performed to re-introduce NRCAM to the 
Nrcam-/- GNPs to see if this can rescue the normal dynamics of SHH signalling. 
However, there are a number of obstacles to doing this in GNPs: preliminary 
results showed that only 5-8% of GNPs can be electroporated with a GFP 
(Green Fluorescent Protein) construct (data not shown). Even if a higher 
transfection rate could be achieved, high level expression of the transfected 
construct cannot be achieved in the timescale required; as is typical for most 
transient transfections, expression can only be weakly detected, if at all, 6 hours 
after transfection, and the peak of expression comes 24 hours or more after 
transfection. Therefore because GNPs cannot be cultured as progenitors for 
extended periods, even with the addition of SHH (Miyazawa et al., 2000), it is 
not practical to attempt a rescue in GNPs.  
As an alternative, I therefore attempted to overexpress NRCAM in NIH3T3 cells 
which normally do not express NRCAM (see previous chapter, fig 4.1 and 
(Conacci-Sorrell et al., 2002). NIH3T3 cells are easily transfected and this cell 
type is widely used to study the SHH pathway (Hillman et al., 2011, Milenkovic 
et al., 2009, Rohatgi et al., 2007, Humke et al., 2010), so I therefore decided to 
determine whether this might be a suitable system in which to test whether 
NRCAM affects SHH signalling. The levels of GLI1 and PTCH1 in NIH3T3 cells 
have been shown to rise detectably following just 4 hours of SHH induction 
(Humke et al., 2010, Hillman et al., 2011), suggesting that this may be a 
practical approach.  
5.2.3.1 Choice of cell for NRCAM over-expression  
Although I had previously shown that NRCAM can be overexpressed in the 
NIH3T3 cells provided to us by Dr Verdon Taylor (see figure 4.1), I discovered 
that the GLI1 response of these cells was very low, even when stimulated with 
SAG (Fig 5.10A), indicating that this subline has a very different response to 
SHH to that reported in the literature (Hillman et al., 2011). I therefore screened 
other NIH3T3 sublines for SHH responses and NRCAM transfectabilty. A 
subline provided by Prof. Hilary Powers (Sheffield), showed more GLI1 
expression in response to SHH and SAG (Fig 5.10A), however, the cells did not 
express NRCAM when transfected with Nrcam-HA (Fig 5.10B). 
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Fig. 5.10. Verification of GLI1 expression in 2 lines of NIH3T3 cells. 
Immunoblots with antibodies to GLI1, NRCAM and TUBULIN were used to 
assess amount of protein in extracts from NIH3T3 cells. Immunoblotting for 
TUBULIN served as a control for equal well loading (A) The level of GLI1 
expression was observed after addition of SHH and SAG for 24 hours to 2 lines 
of NIH3T3 cells. The NIH3T3 cells, kindly provided from Prof. Hilary Powers 
showed more GLI1 expression in response to either SHH (lane 5) or SAG (lane 
6) than NIH3T3 cells, kindly provided from Dr. Verdon Taylor. (B) Immunoblot of 
protein from NIH3T3 cells, kindly provided from Prof. Hilary Powers, showed 
GLI1 response after addition of SHH (lane 2) or SAG (lane 3), however, the cells 
were not able to express NRCAM when they were transfected with Nrcam-HA. 
Positive control is protein from mouse embryo at E13.5 (lane 4). 
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Fortunately, I received 2 further sublines of NIH3T3 cells (which I refer to as 
NIH3T3-FC and NIH3T3-GL), kindly provided by Dr. Frederic Charron (Montreal, 
Canada), originally constructed in the lab of Dr. Stephane Angers (Toronto, 
Canada). NIH3T3-GL cells are stably transfected with a firefly luciferase reporter 
construct that is driven by a concatemer of GLI1 (8xgli) binding sites and has 
been used previously to monitor SHH responses (Charron, Pers. Comm.). As 
shown in Fig 5.11A, the NIH3T3-FC cells were successfully transfected with 
Nrcam-HA, but there was no response to SHH or SAG even in the controls. By 
contrast, the NIH3T3-GL subline (Fig 5.11B) was SHH-responsive and able to 
express transfected Nrcam. For these reasons, NIH3T3-GL cells were used in 
subsequent studies.  
 
Fig. 5.11. Verification of GLI1 expression in NIH3T3-FC and NIH3T3-GL 
cells. Immunoblots with antibodies to GLI1, NRCAM and TUBULIN were used 
to access amount of protein in extracts from NIH3T3-FC and NIH3T3-GL cells, 
kindly provided from Dr. Frederic Charron (Montreal, Canada) and Associate 
Professor Stephane Angers (Toronto, Canada), transfected with Nrcam-HA and 
treated with SHH and SAG for 24 hours (A) Although the NIH3T3-FC cells were 
able to express NRCAM after Nrcam-HA transfection, they hardly showed GLI1 
expression in response to SHH or SAG; whereas, (B) NIH3T3-GL cells can 
express more NRCAM after Nrcam-HA transfection and also showed more GLI1 
response when SHH or SAG was added to the cells. Positive control is protein 
from mouse embryo at E13.5 (lane 7). 
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5.2.3.2 SHH signalling is not significantly affected in Nrcam-HA 
transfected NIH3T3-GL cells 
To investigate whether NRCAM affects SHH signalling in NIH3T3-GL cells, I 
transfected Nrcam-HA after plating the cells for 24 hours. After 24-hour-
transfection, the cells were serum-starved for 24 hours, followed by 4.5/24 hour-
SHH or SAG treatment and then tested responses by evaluating GLI1 protein 
expression on western blots (see Methods, section 2.11).  As shown in Fig 5.12, 
although there was not a significant induction of GLI1 protein 4.5 hours post-
SHH/SAG treatment, there was a strong induction at 24 hours post-SHH/SAG 
treatment in both transfected and non-transfected Nrcam-HA NIH3T3-GL cells. 
The amount of GLI1 response was not significantly affected by NRCAM 
expression, however in both cases at 24 hours the trend was towards lowered 
GLI1 levels when NRCAM was present.  
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Fig 5.12. The Expression level of GLI1 in NIH3T3-GL cells after Nrcam-HA 
transfection. (A) Immunoblots of GLI1 protein after transfection of Nrcam-HA in 
NIH3T3-GL cells in response to SHH or SAG for 4.5 and 24 hours (B) 
Quantitation of GLI1 protein by densitometry of three independent immunoblots 
(3n) normalised to tubulin in the same lane. The data are graphed showing the 
Standard Error of the Mean (SEM) and tested for statistically significant 
differences among the control and treated samples using one-way ANOVA, 
followed by Bonferroni’s post-test. The bar graphs show Mean±SEM. 
Confidence interval was set to 95%, with a p-value less than 0.05 taken as 
statistically significant. Statistical significances are indicated as asterisks; *: 
p<0.05, **: p<0.01, ***: p<0.001, ****: p<0.0001 and N.S.: not significant. (C) 
The different data groups were analysed using 1-way ANOVA and statistic 
details are shown in the tables. 
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5.3  Discussion 
In this chapter, I attempted to investigate whether NRCAM has an effect on SHH 
signalling, by looking at both loss of NRCAM function in GNPs and gain of 
NRCAM function in NIH3T3-GL cells. The loss of function experiments in GNPs 
seemed to indicate that SHH signalling might be increased at 4.5 hours post-
induction, but subsequently decreased at 24 hours post-induction. However, the 
gain of function experiment failed to demonstrate a significant effect of NRCAM 
overexpression on SHH signalling in NIH3T3-GL cells.  
Although the results demonstrating that loss of NRCAM increased the Gli1 
transcription levels at 4.5 hours after addition of SHH are in agreement with the 
results from GLI fluorescent intensity at the same time point, I am still uncertain 
about the later time point results, in which the qPCR data showed that the Gli1 
transcription levels were decreased at 24 hours in response to SHH when 
NRCAM is missing, as one important data point, GLI1 fluorescent intensity after 
24 hours of SHH addition to GNPs, was omitted. This clearly will need to be 
investigated further in the future. However, there are a few important points that 
I am able to discuss as follows. 
5.3.1 Is SHH signalling really affected by loss of NRCAM? 
Although the Gli1 transcription levels were significantly affected when NRCAM is 
missing at early and late time points, my inability to demonstrate a significant 
induction of Ptch1 gene expression by SHH, even when the results were also 
statistically post-tested by the Tukey test (data not shown), suggests that the 
qPCR assay may be inadequate, because Ptch1 induction after SHH treatment 
has previously been reported in GNPs (Wechsler-Reya and Scott, 1999). 
Notably, our data showed that there was a high Ptch1 induction even in the 
untreated WT control at 24 hours when compared with to that at 4.5 hours, 
which suggests that somehow Ptch1 is being induced in our culture conditions. 
Although using Northern blotting rather than qPCR, Wechsler-Reya et al. also 
reported an increase in Ptch1 expressions 24 hours after GNPs were treated 
with SHH at different time points, maximally at 24 hours, but interestingly they 
did not include a non-induced control at the later time point (Wechsler-Reya and 
Scott, 1999), making it unclear whether the induction of Ptch1 was due solely to 
the addition of SHH. Indeed, it is known that GNPs will proliferate autonomously 
if plated at a sufficiently high density, most likely mediated by the Notch pathway 
(Solecki et al., 2001), and there is complex cross-talk between the SHH, Wnt 
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and Notch pathways (Behesti and Marino, 2009) that may contribute to this 
Ptch1 activation. For this reason, Ptch1 induction may not be the best readout of 
SHH signalling and indeed Ptch1 and Gli1 expression in vivo are not always 
exactly coincident (compare figure 2s in Corrales et al., 2004 and Lewis et al., 
2004, for example). Nonetheless, although loss of NRCAM did not significantly 
affect Ptch1 transcripts, it at least showed a trend towards induction of Ptch1 at 
4.5 and 24 hours SHH treatment (Fig 5.7), consistent with the Gli1 transcription 
results  (Figs 5.5).  
Even though my results appear to show a significant effect on Gli1 transcription 
levels of the loss of NRCAM, there are a number of technical caveats that 
should be taken into account. The first is that the experiments were set up in 
parallel each with its own standard curve derived from the untreated wild type 
GNPs control at 4.5 hour. Because there were not a sufficient number of wells to 
run every condition at the same time, I decided not to run the WT GNPs 
untreated control again, but to use the value from the standard curve. This 
means that the value of the WT GNPs untreated control at 4.5 hour is equal to 1 
in every biological replication and there is, therefore, no variation in the control 
samples, which complicates comparisons to the other samples. I am aware that 
this was not the perfect way to perform the experiments and if I were to repeat 
this I would have used a separate cDNA to make the standard curve for each 
experiment.  
The second caveat is that in light of the highly variable Ptch1 results I obtained 
(see above), and similar variability in the results of other users assaying other 
cells and genes, the qPCR machine was re-calibrated shortly after I completed 
my experiments. A comparison of the reproducibility of the results across the 
PCR plate before and after the re-calibration demonstrated that the machine 
indeed showed considerable variability across the plate at the time I performed 
my Ptch1 experiments (Fig. 5.13), which may also have affected the Gli1 
experiments done prior to that. As indicated above, we had had some doubts 
about the Ptch1 data at the time and had tried to remove some outliers to 
correct for the variability, although the Ct variability remained high, even after 
these removals.  Outliers were also removed from Gli1 data (see methods, 
section 2.12.6), but to a much lesser extent than was the case for Ptch1. 
Unfortunately, lack of time has prevented me repeating these experiments. This 
variability may explain my inability to detect statistically significant variation 
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between samples despite the appearance of some suggestive trends in the 
results. 
 
Fig 5.13. qPCR machine performances before and after standardization. 
The qPCR reactions were performed using the same sample in every well 
before and after qPCR machine servicing. Before machine standardization, the 
red graphs showed high variation between each sample; however, they looked 
more consistent after the qPCR machine was recently serviced and 
standardised (blue graphs). The qPCR reactions were performed by Sarah 
Jacob Eshtan and Milene Massucci Bissoli, PhD students in Rivolta lab, 
University of Sheffield. 
 
Despite these caveats, a number of points suggest that loss of NRCAM does 
affect SHH signalling in GNPs: first, as shown in previous chapters, the absence 
of NRCAM affects the translocation of SMO and PTCH1 in cilia. Second, despite 
the lack of statistical proof, Ptch1 transcription levels showed a trend in the 
same direction as that of Gli1, which was that when NRCAM is missing there 
appeared to be more Gli1 and Ptch1 transcripts at 4.5 hours, but less at 24 
hours (Fig 5.5 and 5.7), suggesting that when NRCAM is missing, SHH 
signalling was increased at the early time point and yet decreased at 24 hours. 
An increase in SHH signalling at 4.5 hours with NRCAM loss is also consistent 
with that seen in the assay of GLI1 protein levels by anti-GLI1 fluorescence 
intensity of GNPs at 4.5 hours. Unfortunately, we do not know what occurs later 
because I ran out of time to perform the experiment at the later time point (24 
hours).  
In the gain of function study, I tested to see if NRCAM has any effect on SHH 
signalling by overexpressing it in NIH3T3-GL cells. The GLI1 induction was 
shown after 24 hours of SHH or SAG treatment, consistent with (Hillman et al., 
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2011) in both non-transfected and NRCAM transfected NIH3T3-GL cells. 
However, I found that this SHH signalling was not significantly changed with 
NRCAM overexpression, although at 24 hour post-SHH induction, there was a 
trend to suggest that GLI1 expression might be decreasing.  
This suggestive result from the gain function experiment might appear to 
contradict those from the loss of function of NRCAM experiments because in 
both cases SHH signalling seems to be reduced at 24 hours. However, there 
are a number of reasons that it is difficult to compare these results: Firstly, the 
experiments were performed in different cell types (GNPs and NIH3T3-GL 
cells). Although both of them respond to SHH (and SAG), it is not clear that they 
necessarily will respond in the same way. For example, it is known that different 
cell types express different combinations of accessory SHH-binding molecules 
that affect the SHH response (Tenzen et al., 2006, Izzi et al., 2011). Secondly, 
NIH3T3 cells not only do not express NRCAM, but they also are unlikely to 
express at least two ligands for NRCAM, TAG-1 and F3, which are expressed 
by GNPs. This may be important, as binding of these ligands appears to affect 
the response of GNPs to SHH (Xenaki et al., 2011). Lastly, it is also difficult to 
compare Gli1 mRNA levels with GLI1 protein levels. Clearly it might have been 
better to have compared the same readout, whether this should have been 
mRNA transcription or protein expression is a good point for discussion as 
obviously the further downstream of the initial signalling monitors, the more 
opportunity there is for other regulation to occur. 
Despite the difficulties discussed above, the results of this chapter seem to 
tentatively to suggest that Nrcam-/- GNPs, perhaps surprisingly, exhibit relatively 
more SHH signalling early on followed by a subsequent relative fall in signalling. 
Exactly, how these results are related to the results from the previous chapters 
and what this might mean will be discussed in the next chapter. 
  
 
 
 
 
Chapter 6 
General discussion 
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Despite considerable research into the area, how tissue and organ 
morphogenesis is regulated, particularly how growth is controlled is still not 
clearly understood. At an organismal level, hormones and growth factors 
(especially insulin-like growth factors; IGFs) in the circulation play an important 
role in size control, as do other extrinsic factors such as availability of nutrients. 
However, intrinsic mechanisms also limit growth and organs somehow ‘know’ 
when they reach the correct size (Leevers and McNeill, 2005). A central role in 
many tissues is played by the Hippo pathway intracellularly and, although 
extracellular secreted factors such as DPP/BMPs and Wnts impinge on its 
regulation, major regulation of the pathway appears to come from cell adhesion 
and cell polarity inputs (Zhao et al., 2011). Exactly how these inputs detect 
growth and size is not understood, but it is perhaps not surprising that cells are 
not simply programmed to undergo a specific number of cell divisions and then 
stop, but instead constantly receive inputs from their neighbors to enable them 
to proliferate and then differentiate in a co-ordinated manner. Understanding 
how this occurs is important for understanding development, cancer and tissue 
regeneration. 
Previous work from our lab and others has strongly suggested that L1-CNTN 
adhesion molecules play a role in controlling the growth of the cerebellum. 
Sakurai et al. (2001) showed that L1 and Nrcam null mice exhibit small 
reductions in the size of specific, yet distinct cerebellar lobules as single 
mutants, and that combination of these mutations results in severe cerebellar 
defects, including the reduction or disappearance of some fissures, a decrease 
of the thickness of IGL and a dramatic decrease in overall cerebellar size. This 
suggested the functional redundancy of L1 and NRCAM in cerebellar 
morphogenesis, most likely affecting granule cell development (Sakurai et al., 
2001). Premature expression of F3/contactin – a ligand of L1 and NRCAM 
normally expressed only by post-mitotic granule neurons – on proliferating 
granule neuron progenitors, also suppressed cerebellar growth, albeit it 
transiently, and inhibited GNP proliferation in vitro (Bizzoca et al., 2003). 
Our laboratory subsequently demonstrated that purified F3 protein can suppress 
SHH-induced GNP proliferation in vitro (Xenaki et al., 2011). Modulation of SHH 
can control both the shape and size of the cerebellum (Corrales et al., 2004, 
Corrales et al., 2006, Lewis et al., 2004). Although L1-CNTNs have been shown 
to modulate the proliferation of the progenitors of other cell types through Notch 
(F3 acting on oligodendrocytes; (Hu et al., 2003)) or Amyloid β precursor protein 
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(TAG-1 acting on cortical progenitors; (Ma et al., 2008), the results of Xenaki et 
al., strongly suggested that F3 has its effect through binding to NRCAM on the 
surface of GNPs. Therefore, the key question in this study is how L1-CNTNs 
function in regulating SHH activity.  
Through the previous three chapters, several approaches were used to 
understand the mechanism underlying how NRCAM modulates SHH-induced 
proliferation of GNPs. The key findings in this study are summarised as follows: 
First, I showed for the first time that L1-CNTNs can be found located in the 
primary cilium. Second, I showed that loss of NRCAM from GNPs suppresses 
the translocation of PTCH1 out of the primary cilium of GNPs in response to 
SHH and also the subsequent translocation into the cilium of SMO. Third, my 
co-immunoprecipitation results indicate that NRCAM directly associates with 
PTCH1, but not SMO, consistent with the idea that NRCAM may be involved in 
the trafficking of PTCH1. Finally, my preliminary analysis of immediate early 
responses to SHH, notably induction of Gli1 mRNA transcription, suggests that 
loss of NRCAM may affect the kinetics of the SHH response: Unexpectedly, 
SHH signalling in NRCAM null GNPs appeared to be increased at the early, 4.5-
hour time point, at which I had previously seen an apparent failure of PTCH1 to 
leave, and of SMO to enter the primary cilium. However, by 24 hours, levels of 
Gli1 mRNA were significantly less than in WT GNPs. The significance of these 
findings is discussed below. 
6.1 The presence of NRCAM and TAG-1 in primary cilia of GNPs  
Our immunofluorescence visualisation of NRCAM and TAG-1 in the primary 
cilium of GNPs is, as far as we are aware, the first direct imaging of this class of 
molecule in cilia. Although the specificity of antibodies is always to be treated 
with caution, especially when using polyclonal antibodies to molecules that 
belong to a closely related family, we have good reason to be confident that 
NRCAM is indeed present in GNP primary cilia, not least because the 
immunoreactivity we saw was not present in the cilia of Nrcam-/- GNPs (Fig 
3.9B). Similarly, although we did not test GNPs from TAG-1 null animals, the 
4D7 antibody is a monoclonal of well-characterised specificity (Furley et al., 
1990) that is widely used.  
There is, in fact, evidence from other sources that L1-CNTNs are present in 
cilia. For example, L1 can be found in the Blacque serial analysis of gene 
expression (SAGE) ciliome database (Blacque et al., 2005) 
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(http://www.sfu.ca/~leroux/ciliome_database.htm) and reviewed in (Inglis et al., 
2006). That L1 might be involved in ciliary function is interesting since the L1 
knockout mouse displays some of the characteristics of the ciliopathies, for 
example hydrocephalus and infertility (see also discussion, Chapter 3).  
Perhaps surprisingly, F3 is reported to be present, among some 868 other 
proteins, in the primary cilia of choroid plexus epithelium cells (CPECs) (Narita 
et al., 2012). No role for F3 in choroid plexus (CP) function has been described 
and, although it is interesting to speculate whether the presence of an L1 ligand 
in the CP has anything to do with the hydrocephalus seen in L1 null mice. L1 
also has not been reported to be expressed in the CP and indeed 
hydrocephalus is not associated with the F3-binding domains of L1 (Itoh et al., 
2004).  
The inclusion of F3 in the ciliome of CPECs but not, as I have shown, in that of 
cerebellar GNPs, makes the important point that the ‘ciliome’ is not a fixed set of 
proteins. However, there are clearly proteins common to most cilia (Inglis et al., 
2006). Among these are a set of Rab GTPases that are involved in ciliary 
trafficking, including Rab5, Rab8, Rab10, Rab11 and Rab23, (Hsiao et al., 
2012). Boehlke et al (2010) demonstrated that different Rabs have distinct 
functions. For example, trafficking of KIM1, an apical membrane receptor, but 
not SMO, is influenced by Rab5, whereas, Rab8 mediates ciliary protein 
transport of SMO, KIM1 and EB1, the microtubular tip protein. Rab23, a 
negative regulator of SHH signalling (Eggenschwiler et al., 2001), is known to be 
involved in regulating SMO levels (Boehlke et al., 2010). Babbey et al. showed 
that the colocalisation of Rab10 and Sec8, an exocyst protein, at the base of 
cilia in renal epithelial cells, together with the physical interaction of Rab10 and 
Sec8 suggests that Rab10 is associated with the membrane transport to the 
primary cilia (Babbey et al., 2010). Rab11 was originally identified as a key 
regulator of membrane trafficking from the trans-Golgi network and recycling 
endosome to the plasma membrane, but is also found enriched at the base of 
the primary cilium and suppression of its function affects primary ciliogenesis 
(Knodler et al., 2010, Das and Guo, 2011). Recent evidence also suggests that 
interacts genetically with Smo (Alvers et al., 2014). Interestingly, unpublished 
work from our lab (Dang and Furley, unpublished) suggests that in sensory 
growth cones, L1 recycles via the Rab11 recycling pathway, which is another 
potential link of L1-CNTNs to ciliary function.  
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My finding that NRCAM is present in primary cilia of purified P5 cerebellar GNPs 
is somewhat surprising, as these cells in vivo are mainly localised in the oEGL, 
where NRCAM immunostaining relatively weak (Xenaki et al., 2011). One 
possibility is that in these progenitor cells, its critical function occurs in cilia alone 
and therefore its overall low level of expression is not important so long as it is 
present in the cilia. Another possibility is that NRCAM expression in GNPs 
varies with the phase of the cell cycle, reflecting that the presence of the cilium 
on the cell is related to the cell cycle; the generation of primary cilia occurs in 
G1/G0 phase and the cilia is most obviously seen in S phase (Plotnikova et al., 
2009). In this case, cells of the oEGL in other phases of the cell cycle may not 
express high levels of NRCAM explaining why the NRCAM expression is 
relatively weak in oEGL compared to IGL. However, arguing against this is the 
fact that NRCAM immunoreactivity on GNPs was present throughout the cell, 
not only in the primary cilia of GNPs, and there was no major variation in overall 
levels between cells in culture.  
A more likely possibility is that NRCAM plays other roles in addition to its 
function in the SHH signalling pathway, after GNPs exit the cell cycle. In fact, 
most previous studies have focused on post-mitotic roles for NRCAM, although 
these were mainly based on antibody or overexpression perturbations of in vitro 
functions. Thus, for example, Sakurai et al. (2001) suggested that NRCAM and 
L1 are required for survival and neurite outgrowth of differentiated cells; 
although the survival and outgrowth of NRCAM-deficient granule cells was 
similar to WT cells, their survival and to a lesser extent their outgrowth was 
significantly diminished after addition of a function blocking anti-L1 antibody 
(Sakurai et al., 2001). Similarly, Davey et al (2005) demonstrated that neurite 
outgrowth from cerebellar granule cells in culture could be blocked by 
transfection of Nrcam constructs containing deletions of their intracellular 
domains, which were presumed therefore to be acting in a dominant negative 
manner (Davey et al., 2005). However, there is clear evidence that NRCAM has 
roles later in differentiation in the assembly of the Node of Ranvier (Feinberg et 
al., 2010). 
The complexity of the interdependence between granule neurons, Bergmann 
glia and Purkinje cells (Vogel et al., 1989, Roussel and Hatten, 2011) and the 
evident redundancy between L1 and NRCAM makes dissecting which of these 
roles is most significant in producing the phenotype seen by Sakurai difficult. It 
seems unlikely that its role in Node of Ranvier formation plays a part in this. 
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While we cannot rule out that NRCAM may have a role either in GNP migration 
or axon outgrowth that in turn may affect GNP survival, my finding that NRCAM 
can be found in the primary cilia of proliferating GNPs is provocative and clearly 
suggests that NRCAM is important for progenitor responses to SHH. 
 
6.2 NRCAM and the SHH pathway. 
The presence of NRCAM in the cilium in the right time and in the right place to 
affect responses to SHH, led us to propose that NRCAM could play a role in 
either PTCH or SMO trafficking in primary cilia of GNPs. Exactly how either of 
these proteins is tranlocated to or from the cilium is controversial. Most is known 
about SMO: early studies showed its translocation to be dependent on the 
intraflagellar transport complex (May et al., 2005) and to be mediated by ß-
arrestins, which appear to link SMO to the kinesin-2 motor complex via Kif3A 
(Kovacs et al., 2008). ß-arrestins are involved broadly in the internalisation of 
GPCRs (Lefkowitz et al., 2006) and so one model suggests SMO may be 
trafficked to the cilium from the membrane via Golgi or recycling derived 
vesicles present at the base of the cilium. However, using microscopy-based 
pulse-chase analysis, Melenkovic et al. (2009) showed that SMO can 
translocate from the NIH3T3 cell membrane to the primary cilia via the so-called 
lateral transport route, in which SMO in some way is passed directly from the 
plasma membrane to the ciliary membrane without being internalised. 
Interestingly, the same study demonstrates that although lateral transport 
appears to be immediate early route of SMO to the cilium, at later time points 
there is also a contribution from internalised vesicles (Milenkovic et al., 2009).   
By contrast, much less is known about how PTCH translocates in the cilium. 
Early studies indicate that SHH gets internalised to endocytic vesicles after 
binding to PTCH1 (Incardona et al., 2000) and that in Drosophila HH 
internalisation is facilitated by the GPI-linked Dally-like protein (DLP), which is 
required for ‘full-strength’ HH signalling in the wing imaginal disc (Gallet et al., 
2008). However, it is unclear that this is the mechanism by which PTCH is 
removed from the cilia in vertebrates (we speculated that there is physically no 
room for vesicle internalisation in the cilium because it has been shown that 
vesicles are not translocating into the cilium (Finetti et al., 2011)), rather than the 
mechanism by which accumulation of SHH is controlled, which is thought to be 
important in the creation of morphogen gradients (Briscoe and Therond, 2013). 
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My data demonstrates that NRCAM and PTCH1 can be co-immunoprecipitated 
when transfected into Cos-7 cells suggesting that they are closely associated in 
this context. That there is some specificity to this interaction was shown by the 
fact that SMO, also a multipass membrane receptor, does not co-IP with 
NRCAM. However, two other control proteins, TIE-2 and FGFR3, also co-
immunoprecipitated with PTCH1, making us less confident of the significance of 
the interaction. On the other hand, PTCH and NRCAM are clearly both to be 
found co-localised in cilia, although this does not imply that they are interacting 
physically. Corroboration of this idea will require live cell imaging of the two 
molecules following SHH binding to determine whether NRCAM can be seen to 
segregate to the same intracellular vesicles as PTCH1. 
 
6.3  Loss of NRCAM affects SHH signalling pathway 
The results from the third and fourth chapters showed that loss of NRCAM 
affects the localisation of PTCH and SMO, and that NRCAM may interact with 
PTCH1, suggesting that NRCAM may play a role in SHH signalling. We 
therefore asked whether loss of NRCAM affects SHH signalling. Because loss of 
NRCAM led to a failure of PTCH to leave the cilium by 4.5 hours, we supposed 
that this would result in less signalling at the same time point. Unexpectedly, we 
found that in fact SHH signalling is significantly increased by loss of NRCAM at 
early time point, at least as judged by Gli1 mRNA induction. However, after 24 
hours of SHH treatment, SHH signalling levels were significantly lower than in 
WT GNPs.  
In principle, PTCH translocation out of the primary cilium after SHH stimulation 
allows SMO to go into the cilium (Corbit et al., 2005, Rohatgi et al., 2007), 
leading to the generation of activator form of GLIs and stimulation of Ptch1, Gli1 
transcriptions (Wechsler-Reya and Scott, 1999). Here then, the question is why 
NRCAM null GNPs exhibit a failure of SMO ciliary localisation but show an 
increase in SHH signalling after addition of SHH for 4.5 hours, and then 
relatively lower SHH signalling after 24 hours. Corbit et al. showed that SMO 
localisation in primary cilia is required for SHH signalling (Corbit et al., 2005), 
however, in this study I demonstrated that SHH signalling is increased at 4.5 
hours when the cells have low SMO ciliary localisation, but dropped at 24 hours 
in NRCAM knockout GNPs. Some possibilities to explain these results are as 
follows: 
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The first possible explanation could be that in these circumstances SHH is 
signalling via a noncanonical hedgehog signalling-type 1 (Jenkins, 2009), in 
which SHH can independently induce proliferation without SMO involvement 
and independent of transcriptional change of Gli transcriptional factors (Brennan 
et al., 2012). However, that this pathway is used seems unlikely as the Nrcam-/- 
GNPs definitely exhibited an initial increase in GLI1 induction at 4.5 SHH 
treatment.  
The second possibility is that an increase in GLI1 expression at the early time 
point (4.5 hours after addition of SHH) could be due to the small amount of SMO 
that is found in the cilia of Nrcam-/- GNPs: around 12.04±3.64% of cilia are 
occupied by SMO irrespective of whether or not SHH is added (fig 3.9). 
However, this seems unlikely as the immunostaining studies showed that GLI1 
protein expression is elevated in considerably more than just 12% of the GNPs 
from Nrcam-/- mice (Fig. 5.9).  
The next possibility is that SMO does not need to be in the cilia to signal. 
Although the recent model of how SMO is activated in vertebrate SHH signalling 
suggests that this occurs inside primary cilia (Rohatgi and Scott, 2007), it 
remains unproven whether SMO might also be active outside the primary cilium. 
Indeed, recently, it has been shown that the localisation of SMO outside the 
primary cilium can mediate chemotaxis in response to SHH (Bijlsma et al., 
2012). However, that this pathway is active in our Nrcam-/- GNP response 
seems unlikely, as this cilium-independent pathway does not activate GLI1 
(Bijlsma et al., 2012).  
Another possibility is that loss of NRCAM has affected the kinetics of PTCH1 
and SMO ciliary trafficking. Previous work from our lab and others has shown 
that changing the complement of L1-CNTNs present in the cell can change the 
endocytosis and re-cycling of associated cell surface molecules (Dang et al., 
2012). Thus, we might speculate that loss of NRCAM leads to a more rapid 
turnover of PTCH1 and that the apparent failure of PTCH1 to leave the cilium in 
NRCAM null GNPs after 4.5 hours actually reflects that an initial phase of 
signalling has been completed but instead of SMO remaining stably in the cilium 
it has turned over and been replaced by a new lot of PTCH1. This would be 
consistent with the fact that we still see SHH signalling being generated at the 
early time point in NRCAM knockout GNPs.  
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In fact, 4.5 hours is a relatively long time in terms of receptor recycling, indeed 
some receptors, for example the neuropilins, can return to the cell surface within 
minutes of ligand binding (Piper et al., 2005). Looking at SMO and PTCH1 
localisation at earlier time points would help to determine whether this 
hypothesis is correct.  
Why, in this case, SMO would be unstable in the cilium is not clear, but one 
possibility is that this reflects the different pools of SMO that were found to enter 
the cilium after SHH treatment by Milenkovic et al (2009). Interestingly, SMO 
entering the cilium by lateral transport from the plasma membrane peaked 1 
hour after SHH treatment and was subsequently replaced by SMO derived from 
intracellular sources (Milenkovic et al., 2009). If NRCAM somehow affects the 
second wave of SMO entry, not the first, this may explain why SHH signalling is 
not sustained at the 24- hour time point in NRCAM null GNPs. 
Another consideration is whether the level of SHH used to stimulate the cells 
affects the translocation behaviour of SMO. In my experiments, the level of SHH 
I used was determined by titrating SHH with GNPs and using the minimum 
concentration required to drive maximal proliferation of GNPs after 24 hours of 
treatment, rather than that required to drive maximal expression of Ptch and 
Gli1. This equated to about 30nM of recombinant SHH (R&D; see Methods). By 
comparison, Wechsler-Reya and Scott used 150 nM SHH to investigate SHH-
induced proliferation of GNP response at 48 hours and showed maximal Ptch 
and Gli expressions at 24 hours upon the addition of SHH (Wechsler-Reya and 
Scott, 1999). Clearly, the SHH concentration that we used was relatively lower 
and exposure time of the GNPs to SHH shorter at the time proliferation was 
measured (24 hours versus 48 hours). This might affect the level of Gli1 and 
Ptch1 responses, because the exposure time of SHH and the level of SHH 
ligand available to the cells are key factors that influence the response of SHH 
(Dessaud et al., 2007).  
As far as we are aware, no one has determined the minimum levels of SHH 
required to induce SMO translocation into the cilium and, indeed, the levels of 
SHH used in the key study of SMO translocation are not precisely specified 
(Rohatgi et al., 2007), making this hard to relate to our own work. Thus, 
although it is established that cilial function is required for full activation of SHH 
signalling (Corbit et al., 2005), it remains possible that some SHH signalling can 
occur without SMO translocation. An important proof of the requirement for SMO 
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to translocate to cilia in order for Gli1 to be activated was the failure of a ciliary 
localisation defective mutant of SMO (CLDSmo) to induce Gli1 expression 
(Corbit et al., 2005). However, we note that in this case Gli1 expression was 
monitored 18 hours after SHH addition. In Nrcam-/- GNPs, although we saw a 
sizeable induction of Gli1 4.5 hours after SHH addition, by 24 hours Gli1 
expression was not significantly different to control and substantially less than 
WT (Fig 5.5). Further studies in these differing systems, with more precisely 
controlled times and levels of SHH signalling, will be required to establish 
whether in fact some signalling can be generated without the necessity for SMO 
translocation to the cilium. 
A further complication is that we observed that Ptch and Gli1 expression was 
not always exactly coincident, consistent with the observations of others (Rios et 
al., 2004, Bermudez et al., 2013). Thus, it is possible that the Gli1 expression 
we see also does not reflect the initiation of full activation of SHH signalling. The 
use additional targets of SHH signalling, such as Nmyc (Kenney et al., 2003, 
Oliver et al., 2003), would help to confirm the significance of these results.   
Another question that arises is why the NRCAM null GNPs appear still to 
proliferate in response to SHH (Xenaki et al., 2011). In fact, this may reflect the 
early Gli1 induction that I have described. Because the SHH signal is not 
sustained, we might have expected that the level of proliferation induction would 
have been less than in WT. In fact, we have not yet made a careful comparison 
with wild type, so this is still possible and my lab is currently doing experiments 
to determine this. An alternative possibility is that even if the level is the same, it 
is still possible that this reflects the involvement of NRCAM in an unknown 
pathway to enhance the SHH-induced proliferation of GNPs. For example, 
Insulin Growth Factor (IGF) has been shown that it can potentiate cell 
proliferation as IGF signalling synergises with SHH signalling. Moreover, IGF-1 
and IGF2-induced proliferations are not dependent on the function of SMO 
(Fernandez et al., 2010) (see Introduction, section 1.4.5.1). Although, this can 
explain why the GNPs can proliferate without SMO entry to primary cilia and 
why NRCAM knockout mice are not lethal, there is no evidence to suggest that 
NRCAM is involved in the IGF signalling pathway. In addition, it is not clear how 
IGF signalling would result in Gli1 mRNA induction. 
Of particular interest is that two candidate proteins that have been shown to 
affect the strength of SHH signalling are Neuropilins 1 and 2 (NRPs) (Hillman et 
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al., 2011), to which L1 and NRCAM have been shown to bind respectively (Falk 
et al., 2005). Although Hillman et al. did not address whether the time course of 
SHH pathway activation was different when NRP expression was inhibited, the 
strength of the signal was significantly reduced after 24 hours of SHH treatment 
if Nrp mRNA translation was inhibited. Interestingly, NRP1 levels are induced by 
SHH but at a later time point than PTCH1, suggesting a positive feedback loop 
is indirectly activated. We therefore speculate that NRCAM and NRPs may 
together be involved in modulating SHH signalling. Interestingly, preliminary 
results from Matthew Scott’s lab suggest that, although there is no effect on 
SMO translocation, there may be a subtle effect of Nrp knockdown in NIH3T3 
cells on the movement of PTCH1 out of the cilium (Xuecai Ge, Pers. Comm.).  
Therefore future experiments will aim to test whether NRCAM works together 
with NRP1/NRP2 in SHH pathway. In GNPs we will look for co-localisation of 
NRPs with NRCAM and with PTCH1 and/or SMO. PTCH1 and SMO ciliary 
localisation will also be determined both earlier than 4.5 hours (see above) and 
after 24 hour SHH treatment to see whether the response is simply delayed, or 
whether SMO continues to be excluded from cilia in the Nrcam-/- GNPs. These 
sets of future experiment might provide evidence to clearly explain why loss of 
NRCAM increases SHH signalling at early time point but not later and whether 
NRCAM works with NRPs.  
Our working model of how NRCAM might be involved in SHH signalling in the 
primary cilium is depicted in Fig. 6.1. We are biased towards NRCAM interacting 
with PTCH1, partly because of my demonstration that PTCH1 can co-
immunoprecipitate with NRCAM, but also because PTCH1 fails to leave the 
cilium in the NRCAM null GNPs; if NRCAM was regulating SMO entry it is not 
clear why this would affect PTCH1 exit. However, clearly there are complex 
feedback pathways at work in the SHH response, so it remains possible that 
NRCAM controls the access of one or all of the proposed pools of SMO to the 
cilium, either partly or completely. It is also possible that L1 is involved in ths 
process, since it also can bind neuropilins and F3 (Falk et al., 2005). To date our 
protein expression and F3-binding data do not support a role for L1 in controlling 
events prior to cell cycle exit (Xenaki et al., 2011), but given that NRCAM was 
originally said not to be on proliferating GNPs (Sakurai et al., 2001), we may 
need to test this more rigourously. Overall, we expect that more detailed 
observation of the localisation of the relevant proteins will clarify which of these 
possibilities is most relevant. 
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Fig 6.1. Proposed model of the interaction of NRCAM and PTCH1 mediates 
the translocation of PTCH1 in primary cilia. (A) In the absence of SHH, the 
ciliary localisation of PTCH1 inhibits SMO translocating to the primary cilium, 
resulting in no transcription of SHH target genes. (B) In the presence of SHH, 
NRCAM, interacting with PTCH1 mediates the translocation of SHH and PTCH1 
complex out of the primary cilium and this allows SMO entry to the cilium, 
leading to the transcription of SHH target genes and proliferation. (C) In the 
presence of SHH and F3, F3 inhibits the translocation of SHH and PTCH1 
complex out of the primary cilium, resulting in suppression of proliferation. 
 
6.4  Concluding remarks and future perspectives 
We showed here the novel role of NRCAM in primary cilium of GNP and the 
requirement of NRCAM for the ciliary localisations of SHH components, PTCH1 
and SMO. An interaction of PTCH1 and NRCAM in transfected cells was also 
demonstrated. My preliminary results also suggest that SHH signalling is 
significantly increased by loss of NRCAM at the early time point but 
subsequently strongly diminished. We propose a model of how NRCAM is 
involved in PTCH1 trafficking out of the cilium and speculate that NRPs might 
participate in the kinetics of NRCAM-mediated SHH signalling. Future works will 
focus on the kinetics of translocation of SHH protein components in the primary 
cilia of GNPs. Live cell imaging need to be performed to determine whether 
NRCAM really interacts with PTCH1 in the cell and translocate PTCH1 out of 
cilium, how fast this occurs when the cell response to SHH and to investigate if 
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and how NRPs are involved in this situation. Although our results seem to 
suggest that NRCAM physically interacted with PTCH1 not SMO, we do not 
know what happens to downstream SHH signalling targets, such as SuFu, and 
GLIs, and whether loss of NRCAM also affects them. Given that we have 
evidence of NRCAM affecting SHH signalling, it will also be interesting to 
investigate whether there is a genetic interaction of Nrcam and Shh in vivo. We 
hope that the discovery of the role of L1-CNTNs in modulating SHH signaling 
could lead to novel potential treatments for MB in the future.  
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